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GENOME-WIDE ASSOCIATION STUDIES OF NASOPHARYNGEAL 
CARCINOMA IN THE MALAYSIAN CHINESE COHORT USING SINGLE 
GENES, META-ANALYSIS AND PATHWAY ANALYSIS APPROACHES 
 
ABSTRACT 
Nasopharyngeal carcinoma (NPC) is an epithelial squamous cell carcinoma on 
the mucosal lining of the nasopharynx with high incidence in the southern Chinese 
population. NPC is constantly linked to Epstein Barr virus (EBV) infection but its 
etiology remains elusive considering many carriers of EBV never develop NPC. 
Genetic factors play an important role in NPC susceptibility. This study set out to 
identify genetic variants linked to NPC susceptibility using a genome-wide association 
(GWAS) approach in the Malaysian Chinese. The GWAS encompasses single genes, 
meta-analysis with NPC cohorts from Taiwan and southern China and a pathway/gene 
set approach. In the single gene approach, GWAS results confirmed the association of 
HLA-A to NPC with the strongest signal detected in rs3869062 (P=1.73x10-9). Fine 
mapping revealed associations in the amino acid variants as well as its corresponding 
SNPs in the antigen peptide binding groove (PHLA-A-aa-site-99=3.79x10
-8, 
Prs1136697=3.79x10
-8) and T-cell receptor binding site (PHLA-A-aa-site-145=1.41x10
-4, 
Prs1059520=1.41x10
-4) of the HLA-A. HLA-A amino acid variants and SNPs were 
correlated with the effects of HLA-A*02:07. Results showed a protective trend towards 
NPC for HLA-A variants in the Malaysian Chinese, consistent with previous findings of 
HLA-A NPC association. Meta-analysis performed by combining results from NPC 
GWAS of Malaysia, Taiwan and southern China (2,152 cases; 3,740 controls) revealed 
43 noteworthy findings outside the MHC region were identified and targeted for 
replication in a pooled analysis (4,716 cases; 5,379 controls). In the combined meta-
analysis, rs31489, located within the CLPTM1L/TERT region on chromosome 5p15.33, 
was strongly associated with NPC (OR=0.81; P=6.3x10-13). Associations of previously 
reported NPC GWAS were also replicated, namely rs6774494 (P=1.5x10-12; located in 
 iv 
the MECOM gene region), rs9510787 (P=5.0x10-10; located in the TNFRSF19 gene 
region), and rs1412829/rs4977756/rs1063192 (P=2.8x10-8, P=7.0x10-7, and P=8.4x10-7, 
respectively; located in the CDKN2A/B gene region). The TERT gene is important for 
telomere maintenance and is overexpressed in NPC. The EBV protein LMP1 has been 
reported to modulate TERT expression/telomerase activity in NPC. The findings suggest 
that factors involved in telomere length maintenance are involved in NPC pathogenesis. 
An integrated pathway approach was employed to identify dysregulated pathways 
linked to NPC. This approach combines imputation NPC GWAS data from a Malaysian 
Chinese cohort as well as published expression data GSE12452 from both NPC and 
healthy nasopharynx tissues. Results identified NPC association with the Gene 




-21). This association was replicated in a separate 
cohort using gene expression data from NPC and healthy nasopharynx tissues (PAmpliSeq-
GSEA=1.37x10
-3). Loss of function in the axonemal dyenein complex causes impaired 
cilia function, leading to poor mucociliary clearance and subsequently upper or lower 
respiratory tract infection, the former of which includes the nasopharynx. Our approach 
illustrates the potential use of integrated pathway analysis in detecting gene sets 
involved in the development of NPC in the Malaysian Chinese cohort. 
Keywords: nasopharyngeal carcinoma, genome-wide association studies, imputation, 









Karsinoma salur udara nasofarinks (NPC) adalah sejenis karsinoma sel skuamus 
epithelial pada lapisan mukosa salur udara nasofarinks dengan insiden yang tinggi di 
kalangan populasi masyarakat Cina selatan. NPC sentiasa dikaitkan dengan jangkitan 
virus Epstein Barr (EBV) tetapi etiologinya masih sukar difahami memandangkan 
kebanyakan pembawa virus EBV tidak akan menghidap NPC. Adalah dipercayai 
bahawa faktor genetik memainkan peranan penting dalam kerentanan NPC. Oleh itu, 
dalam penyelidikan ini,  variasi genetik yang dikaitkan dengan NPC dikenalpasti 
dengan menggunakan kaedah kajian perkaitan menyeluruh genom (GWAS) dalam 
populasi berketurunan Cina Malaysia. Kajian GWAS ini merangkumi gen tunggal, 
analisis meta terhadap pesakit NPC dari Taiwan dan selatan Cina serta satu kaedah set 
laluan gen. Melalui kaedah gen tunggal, analisis GWAS yang dijalankan telah 
mengesahkan perkaitan antara HLA-A dengan NPC di mana isyarat paling tinggi 
dikesan pada rs3869062 (P=1.73x10-9). Pemetaan terperinci mendedahkan perkaitan 
dalam varian-varian asid amino berserta SNP yang sepadan dalam alur pengikat peptida 
antigen (PHLA-A-aa-site-99=3.79x10
-8, Prs1136697=3.79x10
-8) dan tapak pengikat reseptor sel 
T (PHLA-A-aa-site-145=1.41x10
-4, Prs1059520=1.41x10
-4) HLA-A. Varian-varian asid amino 
dan SNP HLA-A menunjukkan korelasi tinggi dengan kesan HLA-A*02:07. Hasil kajian 
ini menunjukkan varian-varian asid amino HLA-A cenderung sebagai penghindar NPC 
dalam populasi keturunan Cina Malaysia, sejajar dengan penemuan terdahulu bagi 
perkaitan antara HLA-A dan NPC. Kaedah analisis meta  menggabungkan data NPC 
GWAS Malaysia, Taiwan dan selatan China (2,152 kes; 3740 kawalan) yang dijalankan 
mendedahkan 43 penemuan berpotensi di luar rantau MHC yang telah dikenalpasti dan 
disasarkan untuk replikasi dalam analisis gabungan (4,716 kes; 5,379 kawalan). Dalam 
meta-analisis gabungan, rs31489 yang terletak dalam rantau CLPTM1L/TERT pada 
kromosom 5p15.33, dikaitkan dengan NPC (OR=0.81; P=6.3x10-13). Perkaitan variasi 
 vi 
SNP NPC yang dilaporkan sebelum ini juga dikenalpasti, iaitu rs6774494 (P=1.5x10-12; 
terletak di rantau gen MECOM), rs9510787 (P=5.0x10-10; terletak di rantau gen 
TNFRSF19), dan rs1412829/rs4977756/rs1063192 (P=2.8x10-8, P=7.0x10-7 dan 
P=8.4x10-7, masing-masing terletak di rantau gen CDKN2A/B). Gen TERT adalah 
penting untuk penyelenggaraan telomer dan menunjukkan ekspresi tinggi dalam NPC. 
Protein EBV iaitu LMP1 telah dilaporkan mampu mengubah aktiviti TERT dalam NPC. 
Penemuan penyelidikan ini menunjukkan bahawa faktor-faktor yang terlibat dalam 
penyelenggaraan telomer terlibat dalam patogenesis NPC. Pendekatan set laluan gen 
untuk mengenal pasti set gen yang berkait dengan NPC. Pendekatan kami 
menggabungkan data imput NPC GWAS dari populasi Cina Malaysia dan data ekspresi 
gen sedia ada GSE12452 dari kedua-dua tisu NPC dan nasofarinks sihat. Kami 
mengenal pasti perkaitan NPC dengan  Ontologi Gen (GO) kompleks “axonemal 
dynein” (PGWAS-GSEA=1.98x10-2; PExpr-GSEA=1.27x10-24; PBonf-Combined=4.15x10-21). 
Penemuan ini telah disahkan dengan data ekspresi gen tisu NPC dan nasofarinks sihat 
(PAmpliSeq-GSEA=1.37x10
-3). Kehilangan fungsi kompleks “axonemal dynein” 
menyebabkan rencatan fungsi silia, seterusnya mengakibatkan pengumpulan mukus dan 
seterusnya jangkitan di bahagian atas dan bawah saluran pernafasan, di mana jangkitan 
bahagian atas termasuklah salur udara nasofarinks. Pendekatan kami menunjukkan 
potensi kegunaan kaedah integrasi laluan dalam mengesan kumpulan gen yang terlibat 
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CHAPTER 1: INTRODUCTION 
 
Nasopharyngeal carcinoma (NPC) is an epithelial cell carcinoma on the mucosal 
lining of the nasopharynx. It is rare in most parts of the world (Feng, 2013). However, 
in certain regions where NPC is prevalent, it is a major health issue that requires 
immediate attention. In Malaysia, it is the fifth most common cancer among Malaysians 
and third most common among men according to the latest Malaysian Cancer Registry 
Report, 2007-2011 (Azizah et al., 2016).  It is particular prevalent among the Chinese as 
well as the indigenous tribe of Bidayuh people. NPC displays an enigmatic and 
multifactorial etiology, making effective treatment challenging. It is consistently linked 
to Epstein-Barr virus (EBV) infection, making it a viral-induced cancer. However, 
almost 95% of the world population is infected and they are healthy carriers of the EBV 
virus (Kutok & Wang, 2006). Not all EBV carriers develop NPC. Diet also strongly 
influences the onset of NPC. Consumption of Chinese-style salted fish has been 
strongly linked to NPC risk (Jeannel et al., 1999; Zheng et al., 1994). However, for 
Chinese immigrants in non-endemic regions (e.g. North America), the risk of NPC 
remains though at a much lower rate compared to their ancestors (Chang & Adami, 
2006). This proves that evolving lifestyles do not completely eradicate the risk of NPC 
and genetic factors could play an important role in NPC onset, especially for high-risk 
populations like the southern Chinese and its descendants. 
Several NPC GWAS have been reported, with the HLA-A gene continously 
being identified. However, most GWAS studies have yet to identify causal SNPs or 
annotate the functional implication of these polymorphisms. A NPC GWAS was 
performed to fine-map the HLA-A region in high resolution with focus on variants that 
either influence peptide loading or expression of the HLA-A. HLA-A variants with 
potential enhancer and promoter activity could affect differential binding affinity for 
 
2 
nuclear factors, consequently influence eQTL expression trends. In view of the high 
number of variants reported in the HLA-A or even the MHC region, it is imperative to 
identify the key variants driving the associations in the HLA-A region, while the 
remaining variants are mainly proxy association signals due to presence of linkage 
disequilibrium (LD).  
Genetic effects reported from single GWAS studies are generally small, causing 
suspicion of false positives (Chapman et al., 2011; Ioannidis et al., 2006; Moonesinghe 
et al., 2008). Therefore meta-analysis, the statistical analysis of pooling genetic effects 
across different GWAS studies is performed to increase the power of variants 
association and reduce false-positive findings. Meta-analysis is able to utilize summary 
data without resorting to sharing individual genotype data, overcoming restrictions on 
sharing individual-level data (Evangelou & Ioannidis, 2013). Therefore meta-analysis 
has become a popular approach for the discovery of new genetic loci for common 
diseases and phenotypes. This study was a collaborative effort between 1) Sun Yat-sen 
University Cancer Center, Guangzhou, China; 2) Chang Gung University, Taiwan; 3) 
University of Malaya, Kuala Lumpur, Malaysia; 4) Genome Institute of Singapore, 
Singapore. The study was coordinated by the Infections and Immunoepidemiology 
Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
Bethesda, Maryland.  
The search for NPC susceptibility genes have been limited to only single 
platform analysis, in particular GWAS or transcriptomics involving probe-based 
microarrays. Cross platform analysis has not been reported for NPC. There are 
limitations attached to single platform approaches. Firstly, GWAS and microarray 
expression studies report single gene associations, the former under very stringent 
multiple testing correction (Wang et al., 2010). Thus, causal loci with moderate effects 
will be missed. Secondly, complex diseases like NPC arise due to the interplay of 
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several genes (Chou et al., 2008). Single gene analysis would neglect the dynamics of 
gene sets or pathways leading to NPC development, thus ignoring potentially new 
insights pertaining to NPC etiology. By employing an integrated pathway approach 
combining GWAS SNP and gene expression data, dysregulated pathways with relevant 
function to nasopharyngeal carcinoma (NPC) can be identified. This approach moves us 
closer to identifying key pathways or genes affecting NPC. 
This study aims to achieve the following: 1) A genome-wide sweep of 712,717 
SNPs on the Illumina Human OmniExpress platform to identify NPC associated loci; 2) 
Imputation with HapMap, 1000 Genomes datasets and previously reported GWAS data 
(Ng et al., 2009a) to fine-map the HLA-A region; 3) High resolution molecular HLA-A 
allele genotyping to identify HLA-A alleles as well as its corresponding SNP genotypes; 
4) In silico prediction and amino acid variant analysis to identify functional 
associations; 5) Identify new loci outside of the major histocompatibility complex 
(MHC) region associated to NPC by pooling data across 4 NPC GWAS studies; 6) 














CHAPTER 2: LITERATURE REVIEW 
 
2.1 NPC diagnosis and classification 
Nasopharyngeal carcinoma (NPC) is an epithelial cell carcinoma on the mucosal 
lining of the nasopharynx. The nasopharynx is the uppermost part of the pharynx, 
behind the nasal cavity (Khoo & Pua, 2013). The epicenter of NPC begins at the Fossa 
of Rosenmüller and can spread in any direction to adjacent regions such as the nasal 
cavity, the oropharynx, the skull base, the parapahryngeal space or the retropharyngeal 
space (Figure 2.1). Spreading of NPC to different regions would manifest different 
symptoms. For example, when NPC spreads to the skull base, it leads to compression of 
cranial nerves, resulting in cranial nerve palsies. When NPC spreads to the cervical 
lymph nodes from the Fossa of Rosenmüller through the node of Rouvier, a neck lump 




Figure 2.1: Anatomical view of the nasopharynx and possible routes of local spread of 







2.2 NPC symptoms and method of diagnosis 
NPC typically portray atypical symptoms at early stages, making it difficult for 
clinicians to detect. Among the more common symptoms of NPC include appearance of 
neck lumps, nasal symptoms (blood stained nasal discharge, blood stained saliva, or 
nasal blockage), aural symptoms (unilateral blocked ear, pressure in the ear, mild 
hearing loss or tinnitus) and facial neurologic symptoms (unilateral facial numbness, 
diplopia or unilateral headache).  
The nasopharynx is located in an obscure position behind the nasal cavity, 
making visual examination challenging. Examination of this area is carried out with the 
aid of flexible fiber optic or rigid endoscope connected to a camera. NPC appears as a 
mass in the nasopharynx. Biopsies are taken to confirm the diagnosis of NPC. In cases 
where the NPC is a submucosal tumor, magnetic resonance imaging is used to locate the 
tumor and aid the biopsy. 
Serological methods are also useful for early detection of endemic NPC due to 
its close association with EBV infection. Elevated levels of the EBV-IgA-VCA 
antibody preceded the onset of NPC, with a window of about 3 years (Hao et al., 2003). 
Therefore, measuring the IgA antibody titers would be useful for early detection. IgA 
antibody titers to EBV viral capsid antigen (EBV-IgA-VCA) and EBV early antigen 
(EBV-EA) in immunofluorescent assays may be used for the serologic screening of 
NPC (Yi et al., 1980; Zeng et al., 1982). However, in recent years, immunofluorescent 
assays have largely been replaced with enzyme-linked immunosorbent assays (ELISA) 
employing purified recombinant EBV antigens (Nadala et al., 1996). These tests serve 





NPC classification is achieved through histopathological examination of the 
biopsy. The current classification system follows the WHO classification of 2005 (Chan 
et al., 2005) after many revisions from previous classification systems. The challenges 
of classifying NPC lie in lack of acceptance by pathologists because tumor gradations 
are not correlated with eventual treatment options. NPC is classified as keratinizing and 
non-keratinizing (Table 2.1). Non-keratinizing NPC is the pre-dominant type in 
endemic areas (Nicholls, 1997; Wei & Sham, 2005). A third type of NPC introduced by 
the WHO classification of 2005 is basaloid squamous cell carcinoma. As most NPC is 
detected at later stages where neck lumps appear, fine needle aspiration cytology of 
enlarged lymph nodes is performed to detect nodal spread. 
NPC staging is performed to evaluate extent of the cancer, determine prognosis 
and recommend treatment. Staging is deduced from information obtained from 
symptoms, physical examination, endoscopy, imaging of the tumor, lymph node spread 
and metastases (Edge et al., 2010). Imaging techniques employed in NPC staging 
include computerized tomography (CT), magnetic resonance imaging (MRI), chest X-
ray, ultrasound, bone scintigraphy and positron emission tomography (PET) scan (Khoo 
& Pua, 2013). Combination of techniques employed for NPC staging is dependent on 
cost, availability as well as the extent of NPC. As per recommendation by the National 
Comprehensive Cancer Network (NCCN), CT with contrast or MRI with gadolinium is 
performed for NPC imaging. For more advanced stages of NPC (Stage III-IV or distant 
metastasis) PET or CT is preferred (National Comprehensive Cancer Network, 2011). 
MRI is superior to PET/CT scan in imaging tumor spread in the areas adjacent to the 
epicenter, namely parapharyngeal space, base of the skull, intracranial area, sphenoid 
sinus and retropharyngeal lymph nodes (Liao et al., 2008). PET/CT scan is more 
superior in capturing distant metastatis (Lin et al., 2008; Ng et al., 2009b) to extent of 
replacing more conventional methods such as chest radiography, abdominal ultrasound 
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and bone scintigraphy (Liu et al., 2007). As such, using inferior imaging equipment 
would result in understaging of the disease. 
 The various symptoms that manifests during NPC progression is a consequence 
of the spread of the tumor. For example, nasal and aural symptoms suggest the tumor is 
still confined to the primary site of the nasopharynx (T1), neck mass suggests tumor 
spread to cervical lymph nodes (N1-3) while facial neurologic symptoms imply spread 
to the skull base (T4).   
 NPC staging follows the “tumor node metastasis” (TNM) staging system, jointly 
developed by The American Joint Committee on Cancer (AJCC) and the International 
Union Against Cancer (UICC) (Edge et al., 2010). The TNM staging describes the 
anatomy of the tumor, in which, T refers to the local extent of the primary tumor, N 
refers to the extent of regional nodes involvement and M refers to the distant spread 
(metastasis) of the tumor. The TNM scores are then combined to determine the overall 




Table 2.1: WHO histopathological classification of NPC (Edge et al., 2010). 
______________________________________________________________________ 
WHO Classification (2005)   Former Terminology (WHO 1998) 
Keratinizing carcinoma    WHO Type 1 
Nonkeratinizing carcinoma 
- differentiated     WHO Type 2 
- undifferentiated    WHO Type 3 
















Table 2.2: TNM clinical classification for tumors of the nasopharynx (Edge et al., 
2010). 
______________________________________________________________________ 
Primary Tumor (T) 
 T1 - Tumor confined to nasopharynx, or extends to oropharynx and/or nasal cavity without 
parapharyngeal extension 
 T2 - Tumor with parapharyngeal extension (posterolateral infiltration of tumor) 
 T3 - Tumor involves bony structures and/or paranasal sinuses 
 T4 - Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or 
with extension to the infratemporal fossa/masticator space 
 
Regional Lymph Nodes (N) 
 N0 - No regional lymph node metastasis 
 N1 - Unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the 
supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less, in 
greatest dimension 
 N2 - Bilateral metastasis in cervial lymph node(s), 6 cm or less in greatest dimension, above the 
supraclavicular fossa 
 N3 - Metastasis in a lymph node(s) greater than 6 cm and/or to supraclavicular fossa 
 N3a - Greater than 6 cm in dimension 
 N3b - Extension to the supraclavicular fossa 
 
Distant Metastasis (M) 
 M0 - No distant metastasis 
 M1 - Distant metastasis 
 
Clinical Stage Groups (Anatomic Stage/Prognostic Groups) 
Stage I: T1, N0, M0 
Stage II: T1, N1, M0; T2, N0, M0; T2, N1, M0 
Stage III: T1, N2, M0; T2, N2, M0; T3, N0, M0; T3, N2, M0 
Stage IVA: T4, N0, M0; T4, N1, M0; T4, N2, M0 
Stage IVB: Any T, N3, M0 
Stage IVC: Any T, any N, M1 
 
 
2.3 NPC treatment 
Radiotherapy remains the mainstay treatment for NPC. Radiation is typically 
concentrated on the adjacent skull base and nasopharynx. The control rate on 
conventional radiotherapy is 75 to 90% in T1 and T2 tumors, and 50 to 75% in T3 and 
T4 tumors (Wei & Kwong, 2010). The control of cervical nodal regions is achieved in 
90% of N0 and N1 cases, and about 70% of N2 and N3 cases (Wei & Kwong, 2010). It 
is mandatory to keep the treatment schedule because interrupted or prolonged treatment 
reduces the benefits of radiotherapy (Kwong et al., 1997). 
Recent studies conclude that the inclusion of chemotherapy to radiotherapy 
improves treatment outcome of NPC patients. Phase III randomized intergroup study 
0099 showed that patients treated with radiation alone had a significantly lower 3-year 
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survival rate than those receiving radiation with cisplatin and 5-fluorouracil 
chemotherapy (Al-Sarraf et al., 1998). Several meta-analysis reported a definite 
improvement of the 5-year survival rate due to the addition of chemotherapy (56% with 
radiotherapy alone versus 62% with chemoradiotherapy) (Baujat et al., 2006). 
Studies and clinical trials are ongoing to find the optimal treatment strategy for 
NPC. These include molecular targeted therapies in NPC, including the epidermal 
growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), epigenetic 
therapy, Epstein-Barr virus (EBV) directed immunotherapy and gene therapy (Hui & 
Chan, 2013). 
 
2.4 NPC epidemiology: Geographic origin 
NPC is a rare cancer in most parts of the world with the exception of certain 
endemic regions (Figure 2.2). In 2012, 87,000 cases of NPC were reported. However, 
this only made up 0.6% of all cancers reported that year (Ferlay et al., 2015). A 
whopping 71% of the 87,000 NPC cases came from highly prevalent regions in 
southern China, Hong Kong, Taiwan, Southeast Asia, Maghrebian countries in northern 
Africa (Algeria, Morocco and Tunisia) and the arctic and sub-arctic region of North 





Figure 2.2: Endemic regions of nasopharyngeal carcinoma occurence. Incidence rates 
at these regions record ASR of > 10 per 105 person-years. In non-endemic regions, NPC 
incidence is 0.5 per 105 person-years. 
 
The populations most affected by NPC are the southern Chinese, Amazigh- and 
Arabic-speaking North Africans and the Inuits (Feng, 2013). Zhongshan city of the 
Guangdong province in southern China reported one of the highest incidence rates of 
NPC, with age-standardized rates (ASR) of 26.9 per 105 person-years for males and 
10.1 for females (Curado et al., 2013). Similar ASRs were observed in neighboring 
cities like Hong Kong and Guangzhou (Curado et al., 2013). The majority of the 
population in these cities is Cantonese. Taiwan recorded a moderate NPC incidence rate 
of ASR 6.96 (Chiang et al., 2016). The inuits in Alaska, Canada and Greenland also 
show high rates of NPC with ASR was 12.1 for males and 7.3 for females (Kelly et al., 
2008). Magrebian countries of Tunisia and Algeria show moderate rates of NPC with 
ASRs of 5.4 and 4.6 per 105 person-years for males and ASRs of 1.7 and 1.9 for 
females (Curado et al., 2013). The incidence rate in other non-endemic countries is 0.5 
per 105 person-years with a general trend of higher incidence in males compared to 




The population of Southeast Asia is an admixed population of major southern 
Chinese dialect groups, namely the Cantonese, Hakka and Teochew people from 
Guangdong province and the Hokkien from Fujian province (Feng, 2013). The 
Cantonese has an NPC risk twice those of other dialect groups in China (Yu & Yuan, 
2002). Other populations showing moderate to high NPC incidence include the Thais, 
Vietnamese and Filipinos with ASRs ranging from 2.5 to 15 for males (Yu & Yuan, 
2002).  
In Malaysia, NPC is the fifth most common cancer among Malaysians and third 
most common among men (Azizah et al., 2016). A general trend is observed where 
NPC incidence is higher in males (ASR 6.4) than in females (ASR 2.2). The disease is 
particularly prevalent in the Chinese, with low incidences in the Malays and Indians. 
Malaysian Chinese record the highest incidence of NPC with ASRs of 11.0 in Chinese 
males and 3.5 in Chinese females (Azizah et al., 2016). The Malays record NPC 
incidence ASRs of 3.3 in males and 1.3 in females while the Indians show low 
incidence rates of ASR 1.1 in males and 0.6 in females (Azizah et al., 2016). A high 
risk of NPC has also been observed in Sarawak, particularly the indigenous tribe of 
Bidayuh people, with ASRs of 31.5 for males and 11.8 for females (Devi et al., 2004). 
The incidence rate for Bidayuhs is much higher than other ethnic groups living in 
Sarawak. Overall, the incidence rate of NPC in Malaysian Chinese, Malays and Indians 
is similar to that of neighboring Singapore (Azizah et al., 2016). NPC incidences in 
Malaysian males are elevated from age 25 years and peaks at age 65 years (Azizah et 
al., 2016). This is somewhat late compared to other high-risk Asian populations with 
peak incidence reported at the age of 45-55 years old (Bray et al., 2008). Most 
nasopharyngeal carcinoma cases detected in Malaysia were of Stage III and IV (Azizah 




Migration does influence the NPC incidence rate for people belonging to high-
risk areas. Immigrants from high-risk regions show higher incidence of NPC than the 
local population after moving to low-risk countries. This has been observed for Chinese 
immigrants in the USA, UK, Canada and Australia (Chang & Adami, 2006), Inuit in 
Denmark (Boysen et al., 2008) and North Africans in several European countries 
(Jeannel et al., 1999). However, the incidence rate tends to decrease with successive 
generations. The disparate NPC incidence rates among pioneering immigrants and 
successive generations points to the influence of environmental factors in NPC 
development. However, in multi-racial countries such as Malaysia and Singapore 
populated by successive generations of immigrants, NPC incidence rates remain high 
with little difference in incidence rates among the different ethnic groups, pointing to 
the probable influence of genetic factors as well as the continued practise of our 
ancestors’ lifestyle. NPC incidence from different populations is summarized in Figure 
2.3. 
 
2.5 Environmental factors 
2.5.1 Diet 
Consumption of preserved food has been constantly linked to NPC. A common 
factor that links NPC to its endemic regions is the low socioeconomic status, leading to 
high consumption of preserved food as a cheap form of sustenance (Jeannel et al., 
1999). Chinese-style salted fish is constantly linked to NPC among the Cantonese as 
well as Thais in South and South East Asia (Jeannel et al., 1999). Chinese-style salted 
fish is prepared by curing the fish in salt and then sun-dried. Other methods of food 
preservation are not linked to NPC. An example would be in among the Eskimos in 
Greenland where consumption of wind-dried and fermented fish is not associated with 





Figure 2.3: Nasopharyngeal carcinoma incidence worldwide. A comparison of NPC 
incidence between Malaysian Chinese and Malay against other populations. Incidence 
reported as age standardized rates (ASR). Image taken from Azizah et al. (2016). NPC 
incidence data taken from Azizah et al. (2016) and Curado et al. (2007).  
 
 
rare (Jeannel et al., 1999). In Thailand, 3 types of salted fish are consumed but only 
Chinese-style salted fish is linked to NPC (Sriamporn et al., 1992). Therefore, the 
consumption of salted-fish leading to risk of NPC is reliant upon the type of fish (salt 
water fish), method of preparation (salt-cured then sun-dried) and method of cooking 
(steamed salted fish) (Jeannel et al., 1999).  
 
14 
Other types of preserved food posing NPC risks are fermented fish sauce, salted 
shrimp paste, moldy bean curd, preserved plums, salted duck eggs, salted mustard 
green, dried fish, and fermented soy bean paste (Jeannel et al., 1999). The age of 
consumption of preserved food is also critical for NPC risks. Studies have shown that 
consumption of preserved food during weaning or childhood increases NPC risks as 
opposed to consumption only in adulthood (Jeannel et al., 1999). Preserved food 
elevates the risk of NPC because it contains volatile N-nitrosamines, namely N-
nitrosodimethylamine (NDMA), N-nitrosopyrrolidine (NPYR) and N-nitrosopiperidine 
(NPIP), compounds that are classified as probably or possibly carcinogenic to humans 
by the International Agency for Research on Cancer, better known as IARC 
(International Agency for Research on Cancer, 1978).  
The link between smoking and risks of NPC is less established. Smoking is 
linked to NPC in low-risk areas like North America (Chow et al., 1993; Mabuchi et al., 
1985; Nam et al., 1992; Vaughan et al., 1996; Zhu et al., 1997). It is linked to a 
particular histological type, namely differentiated NPC (Ou et al., 2007). However, in 
endemic regions, smoking is not linked or only confers moderate risk to NPC (Chen et 
al., 1990; Cheng et al., 1999; Friborg et al., 2007; Yuan et al., 2000). Alcohol 
consumption also shows mixed results when correlated with NPC onset. Most studies 
reveal no association between alcohol consumption and NPC with the exception of 
Malaysia (Armstrong et al., 1983) and the United States (Nam et al., 1992; Vaughan et 
al., 1996). The discrepant observation could be due to the small sample sizes of these 
studies, leading to conflicting results. Therefore, the relationship between smoking and 






2.5.2 Occupational exposures 
Occupational exposures can also elevate the risk of NPC. In a study evaluating 
occupational risk factors and its link to NPC in Hong Kong, exposure to cotton dust 
(OR=1.93; 95% CI=1.13-3.28), chemical fumes (OR=13.11; 95% CI=1.53-112.17), and 
welding fumes (OR=9.18; 95% CI=1.05-80.35) increased the risk of NPC (Xie et al., 
2017). Interestingly, formaldehyde was not linked to elevated NPC risk despite reports 
linking its exposure to NPC risks in non-endemic regions (IARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans, 2006; Xie et al., 2017). Inhalation of 
domestic fumes due to poor ventilation in kitchen or cooking with wood fire has also 
been linked with NPC (Chen & Huang, 1997; Yu et al., 1986; Zheng et al., 1994). 
 
2.5.3 Epstein-Barr virus (EBV) 
Epstein-Barr virus is a double-stranded DNA human herpes virus. Epstein-Barr 
virus has been repeatedly linked with NPC through clinical, epidemiological and 
experimental data (Gourzones et al., 2013). EBV infection is constantly linked with 
non-keratinizing NPC, the more prevalent form of NPC in endemic regions (Andersson-
Anvret et al., 1977; Nicholls et al., 1997) and this association transcends geographic 
origins. The EBV genome is constantly detected in epithelial cells but not lymphoid 
cells. It is interesting to note that despite repeated studies and clinical data reaffirming 
this association, EBV infection and NPC onset are not mutually exclusive occurrences. 
More than 95% adults in all ethnic groups through the world are healthy carriers of 
EBV (Kutok & Wang, 2006) and not all go on to develop NPC. Thus, interaction of 
EBV infection and host genetic factors play an important role in NPC onset. 
Once a subject has been primo-infected, EBV virus enters latency for long-term 
persistence. EBV in latent phase undergoes restricted expression of limited viral genes 
and production of viral particles is ceased. Circular viral genomes co-exist with the host 
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genome. In its latent state, EBV expresses several viral proteins or noncoding RNAs, 
most of them with the potential to contribute to apoptosis resistance or proliferation of 
the host cells. Latent proteins are either nuclear (called Epstein-Barr nuclear antigens: 
EBNA1, EBNA2, EBNA 3a,b,c, EBNA-LP) or associated to the cell membrane 
network (called latent membrane proteins : LMP1, LMP2 a and b) (Kutok & Wang, 
2006). The oncogenic function of key EBV latent proteins is discussed below. 
LMP1 is able to modulate the expression of key tumor suppressor genes by 
repressing p53-mediated apoptosis. This is achieved by inducing TNFAIP3/A20 that 
blocks p53-mediated apoptosis (Fries et al., 1996), activating MAPK/SAPK complex to 
modulate p53 expression through phosphorylation (Li et al., 2007) or by working 
together with Bcl-2 to override the growth suppression induced by wild-type p53 (Sheu 
et al., 2004). LMP1 is also capable of modulating the G1-S cell-cycle checkpoint. In 
epithelial cells, LMP1 down regulate p16INK4a and p21, and induces Cdk2 and cyclin 
D1, resulting in progression from G1 phase to S phase (Huang & Huang, 2003; Lo et 
al., 2004). 
There is little evidence to illustrate the oncogenic role of LMP2 in epithelial 
cells. The most prominent being its ability to activate the PI3-K/Akt pathway, which, in 
turn, affects cell survival, apoptosis, proliferation and genomic instability via its 
downstream target proteins to cause cancer (Allen et al., 2005; Fukuda & Longnecker, 
2007; Lu et al., 2006; Morrison & Raab-Traub, 2005; Scholle et al., 2000). 
EBNA1 is a EBV nuclear protein, consistently expressed in NPC cells and it 
was the first viral protein to be detected in this tumor (Huang et al., 1978). It is required 
in proliferating latently infected cells as a critical factor for the replication of the viral 
episomes and their balanced segregation in dividing cells (Sivachandran et al., 2011). 
BARF1 is an EBV oncoprotein that has oncogenic and anti-apototic effects in various 
types of epithelial cells (Seto et al., 2008; Wang et al., 2006; Wei et al., 1997). It is 
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speculated to be a decoy receptor for the m-CSF (Strockbine et al., 1998). M-CSF 
affects macrophages and monocytes in several ways, including stimulating increased 
phagocytic and chemotactic activity, and increased tumor cell cytotoxicity (Cohen & 
Lekstrom, 1999).  
Epstein-Barr encoded RNA or EBERs are small nuclear untranslated RNAs and 
they are the most abundant viral RNAs in NPC cells. EBERs have been linked to 
malignant phenotypes leading to oncogenesis. In vitro studies in B-lymphocyte (BL)-
derived Akata cells and immune-deficient mice have shown that EBER genes 
expression inhibit apoptosis (Komano et al., 1999; Ruf et al., 2000; Shimizu et al., 
1994; Yamamoto et al., 2000), induce IGF1, which acts as an autocrine growth factor 
for NPC cells (Iwakiri et al., 2003; Iwakiri et al., 2005). EBERs are also known to 
mediate pathogenesis by modulating innate immune signals. Through constitutive 
activation of RIG-I by EBERs, NFκB and IRF-3 are activated, subsequently induction 
of type-I IFN (Samanta et al., 2006). The induction of IFN induction appears 
disadvantageous for EBV, though it enables the virus to maintain a latent infection state 
because of resistance to IFN, which is provided by EBER-mediated PKR inhibition 
(Nanbo et al., 2002). 
Based on data and information currently available, a hypothesis is put forth 
suggesting EBV as a tumor promoting agent rather than an initiator. Nasopharynx 
epithelial cells with pre-existing molecular aberrations come in contact with EBV, 
establishing a latent infection. Over time, the EBV infected cells progress to severe 







2.6 Genetic factors 
2.6.1 Familial studies of NPC 
Familial studies or linkage analysis entails genotyping relatives and family 
members with a set or panel of genetic markers, calculating the linkage statistics and 
identifying the inherited genes predisposing to NPC among the affected relatives 
(Lander & Kruglyak, 1995). Two important designs of familial studies is affected sib-
pair (ASP) and extended pedigree analysis (Freimer & Sabatti, 2004). To date, four 
linkage studies of NPC have been reported where the linkage of 3p21 (Xiong et al., 
2004), 4p15-q12 (Feng et al., 2002), 5p13 (Hu et al., 2008), and 6p21 (Lu et al., 1990) 
were identified. 
The earliest linkage analysis was reported by Lu et al. (1990) using an affected 
sib-pair design, focusing on the HLA region due to previous reports linking HLA 
antigens to NPC risk in the Chinese (Chan et al., 1983; Simons et al., 1974; Simons et 
al., 1975). The study recruited 30 sibships from Guangxi and Hong Kong in China, 
Singapore and Malaysia and performed HLA typing using allelic typing antisera 
corresponding to HLA alleles (Lu et al., 1990). Results indicate a recessive 
susceptibility gene(s) with logarithm of odds for linkage (LOD) score +2.39 and P-
values 0.004. The HLA region confers an increased risk of 20.9 (95% CI = 5.1 to 
infinite) for NPC, which is around 10-fold greater than previously reported associations 
with HLA Bw46 or B17, suggesting the genetic lesion is HLA-linked but might be 
distinct from HLA Bw46 or B17 (Lu et al., 1990). 
The first extensive linkage study of NPC was done by Feng et al. (2002). The 
study utilized an extended pedigree design; with genome-wide microsatellite markers 
placed 10 cM apart covering 22 autosomes. This study examined members among 20 
high-risk Cantonese-speaking families in the Guangdong region. The study identified 
strong linkage to the D4S405 marker on chromosome 4p15–q12 with a logarithm of 
 
19 
odds (LOD) score of 3.06 (Feng et al., 2002). Fine mapping using denser microsatellite 
markers and SNPs pinpointed a smaller region of 8.29 cM in genetic length at 4p11–
p14 (Feng et al., 2002). 
Another linkage study using the extended pedigree design was reported by 
Xiong et al. (2004). The study recruited 18 high-risk NPC families of southern Chinese 
descent from the Hunan province and genotyping was performed using a less extensive 
panel covering only microsatellite markers on the short arms of chromosomes 3, 9, and 
4p15.1–q12. Locus 3p21.31–21.2 showed strong linkage to NPC through adjacent 
markers D3S3624 (LOD=4.177) and D3S1568 (LOD=3.922) (Xiong et al., 2004). 
Linkage of locus 4p15–q12 as reported by Feng et al. (2002) in the Guangdong Chinese 
families was not detected. 
The most recent linkage study was carried out by Hu et al. (2008) utilizing a 
pedigree design with a denser microsatellite marker distribution of 5cM apart. The study 
recruited 15 families from the Guangdong province. Initial analysis identified four loci 
on chromosomes 2q, 5p, 12p, and 18p showing LOD scores for linkage above 1.5. Fine-
mapping with additional markers only identified suggestive linkage at 5p13.1 with its 
corresponding marker D5S2021 showing a LOD score of 2.1 (Hu et al., 2008). 
 
2.6.2 Candidate gene approach 
Most candidate gene approaches employ a case-control study design to detect 
association to NPC. A case-control design is more suited to detect genes or loci 
prediposed to sporadic NPC cases rather than familial NPC. In addition, recruitment of 
samples is easier when extended pedigrees are unavailable. Association is determined if 
a variant, be it an allele, genotype or haplotype, shows a statistically significant bias or 
difference between the affected (in this case NPC patients) and unaffected (healthy 
controls). To rule out false associations, affected and unaffected samples are matched as 
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much as possible in terms of ethnicity, gender, age and other related covariates to 
minimize confounders. Candidate approach studies have identified many susceptible 
genes to NPC, many of which were driven by prior knowledge related to NPC 
carcinogenesis. Many genes associated with NPC are related to immune-related genes 
(HLA class I and II), carcinogenic metabolism (CYP2E1, CYP2A6, GSTM1, NAT2), 
DNA repair (XRCC1 and hOGG1, ERCC1, RAD51L1), cell cycle regulation (TP53, 
CCND1), immune response (TLRs, PLUNC, interleukins, FAS131), or EBV receptors 
(PIGR, TCR).    
 
2.6.3 Immune-related genes 
It is sensible to target immune-related genes as possible NPC susceptibility 
genes considering its EBV etiology. Studies were focused on the HLA antigen 
presenting molecules given its ability to elicit an immune response against viral 
infection. The first study reported NPC susceptible associations of HLA-A2 and -A11 in 
Singapore Chinese (Simons et al., 1974). Subsequent studies on the HLA-A2 have been 
consistent in detecting increased NPC risk in Chinese populations from Taiwan, 
southern China, and Singapore (Hu et al., 2005; Lu et al., 2003; Wu et al., 1989) though 
the same association was not detected in non-Chinese populations (Betuel et al., 1975; 
Burt et al., 1996; Herait et al., 1983; Mokni-Baizig et al., 2001; Moore et al., 1983; 
Zervas et al., 1983). The association of HLA-A11 confers protective effect towards NPC 
and this has been observed in Taiwan (Lu et al., 2003; Wu et al., 1989), Singapore 
(Chan et al., 1983; Ooi et al., 1997) and southern China (Hu et al., 2005). Another class 
I HLA antigen studied was the HLA-B. HLA-B13 conferred a protective effect in the 
Chinese of Taiwan (Hildesheim et al., 2002), Singapore (Chan et al., 1983) and 
southern China (Hu et al., 2005) but not in Caucasian (Moore et al., 1983) and 
Maghrebian populations (Herait et al., 1983). HLA-B46 conferred a risk effect towards 
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NPC in the Chinese of Singapore (Chan et al., 1983) and Taiwan (Hu et al., 2005). 
These early studies utilized the serological typing approach for the HLA allele typing. 
Subsequent HLA typing studies evolved with the emergence of polymerase 
chain reaction and sequencing technologies, giving rise to higher resolution HLA 
typing. HLA-A*0201 (Ren et al., 1995), HLA-A*0203 (Lu et al., 2003) and HLA*0207 
(Hildesheim et al., 2002) were linked to higher risk of NPC in the Chinese. HLA-
A*1101 confers a protective effect against NPC in Taiwanese Chinese (Hildesheim et 
al., 2002). HLA-B*4601 showed a protective effect to NPC in Thais (Pimtanothai et al., 
2002) and Taiwanese (Hildesheim et al., 2002). HLA-DRB1*03 and -DRB1*0301 were 
associated with NPC risk in Tunisian (Mokni-Baizig et al., 2001) and Taiwan Chinese 
(Hildesheim et al., 2002). 
Apart from the antigen presenting molecules, researchers also looked at 
immune-related cytokines and surface proteins on immune cells for NPC susceptibility 
genes. In the southern Chinese, certain interleukin variants conferred risk to NPC, such 
as IL1A (rs3783553, deletion allele) (Yang et al., 2011), IL1B (−511T) (Zhu et al., 
2008), IL2 (−330G) (Wei et al., 2010), IL8 (−251A) (Wei et al., 2007b), IL10 (−1082G) 
(Wei et al., 2007a), IL12 (rs3212227, C allele) (Wei et al., 2009), IL16 (rs11556218, G 
allele) (Gao et al., 2009), and IL18 (−137C) (Nong et al., 2009). In addition, toll-like 
receptors, a critical part of the innate immune surveillance also harbored variants that 
confer risk to NPC. For example TLR3 (829A>C) (He et al., 2007), TLR4 (11350G>C) 
(Song et al., 2006), TLR10 (haplotype GCGTGGC for rs10856837, rs11466651, 
rs11466652, rs11466653, rs11096956, rs11096955 and rs11466655) (Zhou et al., 
2006), DC-SIGN (−139A>G and −939G>A) (Xu et al., 2010), and CTLA-4 (+49A>G) 




Tumorigenesis encompass many genes and cascades of processes, culminating 
in uncontrolled cell division and growth, forming a malignant mass. Some genes related 
to the process were examined for the association with NPC. A case-control study in 
Nanning city, southern China evaluated associations of SNPs along Phosphatase and 
tensin homolog (PTEN) (rs11202592), v-akt murine thymoma viral oncogene homolog 
1 (AKT1) (rs3803300, rs1130214, rs3730358, rs1130233 and rs2494732), mouse double 
minute 2 (MDM2) and p53 (rs1042522) (Zhang et al., 2014). None of the single SNPs 
were associated with NPC risk. However, haplotype analyses indicated that a two-SNP 
core haplotype (rs1130233-A-rs2494732-A) in AKT1 was associated with a 
significantly increased susceptibility to NPC risk (adjusted OR  =  3.87, 95% CI  =  1.96-
7.65; P<0.001). Combined risk genotypes from 3-4 SNPs gave significantly increased 
susceptibility to NPC risk (adjusted OR  =  1.67, 95% CI  =  1.12-2.50; P = 0.012) 
 In Malaysia, Yew et al. (2012) conducted a case-control study on 447 NPC 
cases and 487 controls of Chinese descent. Results found association to NPC risk at 
SNP rs2752903 of SPLUNC1 (P=0.00032, odds ratio = 1.62, 95% confidence interval = 
1.25-2.11) (Yew et al., 2012). Functional analysis identified rs1407019 located in intron 
3 (r2=0.994 with rs2752903) caused allelic difference in the binding of specificity 
protein 1 (Sp1) transcription factor and affected luciferase activity (Yew et al., 2012). 
SPLUNC1 is believed to play a role in innate immune defense in the airway because of 









2.6.4 Metabolic genes  
NPC is heavily influenced by diet, particularly the consumption of salted fish 
containing high amounts of carcinogenic nitrosamines. Thus, research was focused on 
identifying variants in metabolic enzymes that function in metabolizing carcinogens. 
The CYP superfamily has been constantly studied for its relation to NPC susceptibility.  
The earliest report was carried out by Hildesheim et al. (1995) comparing CYP2E1 
RFLP digestion sites between 50 NPC cases and matched control samples in Taiwan. 
Homozygous carriers of the CYP2E1 DraI digestion showed a 5-fold risk of NPC (95% 
CI= 0.95-16) while homozygous carriers of CYP2E1 RsaI digestion conferred a 7.7-fold 
risk of NPC (95% CI=0.87-68) (Hildesheim et al., 1995). An extended study using 364 
NPC cases and 364 controls in a Taiwanese population linked CYP2E1 RsaI digestion 
to elevated NPC risk (relative risk [RR] = 2.6; 95% CI = 1.2-5.7) (Hildesheim et al., 
1997). Similar results were reported by a study investigating CYP2E1 polymorphism in 
Thailand where CYP2E1 RsaI polymorphism elevating NPC risk in the Thais (RR = 
1.51; 95% CI = 0.08-90.06) and Thai Chinese (RR = 1.99; 95% CI = 0.39-10.87). When 
combined, the ethnicity-adjusted odds ratio is 2.39 with 95% CI, 0.72-7.89 
(Kongruttanachok et al., 2001). A separate study from Thailand also reported elevated 
NPC risk for carriers of CYP2A6 mutants (*1B and *4C) when compared to wild type 
*1A/*1A (OR=2.37, 95% CI=1.27-4.46) (Tiwawech et al., 2006). 
More recent CYP typing utilizes high-resolution genotyping. A study in 
Guangdong, southern China employed both a family-based and case-control design to 
investigate CYP2E1 association between CYP2E1 and NPC susceptibility (Jia et al., 
2009). In the case-control analysis, 755 NPC cases and 755 controls were compared and 
SNP rs9418990, rs3813865, rs915906, rs2249695, rs8192780, rs1536826, rs3827688 
(OR=1.88-2.99; P<0.015) and haplotypes h2 with OR = 1.65 (P = 0.026), h5 
(CCCGTTAA) with OR = 2.58 (P = 0.007) were found to increase NPC risk (Jia et al., 
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2009). Recently, a meta-analysis combining previous case-control CYP2E1 NPC studies 
(Ben Chaaben et al., 2015; Guo et al., 2010; Hildesheim et al., 1995; Hildesheim et al., 
1997; Kongruttanachok et al., 2001; Lourembam et al., 2015) found association of 
RsaI/PstI polymorphism with NPC, however only under recessive and homozygote 
genetic models (OR = 2.72, 95% CI 1.73–4.25; OR = 2.64, 95% CI=1.68–4.16, 
respectively) (Yao et al., 2017). 
 
2.6.5 DNA repair genes 
Due to the notion that both EBV and environmental carcinogens may promote 
DNA damage (Frenkel, 1992; Gruhne et al., 2009), subsequently contributing to NPC 
carcinogenesis, association of the genetic variants of genes related to DNA repair and 
damage was widely studied. Cho et al. (2003) conducted a case-control study to 
investigate the genotypes of 334 NPC patients and 283 healthy controls in a Taiwanese 
population and found increased NPC risk for hOGG1 codon 326 genotypes of Ser/Cys 
and Cys/Cys compared with the Ser/Ser genotype (OR=1.6; 95% CI=1.0-2.6). For 
XRCC1 codon 280 genotypes of Arg/His and His/His compared with the Arg/Arg 
genotype, the OR was 0.64 (95% CI=0.43-0.96) (Cho et al., 2003). When high-risk 
genotypes for both hOGG1 and XRCC1 were combined, the OR was 3.0 (95% CI=1.0-
8.8) (Cho et al., 2003). Another study by Cao et al. (2006) found reduced risk of 
developing NPC in individuals with the Trp194Trp genotype (OR=0.48; 95% CI=0.27-
0.86). Further analysis stratified by gender and smoking status revealed a significantly 
reduced risk of NPC among males (OR = 0.32; 95% CI, 0.14-0.70) and smokers (OR = 
0.34; 95% CI=0.14-0.82) carrying the XRCC1 194Trp/Trp genotype (Cao et al., 2006). 
XRCC1 and hOGG1 associations were not replicated in the Maghrebian population of 
north Africa (Laantri et al., 2011). The XRCC1 Codon399 Gln/Gln allele may also be 
associated with better tumor regression (Zhai et al., 2016). A large scale case-control 
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study of XRCC3 in the southern Chinese found association of rs861539 and NPC risk 
under the recessive model (TT vs. CT + CC) (OR = 2.72; 95 % CI=1.10-6.72; P = 0.03) 
(Cui et al., 2016b). 
Yang et al. (2008) performed a case-control study in Sichuan province, southern 
China. The results identified ERCC1 SNP 8092 C>A, with 8092 C allele showing 
1.411-fold (OR = 1.411, 95% CI, 1.076–1.850, P = 0.014) increased risk of developing 
NPC (Yang et al., 2009). However, a separate study arrived at a contradictory 
conclusion. Patients with the ERCC1 SNP 8092 C/A or A/A genotype had an increased 
risk of disease progression on cisplatin-based chemotherapy (7.9 vs. 9.3 months; HR 
1.61; 95 % CI 1.08-2.61; P = 0.047) (Chen et al., 2013). 
 Lye et al. (2015) reported association of xeroderma pigmentosum group D 
(XPD) K751Q polymorphism to NPC risk. Subjects with homozygous Lys/Lys 
(wildtype) genotype have 1.58 times higher odds of developing NPC compared to 
subjects with recessive combination of heterozygous Lys/Gln and homozygous Gln/Gln 
genotypes (OR = 1.58, 95% CI = 1.05-2.38 p = 0.028) (Lye et al., 2015). 
 
2.7 Association studies in the age of genomics 
The widespread adoption of genomics and bioinformatics started after the 
completion of the first human genome draft in 2001 (Lander et al., 2001). Since then, 
the reference genome has gone through several revisions, and at the time of writing, it is 
currently on build GRCh38.p7. With the emergence of detailed genetic and physical 







2.7.1 The HapMap and 1000 genomes project 
The completion of the human genome project spurred the establishment of the 
HapMap (International HapMap Consortium, 2003, 2005) and 1000 genomes (1000 
Genomes Project Consortium, 2015; Sudmant et al., 2015) databases to catalog 
distribution of genomic variants in major populations in the world. The International 
HapMap project was established with the aim of mapping haplotypes and SNPs due to 
the presence of linkage disequilibrium (LD)- the co-inheritance of SNP alleles in 
haplotypes. This strong correlation between SNPs enables the genotyping of tag SNPs, 
representative SNPs that are able to provide enough information to predict much of the 
information about the remainder of the common SNPs in that region (Carlson et al., 
2003; Daly et al., 2001; Johnson et al., 2001). The pilot study recruited 270 DNA 
samples: 90 samples from a US Utah population with Northern and Western European 
ancestry (samples collected in 1980 by the Centre d’Etude du Polymorphisme Humain 
(CEPH) (49) and used for other human genetic maps, 30 trios of two parents and an 
adult child), and new samples collected from 90 Yoruba people in Ibadan, Nigeria (30 
trios), 45 unrelated Japanese in Tokyo, Japan, and 45 unrelated Han Chinese in Beijing, 
China (International HapMap Consortium, 2003). Genotyping was performed across 
different centers in Japan, China, Europe and the United States using various platforms, 
namely Thirdwave Invader Asssay, Illumina Beadarrays, Sequenom MassExtend, 
ParAllele MIP and PerkinElmer AcycloPrime-FP. This pilot effort identified 2.8 million 
SNPs (International HapMap Consortium, 2003). However, the HapMap project is 
currently superseded by the 1000 genomes project (1000 Genomes Project Consortium, 
2015; Sudmant et al., 2015), which remains the current reference database for SNPs, 




The 1000 genomes project set out to comprehensively catalog all forms of 
genomic variants using low-coverage whole-genome sequencing, deep exome 
sequencing, and dense microarray genotyping (1000 Genomes Project Consortium, 
2015; Sudmant et al., 2015). The project surveys the genomes of 2,504 individuals from 
26 populations. The 1000 genomes project improved upon the HapMap initiative by 
profiling a larger number of SNPs (80 million) in addition to structural variants such as 
deletion, insertion, CNV (1000 Genomes Project Consortium, 2015; Sudmant et al., 
2015). The larger number of samples also enable discovery of rare variants with 
frequency <0.5%. With the availability of the 1000 genomes haplotypes, a detailed and 
more comprehensive investigation of disease genes is made possible either through 
physical genotyping or in silico imputation methods (Browning & Browning, 2007; 
Browning & Browning, 2013, 2016; Howie et al., 2009; Howie et al., 2011; Howie et 
al., 2012; Marchini et al., 2007).  
 
2.7.2 Imputation 
Imputation is an in silico method to predict or impute genotypes that are not 
directly assayed in samples (Figure 2.4). This method takes into consideration the 
reference dataset in use, LD structure and the recombination rate (Marchini & Howie, 
2010; Marchini et al., 2007). The current recommended reference phased haplotypes are 
from the 1000 genomes project phase 3 data (1000 Genomes Project Consortium, 2015; 
Sudmant et al., 2015), with all phased haplotypes used for imputation rather than 
samples of the population in study (Delaneau et al., 2013a; Howie et al., 2011). 
Imputation is done using different algorithms, though more common methods in use 
currently are IMPUTE2 (Howie et al., 2009; Howie et al., 2011; Howie et al., 2012; 
Marchini et al., 2007) and BEAGLE v4.1 (Browning & Browning, 2007; Browning & 
Browning, 2013, 2016). Imputation is especially useful for fine mapping of a particular 
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region or for meta-analysis. In fine mapping, imputation allows a high-resolution view 
of an associated region with the possibility of finding the causal variant. As in the case 
of meta-analysis, when combining studies using different genotyping chips, very rarely 
do the variants overlap. To avoid direct genotyping of the missing variants, imputation 
is able to “fill-in” missing genotypes, thus combining analysis across different studies. 
This method not only can boost up the power of association but also uncover new 
genotypes. Though promising, the accuracy of imputation varies and is affected by 
factors such as variant density, frequency of variants (imputation fares poorly for rare 
alleles), recombination hotspots and LD structure. Therefore, it is imperative to evaluate 
imputation accuracy prior to selection for association analysis. IMPUTE2 uses an 
information measure (Howie et al., 2009) to assess post imputation accuracy while 
BEAGLE v4.1 relies on the R2 correlation (Browning & Browning, 2013). Variants that 
are genotyped in the GWAS can be masked and imputed to evaluate imputation 
accuracy (Marchini & Howie, 2010).  
 
 
Figure 2.4: Imputation work flow for genome-wide association studies (GWAS). 
Missing genotypes in the GWAS data set are ‘filled’ in by matching with the reference 
data set (e.g. the Hapmap or 1000 Genomes reference haplotypes). The existing 
genotypes on the GWAS data set act as reference points or markers to match the data 
set. The subsequent step of ‘filling in’ the missing genotypes is performed, taking into 
account the linkage disequilibrium (LD) and recombination rate of the target region. 




2.7.3 Genome-wide association studies (GWAS) 
GWAS is a large-scale association study, typically using a case-control 
approach, testing hundreds or even millions of SNPs concurrently to identify disease 
risk (Figure 2.5). The difference between GWAS and candidate gene approach is: 1) 
Candidate gene approach is hypothesis driven while GWAS is not - variants 
encompassing the whole genome is analyzed simultaneously; 2) Magnitude of variants - 
candidate approach usually studies limited variants on the genes of choice while GWAS 
screening can include up to millions of variants. GWAS screening can be performed 
either using a 2-tier or 3-tier design. The preliminary screening involves GWAS 
genotyping and association analysis followed either 1 or 2 separate replication cohorts. 
Replication is essential to identify variants showing a true association rather than by 
chance due to small sample size. Typically the selection of case and control subjects is 
crucial to avoid false positive associations. The case and control subjects ideally should 
be matched in terms of ethnicity, age and gender (McCarthy et al., 2008). Subjects 
showing population stratification or cryptic relatedness should be removed to avoid 
inflation of the type I error with the remaining spurious population structure to be 
corrected using genomic control (Zheng et al., 2006) or principal components (Price et 
al., 2006). Genotyping is performed using proprietary microarray platforms, with 
varying configuration of SNPs to best capture variants of a particular ethnicity or across 
different populations. Marker selection is based on data generated from the 1000 
genomes project, with tag SNPs selected to maximize coverage of all available variants. 
Association analysis adopts the frequentist method (McCarthy et al., 2008), 
sometimes including covariates such as age, gender, populations structure and lifestyle 
habits. Frequentists methods can also account for various genetic models: additive, 
dominant, recessive or even co-dominant models. Though accounting for different 
genetic models could enhance the association of some variants (Lettre et al., 2007), the 
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use of multiple genetic models also complicates computation of type 1 error rates by 
increasing the stringency of the multiple-testing threshold. This in turn reduces the 
number of potential disease loci and subsequent follow-up efforts. In addition, without 
confirmation of the causal function of SNPs, the adoption of genetic models at the 





Figure 2.5: The case-control genome-wide association study (GWAS) design. A. 
Polymorphic SNP sites in the genome. B. Association analysis is done using a case 
control design testing for association of SNPs on a genome-wide scale. C. Manhattan 





 To date, there are 2838 GWAS publications and 33353 unique SNP-trait 
associations reported (MacArthur et al., 2017), surpassing the genome-wide threshold 
of P≤5.0x10-8 (Hoggart et al., 2008). The introduction of GWAS has improved the 
understanding of genetic basis of particular diseases, for example type 1 (Hakonarson et 
al., 2007; Todd et al., 2007) and type 2 diabetes (Saxena et al., 2007; Scott et al., 2007; 
Sladek et al., 2007; Steinthorsdottir et al., 2007; Zeggini et al., 2007; Zeggini et al., 
2008), inflammatory bowel disease (Duerr et al., 2006; Hampe et al., 2007; Libioulle et 
al., 2007; Parkes et al., 2007; Rioux et al., 2007), prostate cancer (Eeles et al., 2008; 
Gudmundsson et al., 2007a; Gudmundsson, et al., 2007b; Gudmundsson et al., 2008; 
Thomas et al., 2008; Yeager et al., 2007) and breast cancer (Easton et al., 2007; Hunter 
et al., 2007; Stacey et al., 2007). Results from GWAS studies have confirmed 
previously hypothesized risk gene, though there are also instances whereby genes 
originally not thought to have a role in a given disease showed consistent association 
(Helgadottir et al., 2007; Klein et al., 2005; Moffatt et al., 2007; Rioux et al., 2007; 
Scott et al., 2007). The bulk of variants identified through GWAS falls in the low 
penetrance, high prevalence category (Manolio, 2010; McCarthy et al., 2008). In 
addition, most variants have modest effect sizes, with a median of 1.33 (Hindorff et al., 
2009). Many of the variants are situated in non-coding regions (Manolio, 2010), making 
functional interpretation difficult. It is suggested these GWAS signals could perhaps tag 
nearby causal variants. Perhaps, with the emergence of epigenetic initiatives like the 
ENCODE project (ENCODE Project Consortium, 2004; Kellis et al., 2014) and the 
Roadmap Epigenomics project (Bernstein et al., 2010), potential roles of intronic, and 
particularly intergenic regions in regulating gene expression can be identified. 
The transition from identifying genetic variants to understanding its functional 
relevance remains elusive. However, with the emergence of new and more affordable 
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technologies, it is hoped this gap can be bridged, paving the way for widespread 
adoption of genomics in a clinical setting. 
 
2.7.4 GWAS in NPC 
To date, there are 6 GWAS studies conducted on NPC (Bei et al., 2010; Chin et 
al., 2015; Cui et al., 2016a; Ng et al., 2009a; Tang et al., 2012; Tse et al., 2009). The 
details of the Malaysian GWAS published in 2015 (Chin et al., 2015) will be discussed 
in detail in subsequent chapters of this thesis. Thus it will be omitted from discussion at 
this point. All the GWAS studies are concentrated in the Chinese population, be it from 
southern China, Taiwan or Malaysian Chinese. Previous studies have indicated the 
sporadic nature of NPC, involving multiple genetic variants, each with low penetrance.  
The first GWAS of NPC was carried out in the Malaysian Chinese using a 2-tier 
case-control design (Ng et al., 2009a). At the discovery stage, 111 NPC cases and 260 
unrelated controls were genotyped at the genome-wide scale of 533,048 SNPs. The top 
200 GWAS SNPs were replicated in a separate set of 168 cases and 252 controls. The 
combined analysis identified a SNP in intron 3 of the ITGA9 (integrin-alpha 9) gene, 
rs2212020, is strongly associated with NPC (P=8.27x10-7, OR=2.24, 95% CI=1.59-
3.15). Fine mapping of the surrounding region was also done, genotyping an additional 
19 tag SNPs within a 40-kb linkage disequilibrium (LD) block surrounding rs2212020. 
SNP rs189897 was identified, showing improved an improved association to NPC risk 
(P=6.85x10-8, OR=3.18, 95% CI=1.94-5.21). ITGA9 encodes a subunit of integrin, 
which mediates many biological processes such as cell-cell adhesion, proliferation, 
apoptosis, and differentiation (Birkenbach et al., 1992; Lin et al., 1997; Stewart & 




At about the same time, a separate GWAS study was conducted in Taiwan, 
using a 3-tier case-control design (Tse et al., 2009). The discovery stage recruited 277 
NPC patients and 285 healthy controls, analyzing 480,365 single-nucleotide 
polymorphisms (SNPs). This identified 12 statistically significant SNPs at the 6p21.3 
region. The GWAS signals were replicated in 2 independent sets of case-controls 
(replication 1=339 NPC-696 controls; replication 2=296 NPC-944 controls). The results 
identified SNPs in the following genes: 1) rs2517713 (P=3.9x10-20) and rs2975042 
(P=1.6x10-19), located downstream of the HLA-A gene; 2) rs29232 (P=8.97x10-17) 
gamma aminobutyric acid b receptor 1 (GABBR1); 3) rs3129055 (P=7.36x10-11) and 
rs9258122 (P=3.33x10-10) on HLA-F. rs29232 retained its association (P<5x10-4) after 
adjustment with HLA-related SNPs, proving its association to be independent and not 
correlated with HLA SNPs. Immunohistochemical staining of NPC biopsies showed 
that the expression of GABBR1 protein in tumor cells was significantly higher than that 
in adjacent normal epithelial cells (P<0.001). GABA may affect cancer growth through 
activation GABA receptors (Zhang et al., 2013). 
Bei et al. (2010) reported a large NPC GWAS from populations of southern 
Chinese descent. A 2-tier case control desgin was employed, supported by a trio linkage 
study. The discovery stage recruited 1,583 NPC cases and 1,894 controls, analyzing 
464,328 autosomal SNPs. The top 49 SNPs from the GWAS were replicated in 3,507 
cases and 3,063 controls of southern Chinese descent from Guangdong and Guangxi. 
The seven SNPs showing genome-wide association significance (P≤5.0x10-8) were 
further confirmed by transmission disequilibrium test analysis in 279 trios from 
Guangdong. This study identified three new susceptibility loci, TNFRSF19 on 13q12 
(rs9510787, P=1.53x10−9, OR=1.20), MDS1-EVI1 on 3q26 (rs6774494, P=1.34x10−8, 
OR=0.84) and the CDKN2A-CDKN2B gene cluster on 9p21 (rs1412829, P=4.84x10−7, 
OR=0.78) (Bei et al., 2010). The study also confirmed the association of HLA by 
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revealing independent associations at rs2860580 (P=4.88x10−67, OR=0.58), rs2894207 
(P=3.42x10−33, OR=0.61) and rs28421666 (P= 2.49x10−18, OR=0.67) (Bei et al., 2010). 
TNFRSF19 encodes a member of the TNF receptor superfamily (Hu et al., 1999), and 
when overexpressed, activates the c-Jun N-terminal kinase (JNK) pathway and induces 
caspase-independent cell death (Eby et al., 2000). EVI1 can suppress the effect of 
transforming growth factor (TGF)-β on growth inhibition, which in turn promotes tumor 
growth. EVI1 can also protect cells from stress-induced cell death by inhibiting c-JNK 
(Kurokawa et al., 2000; Nitta et al., 2005). Fusion of EVI1 with MDS1 impairs its 
capacity to repress TGF-β signaling (Nitta et al., 2005). Presence of SNPs in the MDS1-
EVI1 might interrupt the balance between EVI1 and MDS1, and subsequently the 
regulation of (TGF)-β. CDKN2A and CDKN2B are known tumor suppressor genes 
(Krimpenfort et al., 2007; Sharpless et al., 2001). 
A separate GWAS was conducted by Tang et al. (2012) from Guangxi Zhuang 
Autonomous Region and Guangdong province of southern China. In this study, the 
authors focused on the amino acid variants of the HLA class I genes, complementing 
GWAS results with HLA class I typing. The results identified strong association signals 
involving SNPs, HLA alleles, and amino acid (aa) variants across the major 
histocompatibility complex-HLA-A (PHLA-A-aa-site-62 = 7.4x10−29), HLA-B (PHLA-B-aa-site-
116 = 6.5x10−19), and HLA-C class I genes (PHLA-C-aa-site-156 = 6.8x10−8) (Tang et al., 2012). 
Multivariate logistic regression of adjacent regions found that all association signals 
were driven by effects of HLA- A*11:01, HLA-B*13:01, B*38:02 and B*55:02 (Tang et 
al., 2012). The strong association of amino acid variants implicate specific class I 
peptide recognition motifs in HLA-A and -B peptide binding groove as conferring strong 




The latest NPC GWAS study by Cui et al. (2016a) is an extension of the GWAS 
reported by Bei et al. (2010). The study recruited samples of southern Chinese ancestry, 
and the GWAS was done using a 3-tier case-control design. The discovery stage 
consisting of 463,250 SNPs in 1,583 NPC cases and 2,979 controls of southern Chinese 
ancestry revealed 1,257 top SNPs to be associated with NPC, which were validated in a 
separate case-control set of 1,925 NPC cases and 1,947 controls of southern Chinese 
(Cui et al., 2016a). Further 11 SNPs were selected for another independent validation in 
3,538 NPC cases and 3,644 controls of southern Chinese giving a total set of 7,046 NPC 
cases and 8,570 controls. This study found associations with genome-wide significance 
(P≤5.0x10−8) at TERT-CLPTM1L at chromosome 5p15 (rs401681; P=2.65x10−14; OR = 
0.82) and CIITA at chromosome 16p13 (rs6498114; P=4.01x10−9; OR=0.87) (Cui et al., 
2016a). CLPTM1L and TERT have been implicated in cancers (Blasco, 2005; James et 
al., 2014) and CIITA is considered as the “master control factor” for the expression of 
NPC-associated MHC class II genes (Steimle et al., 1993). Table 2.3 summarizes all the 
NPC GWAS studies reported to date. 
 
2.7.5 Meta-analysis of NPC GWAS studies 
There are several approaches to GWAS meta-analysis (Cooper et al., 2009), the 
most commonly adopted method being the fixed effects (Pfeiffer et al., 2009) or random 
effects method (Pereira et al., 2009). Fixed effects meta-analysis assumes that the true 
effect of each risk allele is the same in each data set. In other words, fixed effects is 
used when there is no heterogeneity across meta-analysis studies. Fixed effects method 
employs inverse variance weighting (Kavvoura & Ioannidis, 2008) to weight genetic 
effects across different studies. Each study is weighted according to the inverse of its 
squared standard error (Zeggini & Ioannidis, 2009). Random effects method is used 
when there is probable between-study heterogeneity (Ioannidis et al., 2007; Pereira et 
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al., 2009). The most popular estimator used is the DerSimonian and Laird estimator 
(DerSimonian & Laird, 1986), though many other approaches do exist. Weighting of 
genetic effects also use the inverse variance method. The bayesian method is another 
alternative method for meta-analysis. However, bayesian models may depend on 
assumptions made about the prior distributions of parameters of interest, and their 
genome-wide implementation can become computationally intensive (Evangelou & 
Ioannidis, 2013). 
Nasopharyngeal carcinoma (NPC) is linked to Epstein-Barr virus (EBV) 
infection. While EBV infection is ubiquitous, NPC incidence varies considerably 
around the world (Chang & Adami, 2006). It is hypothesized that genetic differences 
across populations partly explain the predisposition of this cancer to individuals of 
Southeast Asian descent. Several lines of evidence support a role for genetic 
susceptibility in NPC. The disease clusters within families (Chang & Adami, 2006). 
Also, numerous studies have implicated polymorphisms in candidate genes in NPC (Bei 
et al., 2012; Hildesheim & Wang, 2012). The most consistent evidence has been for an 
association between HLA and NPC, an association that is biologically plausible given 











Many major GWAS meta-analyses have been published thus far, though not for 
NPC. Several NPC GWAS have recently been published (Bei et al., 2010; Chin et al., 
2015; Ng et al., 2009a; Tang et al., 2012; Tse et al., 2009); all provided support for the 
importance of genetic factors and clearly confirmed the involvement of genes in the 
MHC region (region where HLA genes reside) in NPC. Associations outside the MHC 
were also reported from these GWAS but were not as strong or consistent, suggesting 
the need for pooling across studies and larger efforts to identify novel genes involved in 
this disease (Bei et al., 2010; Chin et al., 2015; Ng et al., 2009a; Tang et al., 2012; Tse 
et al., 2009). 
 
2.7.6 Pathway analysis of NPC GWAS studies 
Pathway or ‘gene-set’ analysis on GWAS has been gaining traction of late. 
However, this approach has not been popular for NPC, with only two candidate gene 
approaches implicating DNA repair (Qin et al., 2011) and TERT-CLPTM1L (Yee Ko et 
al., 2014) pathways in NPC etiology.  Pathway analysis is appealing as it tests the 
cumulative association for gene sets of related function without the constraints of 
stringent multiple testing threshold. The inclusion of genes or loci with moderate to 
small effects better represent the gene interaction dynamics of NPC. This study aims to 
identify aberrant pathways associated to NPC in both GWAS and gene expression 
platforms. Pathway analyses employ either a competitive or self-contained hypothesis 













Table 2.3: Summary of NPC association results based on GWAS studies. 
 



















































































































































































































































































































(Ng et al., 
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CHAPTER 3: METHODOLOGY 
 
3.1 Methodology for NPC GWAS study 
3.1.1 Study cohort 
NPC patients were recruited from University Malaya Medical Centre (UMMC), 
Tung Shin Hospital, Kuala Lumpur General Hospital (HKL), Penang General Hospital 
(HPP), Nilai Cancer Institute Hospital (NCI), Hospital University Sarawak (HUS) and 
Queen Elizabeth Hospital Sabah (QES). All cases were histo-pathologically diagnosed 
according to the World Health Organization (WHO) classification. All healthy controls 
were blood donors recruited from the UMMC blood bank with no familial history of 
cancer. All NPC patients and healthy control samples were unrelated self-reported 
Malaysian Chinese of Southern Chinese descent. All participants gave their written 
informed consent. The study was approved by the ethics committee of RIKEN, 
Yokohama, Japan and UMMC as well as the Ministry of Health, Malaysia. The 
genome-wide analysis was performed using a GWAS cohort of 193 NPC patients and 
260 healthy controls followed by a second replication cohort of 260 NPC patients and 
245 healthy controls.  
 
3.1.2 Genotyping of SNPs and statistical analysis 
Genomic DNA was extracted from the peripheral leukocytes using well 
established phenol-chloroform methods (Ausubel et al., 1987). GWAS genotyping was 
performed by the Laboratory for Genotyping Development at RIKEN Center for 
Integrative Medical Sciences, Yokohama using the Illumina HumanOmniExpress_12 
v1.1 Beadchips (San Diego, CA, USA). Quality control removed 9 NPC patients and 24 
healthy controls due to gender mismatches, cryptic relatedness or were outliers of the 
study population. Principal component analysis (PCA) indicated that NPC patients and 
controls were genetically matched, with minimal evidence of population stratification.  
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For SNP quality control, 137,470 SNPs were excluded where 29,876 SNPs had call 
rates < 99%, 107,589 SNPs had minor allele frequency (MAF) < 1% (74,883 SNPs 
were mono-allelic) and 5 SNPs showed significant deviation from Hardy-Weinberg 
equilibrium (HWE) in controls (P<1.0x10-6). A total of 575,247 autosomal SNPs passed 
quality control in a GWAS cohort of 184 NPC patients and 236 healthy controls. 
Validation of the GWAS genotyping results as well as genotyping of replication 
samples were performed using multiplex-PCR-based invader assay (Third Wave 
Technologies, Madison, WI, USA). The same quality control measures as the genome-
wide analysis were applied but with more stringent HWE thresholds in controls 
(P<0.05). Genotyping of previously reported GWAS SNPs from Ng et al. (2009a), Tse 
et al. (2009), Bei et al. (2010), Tang et al. (2012) were performed in the same manner. 
The quantile-quantile plot (Q-Q plot) of trend test was generated using R (https://cran.r-
project.org/) to evaluate overall association of GWAS and presence of population 
stratification inferred through genomic control inflation factor (λgc). The Manhattan plot 
of –log10(PGWAS) for autosomal SNPs was generated using Haploview (Barrett et al., 
2005). The genome-wide association analysis was performed in PLINK (Purcell et al., 
2007) using multivariate logistic regression assuming an additive model (0, 1, 2 allele 
dosage coding for minor allele) adjusting for age, gender and the first principal 
component (PC1). Only PC1 was estimated to be significant by the Tracy-Widom 
statistic (P<0.05). Odds ratios (OR) and 95% confidence intervals (95% CI) were 
calculated per risk allele assuming an additive model. SNPs were ranked in order of the 
lowest P-value. Association of previously reported GWAS SNPs from Ng et al. 







Imputation of all HLA-A region SNPs were performed using IMPUTE (Marchini 
et al., 2007) utilizing HapMap 2 (CHB & JPN), HapMap 3 Mixed Population, 1000 
Genomes Asian population and previously reported GWAS data (Ng et al., 2009a). 
SNPs showing MAF ≥ 1%, imputation power (INFO) > 0.5 and imputation confidence 
(CERTAINTY) > 0.9 were selected for validation and replication through multiplex-
PCR-based invader assay (Third Wave Technologies, Madison, WI, USA). Statistical 
analysis and quality control measures were performed similar to the GWAS analysis. 
 
3.1.4 HLA-A SNP and amino acid variants analysis 
HLA-A genotyping was carried out using a WAKFlow HLA typing kit and the 
data was analyzed using the WAKFlow HLA typing software (Wakunaga, Hiroshima, 
Japan). We mapped HLA-A SNPs and amino acid variants referencing the HLA-A sub-
type sequences from dbMHC using the WAKFlow HLA-A typing data 
(www.ncbi.nlm.nih.gov/projects/gv/mhc/). Statistical analysis and quality control 
measures for HLA-A alleles and HLA-A single SNPs were performed in PLINK similar 
to the GWAS analysis. For multi-allelic SNPs and amino acid variants, statistical 
analysis was performed in R employing a Fisher’s Exact Test in R x C contingency 
table. OR and 95% CI were calculated with reference to the major allele. To identify 
LD-driven associations, Multivariate logistic regression was used to adjust for the 
additive effects of both HLA-A single SNPs and HLA-A alleles, entered as 0, 1, 2 allele 
dosage coding. The coded allele was either the minor allele of a HLA-A SNP, a carrier 
allele of a HLA-A allele or the rare amino acid variant. Same approach was used to 
analyse multi-allelic SNPs by only considering the strongest bi-allelic or 
damaging/deleterious combination. All P-values were also adjusted for age, gender and 
PC1. Corresponding function of amino acid residues were annotated with reference to 
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the Immunology Database and Analysis Portal (ImmPort) system 
(immport.niaid.nih.gov/). Functional impact of HLA-A gene SNPs were annotated using 
PROVEAN (Choi et al., 2012), SIFT (Kumar et al., 2009) and Polyphen-2 (Adzhubei et 
al., 2010) prediction scores. Variants were deemed damaging or deleterious if predicted 
in 2 out of 3 of the annotation methods. 
 
3.1.5 Regulatory functions of NPC associated HLA-A SNP variants 
HaploReg (Ward & Kellis, 2012) was used to predict 5’-UTR HLA-A SNP 
variants with function related to transcription regulation. SNP variants were annotated 
to locate epigenetic functions related to i) enhancer (H3K4me1 and H3K27ac histone 
modification) or promoter activity (H3K4me3 histone modification) ii) DNase I enzyme 
hypersensitivity (suggestive of a regulatory region) iii) Protein or transcription factor 
binding iv) Regulatory motif changes as predicted from Position Weight Matrices 
(PWM) of TRANSFAC (Matys et al., 2003), JASPAR (Portales-Casamar et al., 2010) 
and protein-binding microarray experiments (Badis et al., 2009; Berger et al., 2008). 
Strength of regulatory motif binding is inferred by log-of-odds (LOD) of reference and 
alternate alleles. We investigated effects of SNP genotypes on HLA-A expression 
through expression quantitative trait loci analysis (eQTL) data obtained from the Sanger 
Institute Genevar Database (Yang et al., 2010) using fibroblasts, LCLs and T cells 
derived from the umbilical cords from the Geneva GenCord (Dimas et al., 2009) dataset 
and adipose, LCLs and skin tissues from the MuTHER resource (Nica et al., 2011) 
dataset. A cis-eQTL is defined as a SNP located within 2Mb region of the gene of 
interest, in our case the HLA-A gene, with significant Spearman-rank correlation 





3.2 Methodology for meta-analysis of NPC GWAS 
3.2.1 GWAS data for meta-analysis 
The GWAS contributing to the meta-analysis included histologically confirmed 
NPC cases and region-specific controls restricted to individuals of Chinese ethnicity 
(Table 3.1) (Bei et al., 2010; Chin et al., 2015; Ng et al., 2009a; Tang et al., 2012; Tse 
et al., 2009). GWAS genotyping was performed by the Laboratory for Genotyping 
Development at RIKEN Center for Integrative Medical Sciences, Yokohama. 
Genotyping for the Malaysian GWAS was performed using Illumina Hap550v3 
Beadchip and Illumina Human OmniExpress_12 v1.1 Beadchip. Both Malaysian 
GWAS were analyzed as one. All data included passed QC filtering criteria as described 








       Table 3.1: Summary of studies included in the meta-analysis (Bei et al., 2016). 
 
Phase Reference Location Genotyping platform Cases Controls 
GWAS Bei et al., 2010 Southern China Illumina Hap610 1,583 2,979 
GWAS Tse et al., 2009 Taiwan Illumina 600 Hap550v3 Beadchips 277 285 
GWAS Ng et al., 2009 Malaysia 1 Illumina Hap550v3 Beadchip 108 240 
GWAS Chin et al., 2015 Malaysia 2 Illumina Human OmniExpress_12 v1.1 Beadchip 184 236 
GWAS-
SUM 
   2,152 3,740 
Replication I  Southern China I Sequenom custom array 3,525 4,121 
Replication I  Malaysia Sequenom custom array 335 405 
Replication I  Taiwan I Sequenom custom array 352 312 
Replication I  Taiwan II Sequenom custom array 504 541 
Rep I - SUM    4,716 5,379 











3.2.2 Imputation to combine GWAS SNPs 
To maximize coverage across studies, genome-wide imputations were 
performed for both Malaysian NPC GWAS studies using typed SNPs. SNPs with call 
rates >90%, minor allele frequencies >3%, and that had genotype distributions that did 
not deviate from the expected by Hardy-Weinberg equilibrium (in controls; P>10-6) 
were retained for imputation using IMPUTE2 (Howie et al., 2009). HapMap reference 
data were used (HapMap phase III, CHB+CHD+JPN data). Imputated genotypes with 
information score <90%, MAF <3%, or missing >10% were excluded. GTOOL 
(http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html) was used for data 
conversions. 
 
3.2.3 Statistical analysis 
For each GWAS, SNPs were analyzed by logistic regression under a log 
additive model, adjusting for age and cryptic population stratification. To define 
population stratification adjustment factors, principal component analysis was 
performed using EIGENSTRAT (Price et al., 2006) with a pruned set of 30,956 SNPs 
defined based on pairwise linkage disequilibrium (r2 < 0.05 among Chinese) and 
restricted to SNPs with MAF >3%. The top 10 eigenvectors were evaluated for their 
association with NPC (separately for each individual GWAS) and included in the final 
logistic models if P-value <0.05 by the Wald test.  
Using results from individual GWAS, the 500 SNPs with the lowest P-values 
from each of the studies were identified after exclusion of SNPs that could not be 
imputed or failed QC filtering. These study-specific lists of top-SNPs were combined 
into a single list for consideration as part of the present meta-analysis. In total, 1,590 
SNPs were identified through this process and these 1,590 SNPs comprised the basis for 
the present meta-analysis. Summary statistics (number cases/controls, genotype counts, 
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β-coefficients, and SDs) were obtained from individual studies for selected SNPs and a 
meta-analysis was performed using a fixed effects model in R (https://cran.r-
project.org). The merging of post-imputation data from individual GWAS was 
performed by the Biostatistics Branch, Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, Maryland. 
 
3.2.4 Replication of meta-analysis targets 
SNPs were selected for replication as follows. The top 200 hits (all with P-
values <0.0167) from the meta-analysis for which the direction of the association was 
consistent across all individual studies were arbitrarily ranked by P-value. These 
selected SNPs with P-values <1x10-5 were 250 kb+ from other selected SNPs. For SNPs 
within 250kb of another SNP on the list, the SNP with the smaller P-value when the r2 
between SNPs was >0.80 were retained (r2 based on Chinese population from the 1000 
genomes project). Thirty SNPs were selected based on these criteria. A further 14 SNPs 
nominated by consortium members were added based on results from individual GWAS 
and other information from candidate-based studies and other studies in the published 
literature. One SNP that qualified based on the criteria above but failed in the design of 
the custom array described below was excluded (rs11865086). A second SNP that 
qualified but failed in the custom array design (rs6931820) was replaced with a SNP in 
strong LD with the original SNP (rs1324103; r2=0.88). In total, 43 SNPs were evaluated 
in the replication phase in the Malaysian samples. 
Replication studies were restricted to studies among individuals of Chinese 
descent. All four studies were hospital-based, recruiting NPC cases from selected 
hospitals in their respective geographical area. From Malaysia, 335 cases and 405 
controls were recruited for the replication phase. Cases were recruited from the 
University of Malaya Medical Center (Kuala Lumpur, Malaysia) and from a network of 
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additional hospitals across the country. For the southern China study, cases were 
recruited from the Sun Yat-Sen University Cancer Center (Guangzhou, China) and the 
Southern Medical University Hospital. For the Malaysia study, For the two Taiwan 
studies, cases were recruited form the National Taiwan University (Taipei, Taiwan) and 
MacKay Memorial hospitals and from the Chang Gung Memorial and Linkou hospitals, 
respectively. Cases were restricted to adults with histologically confirmed NPC. 
Geographically matched controls of Chinese descent were frequency (southern China, 
Malaysia, and Taiwan II studies) or individually (Taiwan I study) matched to cases on 
age and gender. Controls did not have a history of NPC diagnosis. Studies were 
reviewed/approved by ethical committees and informed consent was obtained from 
participants. In total, 4,716 cases and 5,379 controls across four case–control studies in 
Mainland China, Malaysia, and Taiwan were recruited for the meta-analysis (Table 3.1). 
A custom designed array containing the 43 SNPs selected for replication was 
developed using the Sequenom MassARRAY iPlex assay. To ensure comparable 
quality across laboratories, a common QC panel consisting of 94 HapMap samples was 
tested. Percent agreement across laboratories for the 43 SNPs tested was 97% (range: 
82%–100%; agreement was >85% for all but two SNPs: rs189897 and rs4714505). 
To analyze the replication studies, individual genotyping results were pooled 
and an additive logistic regression model used to evaluate the effect of each SNP, 
adjusting for study. To summarize information across the GWAS and replication 
studies, a meta-analysis was conducted using the fixed effect model to integrate 
estimates from all studies. As for the meta-analysis merging both GWAS and 
replication association data across different study groups, the analysis was performed by 
the Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National 




3.3 Methodology for integrated pathway analysis of NPC 
3.3.1 NPC GWAS data 
Samples for this study were from previous NPC GWAS studies generated on the 
Illumina HumanHap 550K and Illumina Human OmniExpress_12 v1.1 platform in a 
Malaysian Chinese cohort (Chin et al., 2015; Ng et al., 2009a). The details of sample 
recruitment, quality controls and patient consent have been described elsewhere (Chin 
et al., 2015; Ng et al., 2009a). Briefly, SNPs with call rates >99%, minor allele 
frequency (MAF) >1% and minimal Hardy–Weinberg equilibrium (HWE) deviation in 
controls (P>1.0x10-6) were retained. Samples were retained after removing gender 
mismatches, cryptic relatedness and outliers in the study population. Principal 
component analysis (PCA) was performed to adjust for population structure and to 
identify outliers using EIGENSOFT (Patterson et al., 2006) package in a pruned set of 
76,181 overlapping SNPs (r2<0.2) from both Illumina HumanHap 550K v3 and Human 
OmniExpress_12 v1.1. The study cohort after quality control are as follows: (1) 
Illumina HumanHap 550K v3 platform, 441,812 autosomal SNPs were retained in 108 
NPC patients and 240 healthy controls; (2) Illumina Human OmniExpress_12 v1.1 






3.3.2 Imputation and combining GWAS datasets 
Both Illumina HumanHap 550K and Illumina Human OmniExpress_12 v1.1 
datasets were phased using SHAPEIT v2 release 7 (Delaneau et al., 2013b) prior to 
imputation. Imputation was performed using IMPUTE2 (Howie et al., 2009) with 
phased haplotypes from all populations of the December 2013 release of the 1000 
Genomes Project data. SNP genotypes were called from posterior probabilities in 
PLINK 1.9 beta (Chang et al., 2015) using default parameters. Only overlapping SNPs 
found on both Illumina HumanHap 550K and Illumina Human OmniExpress_12 v1.1 
datasets with MAF>1%, imputation confidence (INFO)>0.5 and best called genotype 
certainty (CERTAINTY)>0.9 were retained for pathway analysis. The association 
analysis was also performed in PLINK 1.9 beta using multivariate logistic regression 
assuming an additive model (0, 1, 2 allele dosage coding for minor allele) adjusting for 
age, gender, and the first principal component (PC1). Only PC1 was estimated to be 
statistically associated with case–control status by the Tracy–Widom statistic (P<0.05). 
Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated per minor 
allele assuming an additive model. The quantile–quantile plot (QQ plot) of trend test 
was generated to evaluate overall association of GWAS and presence of population 
stratification inferred through genomic control inflation factor (λgc). The Manhattan plot 
of –log10(Pimp-GWAS) for autosomal SNPs was generated to plot post-imputation GWAS 
signals.  
 
3.3.3 GWAS Pathway analysis 
Pathway analysis was performed in MAGENTA (Segre et al., 2010). Details of 
MAGENTA analysis parameters have been described previously (Segre et al., 2010). 
Briefly, SNPs were mapped onto genes using several boundary settings following the 
gene’s most extreme transcript start and end site: 110kb UTR-40kb DTR; 20kb UTR 
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DTR; 10kb UTR-2kb DTR. Gene scores were calculated adjusting for potential 
confounders using step-wise multiple linear regression and the best SNP (strongest 
adjusted P-value) will be retained to represent the said gene. The confounders include: 
(1) Gene size; (2) Number of SNPs per kb for each gene; (3) Number of independent 
SNPs per kb for each gene (pairwise r2<0.5 based on Malaysian Chinese population); 
(4) Number of recombination hotspots per kb each gene; (5) Genetic distance of each 
gene; (6) Linkage equilibrium units (LDU) per kb for each gene. The MHC region was 
omitted from the analysis. Pathway analysis was performed on 2757 predefined 
pathways from BioCarta, GO, Ingenuity, KEGG, Panther and Reactome databases. 
Pathways were limited to 10-100 gene-sets size. Nominal PGSEA was calculated through 
permutation via random resampling of 10,000 gene sets of identical size. MAGENTA 
sets two thresholds for gene-level significance, 95th percentile and 75th percentile with 
the latter capturing weaker gene-level association signals. In this study, the more 
stringent 95th percentile was set as threshold for gene-level significance. Gene sets with 
P<0.05 were selected for integrated pathway analysis.  
 
3.3.4 GEO Gene expression pathway analysis 
Microarray data from dataset GSE12452 (Sengupta et al., 2006) was chosen to 
corroborate the gene expression profiles of pathways identified by MAGENTA. 
GSE12452 consists of mRNA from laser-captured epithelium of 31 nasopharyngeal 
carcinomas and 10 non-NPC nasopharynx tissues from a Taiwanese case control cohort. 
The mRNA profiling was performed on Affymetrix Human Genome U133 Plus 2.0 
Array. Normalization of gene expression values are as described previously (Sengupta 
et al., 2006). Differential gene expression analysis was performed in GEO2R employing 
the limma package. A t-test was performed, adjusting for log2 fold-change of expression 
in the direction of NPC cases vs healthy nasopharynx tissues. P-values were used as 
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gene-level input for GSEA in GSA-SNP (Nam et al., 2010). Pathway sizes were limited 
to 10-100 gene-sets size. For purpose of consistency, gene sets used for GSEA in GSA-
SNP were the same gene sets used for MAGENTA covering 2757 predefined pathways 
from BioCarta, GO, Ingenuity, KEGG, Panther and Reactome databases. Pathways 
showing nominal P<0.05 were selected for integrated pathway analysis.  
 
3.3.5 Fisher’s method for integrating GWAS and expression data 
Fisher’s method was used to combine FDR-corrected GWAS pathway and gene 
expression pathway P-values. Pathways selected for integrated pathway analysis must 
show nominal P<0.05 in both platforms. Fisher’s method is a combined probability test 
of results from independent tests sharing the same null hypothesis H0 (Fisher, 1925), 







pi is the p-value for the ith hypothesis test 
2 is the chi-square critical value with 2k degrees of freedom 
 
3.3.6 Sample collection for gene expression analysis 
A total of 10 NPC and 7 non-NPC nasopharynx tissues were collected from the 
Queen Elizabeth Hospital (QES), Kuala Lumpur General hospital (HKL), and Pulau 
Pinang General Hospital (HPP). Tissues were snap frozen and stored at -80oC. All NPC 
cases were histologically diagnosed following the World Health Organization (WHO) 
classification. Non-NPC nasopharynx tissues were from patients initially suspected for 
NPC but histologically diagnosed otherwise. All patients provided written, informed 
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consent prior to tissue collection for the purposes of research. The Medical Review and 
Ethics Committee of the Ministry of Health, Malaysia, approved the study. 
 
3.3.7 Tissue processing and RNA isolation for gene expression analysis 
Snap frozen tissue samples were embedded into Optimal Cutting Temperature 
(OCT) compound for cryosectioning. For every 9 sections of 8 micron thick tissue 
sections, a H&E slide was made for histology review. For NPC, RNA was extracted 
from laser capture microdissection or whole tissue sections of tumour tissue with at 
least 80% of cancer cells. Non-NPC nasopharynx tissue sections were lymphoid tissues 
with 20% to 40% normal epithelial cells. Total RNA was isolated using AllPrep 
DNA/RNA/miRNA universal kit (Qiagen, Germany). RNA yield was assessed using 
Qubit® RNA HS Assay Kit (Thermo Fisher Scientific, USA) and RNA quality was 
assessed using Fragment Analyzer (Advanced Analytical, Germany). RNA samples 
with at least 10 ng of material and DV200 (percentage of RNA fragments larger than 
200 nt) >30% were used for RNA sequencing. 
Whole genome gene expression analysis was performed by Lotterywest State 
Biomedical Facility Genomics in the University of Western Australia using the 
Ion AmpliSeq™ Transcriptome Human Gene Expression Kit (Thermo Fisher Scientific, 
USA). Briefly, 10 ng of total RNA is reverse transcribed to construct a barcoded cDNA 
library using the SuperScript® VILO™ cDNA Synthesis kit. Then, cDNA is amplified 
using Ion AmpliSeq™ technology to produce a single amplicon spanning 2 exons for 
each gene (20,813 genes). Library quality was evaluated using Agilent Bioanalyzer. 
Libraries were then amplified using emulsion PCR and enriched following 
manufacturer’s instructions. The final mixture was then sequenced on a Ion PITM chip 




3.3.8 Read alignment and differential gene expression analysis 
Primary analysis of Ion AmpliSeq™ Transcriptome data was done using the 
Torrent SuiteTM software. Raw reads are mapped to a custom reference sequence set 
using the Torrent Mapping Alignment Program (TMAP) (Li et al., 2015). The custom 
reference set contains all transcripts targeted by the AmpliSeq kit. This method greatly 
improves alignment time. The number of reads mapping to each target is counted using 
samtools (Li et al., 2009), giving  the raw total read counts. Differential gene expression 
analysis was performed in DESeq2 (Love et al., 2014) with raw read counts from 
AmpliSeq. Raw counts were normalized and transformed using the regularized 
logarithm (rlog) method in DESeq2. Genes showing normalized read counts <10 were 
removed from analysis. Sample quality was evaluated using sample-to-sample distance 
heatmap and the PCA plot. Differential expression P-values calculated through FDR-
corrected Wald test were used as gene-level input for GSEA of axonemal dynein 
complex and chromosomal centromeric region pathways in GSA-SNP following similar 














CHAPTER 4: RESULTS 
 
4.1 Results for NPC GWAS study  
4.1.1 GWAS genotyping and validation 
The PCA indicated that NPC patients and controls were genetically matched, 
with minimal evidence of population stratification (Figure 4.1). Quantile-quantile plot 
analysis detected a small inflation factor (λgc) of 1.04, indicating minimal inflation of 
the genome-wide association significance due to population stratification (Figure 4.2). 
Several loci showed potential association to NPC susceptibility, although not genome-
wide significant (PGWAS<5.0x10
-8) (Figure 4.3). A total of 45 SNPs showing PSNP-
GWAS<1.0x10
-4 were selected for validation and replication analysis through multiplex-
PCR-based-Invader assay. Only the PSNP-Combined for the top 20 GWAS SNPs are shown 
(Appendix A). Strong association signals were detected in only the major 
histocompatibility complex HLA-A region. These 6 HLA-A region SNPs showed PSNP-
Combined ranging from 10
-8 to 10-9 and are located upstream or downstream of the HLA-A 
(Table 4.1, Figure 4.4). All 6 SNPs render a protective effect against NPC with 
rs3869062 showing the strongest association (PSNP-Combined=1.73x10
-9; odds ratio (OR) 
=2.37; 95% confidence interval (CI) =1.79-3.14) and is located 13-kb downstream of 
the HLA-A gene. All 6 SNPs are in high linkage disequilibrium (LD) with each other 
(r2=0.72-0.99) (Figure 4.4). Association signals of the 6 HLA-A region SNPs were lost 









Figure 4.1: Plots of principal components from PCA analysis of NPC GWAS samples. 
(Top) Plot of PC1 and PC2 from the PCA of 184 NPC patients and 236 healthy 
controls. Orange markers signify GWAS cases (NPC patients) while purple markers 
signify GWAS controls (healthy controls). (Bottom) Plot of PC1 and PC2 from the PCA 
of 184 NPC patients and 236 healthy controls together with 44 Japanese in Tokyo, 
Japan (JPT), 45 Han Chinese in Beijing, China (CHB). Orange markers signify GWAS 
cases (NPC patients) while purple markers signify GWAS controls (healthy controls). 
Hapmap controls were designated with round circles for Han Chinese in Beijing (CHB) 







Figure 4.2: Log10 quantile-quantile (Q-Q) plot for all SNPs from Malaysian NPC GWAS. Q-Q plot showing the distribution of observed statistics by 
trend test for all 575,247 SNPs from our genome-wide study of 184 NPC patients and 236 healthy controls of a Malaysian Chinese population. The 
diagonal line shows the values expected under null hypothesis of a 2 distribution. Genomic control inflation factor (λgc) is 1.04, suggesting little or 











Figure 4.3: Manhattan plot of the genome wide P-values of association in NPC Malaysian Chinese. SNPs were ranked using logistic regression 
assuming an additive model adjusting for age, gender and principal component 1 (PC1). The –log10(PGWAS) (y axis) of 575,247 SNPs in 184 NPC cases 








Figure 4.4: LD structure of GWAS SNPs with genome-wide significant association. LD structure of GWAS SNPs showing moderate to strong LD 
















Table 4.1: Association of GWAS SNPs to NPC in Malaysian Chinese. 
 
No SNP CHR Position Position Risk Panel Case, RAF Control, RAF P-val OR Nearby Gene 
      b36 b37  allele       
 
(95% CI)   
1 rs3869062 6 30042870 29934891 G Cohort 1 (GWAS) 0.81  0.66  2.6 x 10-6 2.57 (1.73-3.81) 3’-UTR HLA-A 
  1/2=A/G        Cohort 2 0.80  0.68  3.51 x 10-4 2.11 (1.4-3.17) 
            Combined 0.80  0.67  1.73 x 10-9 2.37 (1.79-3.14)   
2 rs2735085 6 30035073 29927095 C Cohort 1 (GWAS) 0.79  0.66  7.16 x 10-6 2.41 (1.64-3.53) 3’-UTR HLA-A 
 1/2=T/C     Cohort 2 0.79  0.65  1.95 x 10-4 2.12 (1.43-3.14) 
       Combined 0.79  0.65  1.92 x 10-9 2.31 (1.76-3.03) 
 3 rs7747253 6 30027757 29919779 A Cohort 1 (GWAS) 0.75  0.62  1.58 x 10-5 2.2 (1.54-3.15) 3’-UTR HLA-A 
  1/2=C/A        Cohort 2 0.75  0.60  8.44 x 10-5 2.14 (1.47-3.14)  
           Combined 0.75  0.61  2.08 x 10-9 2.21 (1.71-2.86)   
4 rs2893999 6 30051811 29943832 T Cohort 1 (GWAS) 0.81  0.66  1.73 x 10-6 2.63 (1.77-3.9) 3’-UTR HLA-A 
 1/2=C/T     Cohort 2 0.79  0.67  8.12 x 10-4 1.98 (1.33-2.95)  
      Combined 0.80  0.67  2.61 x 10-9 2.32 (1.76-3.07) 
 5 rs9260734 6 30040644 29932666 G Cohort 1 (GWAS) 0.79  0.65  8.25 x 10-6 2.39 (1.63-3.5) 3’-UTR HLA-A 
  1/2=A/G        Cohort 2 0.79  0.66  2.35 x 10-4 2.1 (1.41-3.12)  
           Combined 0.79  0.65  2.96 x 10-9 2.29 (1.74-3)   
6 rs2860580 6 30014669 29906691 C Cohort 1 (GWAS) 0.75  0.79  7.28 x 10-6 2.23 (1.57-3.17) 5’-UTR HLA-A 
 1/2=T/C     Cohort 2 0.73  0.79  1.29 x 10-3 1.8 (1.26-2.58)  
      Combined 0.74  0.79  1.86 x 10-8 2.04 (1.59-2.62) 
  
1=minor allele; 2=major allele; RAF=Risk allele frequency; P-val= Logistic regression P-value adjusting for age, gender and PC1; 
OR=Odds ratio; 95% CI= 95% confidence interval 
Cohort 1 (GWAS): Cases, n=184; Controls, n=236; Total, n=420 
Cohort 2: Cases, n=260; Controls, n=245; Total, n=505 










Table 4.2: Multivariate logistic regression for GWAS SNPs with genome-wide significant association. SNP1 is adjusted against effects of SNP2 
assuming an additive model. Results are also adjusted for age and gender. 
 
SNP1 unadjusted SNP2 
  P-value rs2860580 rs7747253 rs2735085 rs9260734 rs3869062 rs3202637 rs2893999 rs2286404 rs16896044 
rs2860580 1.86x10-08 NA 7.53x10-01 3.02x10-01 6.27x10-01 3.89x10-01 8.36x10-03 3.97x10-01 6.02x10-03 6.02x10-03 
rs7747253 2.08x10-09 3.30x10-02 NA 1.23x10-01 2.15x10-01 1.26x10-01 8.20x10-04 1.28x10-01 9.83x10-04 9.83x10-04 
rs2735085 1.92x10-09 1.06x10-02 7.53x10-02 NA 5.26x10-01 6.24x10-01 4.14x10-04 5.75x10-01 1.79x10-03 1.79x10-03 
rs9260734 2.96x10-09 1.16x10-02 6.72x10-02 2.60x10-01 NA 3.83x10-01 2.83x10-04 3.39x10-01 1.04x10-03 1.04x10-03 
rs3869062 1.73x10-09 1.06x10-02 5.52x10-02 3.02x10-01 3.37x10-01 NA 1.33x10-04 NA 1.50x10-03 1.50x10-03 












4.1.2 Imputation to fine map the HLA-A gene 
Fine mapping of the HLA-A gene region was performed using imputation in 
search of stronger association signals. Imputation was performed using the HapMap 2, 
HapMap 3 and 1000 Genomes reference datasets. Imputated SNPs with MAF ≥ 1%, 
INFO > 0.5, CERTAINTY > 0.9 and PSNP-GWAS<1.0x10
-4 were retained. Total of 20 
SNPs from HapMap 2, 1 SNP from HapMap 3 and 60 SNPs from 1000 Genomes 
imputation were detected. Upon validation of GWAS cohort samples and replication 
cohort samples, all but 4 SNPs (rs7754245, rs3873291, rs2275854, rs16896970) showed 
strong association signals with genome-wide significance (PSNP-Combined 10
-8-10-9) 
(Figure 4.5; Appendix B). All imputation SNPs detected were also protective SNPs. 
The strongest imputation association signals (rs414215, rs9260029, rs9260033 PSNP-
Combined=1.44x10
-8; OR=2.21; 95% CI=1.71-2.86) did not improve upon the strongest 
association signal from the GWAS (rs3869062; PSNP-Combined=1.73x10
-9). None of the 
imputated SNPs were located on exonic or intronic regions of the HLA-A gene. These 

















Figure 4.5: NPC associated SNPs spanning the HLA-A gene and its adjacent regions. 
Black markers signify GWAS SNPs; Grey markers signify imputation obtained SNPs; 
Yellow markers signify HLA-A alleles mapped SNPs; Red triangle markers signify 
multi-allelic SNPs for HLA-A region. Pair-wise LD values are shown as r2. The colour 











4.1.3 Molecular HLA-A alleles genotyping 
HLA-A alleles genotyping identified 23 HLA-A alleles in the Malaysian Chinese 
cohort (Table 4.3). Only 3 HLA-A alleles were associated or showed suggestive 
association to NPC, namely HLA-A*02:06 (PHLA-A-Combined=6.22x10
-3; OR=3.14; 95% 
CI= 1.38-7.14), HLA-A*02:07 (PHLA-A-Combined=7.71x10-5; OR=1.94; 95% CI=1.40-2.69) 
and HLA-A*11:01 (PHLA-A-Combined=4.84x10
-7; OR=0.48; 95% CI=0.36-0.64). The 
association did not reach genome-wide significance. All HLA-A SNPs were derived 
from our HLA-A genotyping data referencing HLA-A allele sequences of the NCBI 
dbMHC database. A total of 187 bi-allelic and 18 multi-allelic SNPs were found on the 
HLA-A gene, with 31 bi-allelic SNPs and 5 multi-allelic SNPs reaching genome-wide 
thresholds (PSNP-Combined <5.0x10
-8) (Figure 4.5; Appendix C-D).  
In order to test the independence of HLA-A single SNPs from the effects of 
HLA-A alleles, association signals of both HLA-A significant single SNPs and the 3 
most prominent HLA-A alleles (HLA-A*02:06, HLA-A*02:07 and HLA-A*11:01) were 
conditioned against each other (Appendix E-F). Controlling for HLA-A*02:06 and 
HLA-A*02:07 only saw marginal reduction in strength of association for HLA-A 
significant single SNPs (Padjusted_ A*02:06 range from 10
-9-10-4; Padjusted_ A*02:07 range from 
10-7-10-2) but controlling for HLA-A*11:01 saw a distinct reduction (Padjusted_ A*11:01 
range from 10-4-10-1) (Appendix E). A similar trend was observed when HLA-A*11:01 
was designated as the index allele, conditioned against all HLA-A significant single 
SNPs (PA*11:01  4.84x10
-7; extreme PA*11:01_index 10
-3-10-1) showing a reduction in 
association strength (Appendix F). The results indicate that HLA-A single SNP is 








Table 4.3: Association of HLA-A alleles to NPC in Malaysian Chinese. 
 
No HLA-A CHR Sample set Case Control P-val OR (95% CI) 
  alleles     Carrier Frequency Carrier Frequency     
1 A*01:01 6 Cohort 1 (GWAS) 0.003  0.011  2.11E-01 0.24 (0.03-2.23) 
      Cohort 2 0.008  0.006  1.87E-01 3.47 (0.55-21.99) 
      Combined 0.006  0.008  8.16E-01 0.86 (0.23-3.17) 
2 A*02:01 6 Cohort 1 (GWAS) 0.099  0.069  2.11E-01 1.49 (0.8-2.79) 
   Cohort 2 0.068  0.088  5.48E-01 0.83 (0.45-1.52) 
   Combined 0.081  0.079  7.47E-01 1.07 (0.7-1.65) 
3 A*02:03 6 Cohort 1 (GWAS) 0.082  0.088  9.44E-01 1.02 (0.55-1.91) 
      Cohort 2 0.076  0.074  5.14E-01 0.81 (0.43-1.53) 
      Combined 0.079  0.081  6.99E-01 0.92 (0.59-1.43) 
4 A*02:06 6 Cohort 1 (GWAS) 0.031  0.022  1.66E-01 2.15 (0.73-6.34) 
   Cohort 2 0.039  0.008  2.02E-02 4.98 (1.29-19.3) 
   Combined 0.036  0.015  6.22E-03 3.14 (1.38-7.14) 
5 A*02:07 6 Cohort 1 (GWAS) 0.165  0.093  4.28E-03 2.11 (1.26-3.51) 
      Cohort 2 0.206  0.113  1.60E-02 1.71 (1.11-2.63) 
      Combined 0.189  0.103  7.71E-05 1.94 (1.4-2.69) 
6 A*02:10 6 Cohort 1 (GWAS) 0.000  0.000  1.00E+00 #N/A 
   Cohort 2 0.000  0.006  9.99E-01 #N/A 
   Combined 0.000  0.003  9.99E-01 #N/A 
7 A*02:18 6 Cohort 1 (GWAS) 0.006  0.000  9.99E-01 #N/A 
      Cohort 2 0.000  0.000  1.00E+00 #N/A 
      Combined 0.002  0.000  9.99E-01 #N/A 
8 A*03:01 6 Cohort 1 (GWAS) 0.003  0.002  4.35E-01 4.19 (0.12-152.4) 
   Cohort 2 0.004  0.006  6.41E-01 0.57 (0.05-6.2) 
   Combined 0.004  0.004  9.29E-01 1.09 (0.17-6.9) 
9 A*03:02 6 Cohort 1 (GWAS) 0.000  0.000  1.00E+00 #N/A 
      Cohort 2 0.002  0.000  9.99E-01 #N/A 
      Combined 0.001  0.000  9.99E-01 #N/A 
10 A*11:01 6 Cohort 1 (GWAS) 0.190  0.300  1.20E-04 0.46 (0.3-0.68) 
   Cohort 2 0.202  0.297  1.32E-03 0.51 (0.34-0.77) 
   Combined 0.197  0.298  4.84E-07 0.48 (0.36-0.64) 
11 A*11:02 6 Cohort 1 (GWAS) 0.023  0.052  5.92E-02 0.39 (0.15-1.04) 
      Cohort 2 0.041  0.043  7.69E-01 1.15 (0.45-2.9) 
      Combined 0.033  0.047  2.05E-01 0.66 (0.35-1.26) 
12 A*24:02 6 Cohort 1 (GWAS) 0.170  0.149  7.65E-01 1.08 (0.67-1.73) 
   Cohort 2 0.158  0.121  5.40E-01 1.16 (0.72-1.89) 
   Combined 0.163  0.134  5.10E-01 1.12 (0.8-1.57) 
13 A*24:03 6 Cohort 1 (GWAS) 0.000  0.000  1.00E+00 #N/A 
      Cohort 2 0.002  0.000  9.99E-01 #N/A 
      Combined 0.001  0.000  9.99E-01 #N/A 
14 A*24:07 6 Cohort 1 (GWAS) 0.009  0.009  9.49E-01 0.94 (0.14-6.36) 
   Cohort 2 0.002  0.000  9.99E-01 #N/A 
   Combined 0.005  0.004  8.10E-01 1.24 (0.22-7.1) 
15 A*24:08 6 Cohort 1 (GWAS) 0.003  0.000  9.99E-01 #N/A 
      Cohort 2 0.000  0.000  NA #N/A 
      Combined 0.001  0.000  9.99E-01 #N/A 
16 A*24:10 6 Cohort 1 (GWAS) 0.000  0.002  9.99E-01 #N/A 
   Cohort 2 0.000  0.004  9.99E-01 #N/A 
   Combined 0.000  0.003  9.99E-01 #N/A 
17 A*24:20 6 Cohort 1 (GWAS) 0.006  0.004  9.75E-01 0.96 (0.06-14.59) 
      Cohort 2 0.004  0.002  3.82E-01 9.06 (0.06-1267) 
      Combined 0.005  0.003  6.37E-01 1.7 (0.19-15.3) 
18 A*26:01 6 Cohort 1 (GWAS) 0.023  0.024  6.06E-01 0.76 (0.26-2.18) 
   Cohort 2 0.033  0.016  3.25E-02 3.14 (1.1-8.95) 
   Combined 0.029  0.020  2.20E-01 1.58 (0.76-3.26) 
19 A*29:01 6 Cohort 1 (GWAS) 0.009  0.002  4.65E-01 3.03 (0.16-58.96) 
      Cohort 2 0.000  0.018  9.98E-01 #N/A 
      Combined 0.004  0.011  3.37E-01 0.44 (0.08-2.34) 
20 A*30:01 6 Cohort 1 (GWAS) 0.009  0.009  7.71E-01 0.78 (0.15-4.09) 
   Cohort 2 0.004  0.014  1.26E-01 0.2 (0.02-1.58) 
   Combined 0.006  0.012  1.79E-01 0.42 (0.12-1.49) 
21 A*31:01 6 Cohort 1 (GWAS) 0.003  0.022  1.59E-01 0.2 (0.02-1.86) 
      Cohort 2 0.006  0.008  6.56E-01 1.52 (0.24-9.53) 
      Combined 0.005  0.015  3.27E-01 0.52 (0.14-1.93) 
22 A*32:01 6 Cohort 1 (GWAS) 0.003  0.000  9.99E-01 #N/A 
   Cohort 2 0.000  0.002  9.99E-01 #N/A 
   Combined 0.001  0.001  8.19E-01 1.44 (0.06-32.48) 
23 A*33:03 6 Cohort 1 (GWAS) 0.148  0.121  9.37E-03 2.36 (1.24-4.51) 
      Cohort 2 0.134  0.141  3.48E-01 1.25 (0.78-2) 
      Combined 0.140  0.131  2.79E-02 1.51 (1.05-2.18) 
P-val=Logistic regression additive model P-value adjusting for age, gender and PC1; OR=Odds ratio; 
95% CI= 95% confidence interval 
Example coding of HLA-A alleles, e.g. A*02:06/A*02:06=1/1; A*02:06/0=1/2; 0/0=2/2 
Multiple testing threshold = 2.17x10-03 
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4.1.4 Amino acid variants 
This study aimed to identify amino acid variants that are also functional variants 
coded by the corresponding HLA-A SNP. HLA-A gene sequence was translated to 
identify amino acid variants using NCBI dbMHC database. Corresponding function of 
amino acid residues were identified using the Immunology Database and Analysis 
Portal (ImmPort) database while functional impact of amino acid/SNP substitutions 
were predicted by PROVEAN (Choi et al., 2012), SIFT (Kumar et al., 2009) and 
Polyphen-2 (Adzhubei et al., 2010). Out of 364 amino acid residues identified (Figure 
4.6, Appendix G-H), 27 amino acid variants were statistically significant after multiple 
testing correction (Paa-Combined<1.37x10
-4) (Table 4.4, Appendix I). These amino acid 
variants have corresponding bi-allelic and multi-allelic SNPs. PROVEAN (Choi et al., 
2012), SIFT (Kumar et al., 2009) and Polyphen-2 (Adzhubei et al., 2010) only 
predicted HLA-A-aa-site-99 (Paa-Combined=3.79x10
-8; ORAA99-Tyr/Cys=2.19; 95% CIAA99-
Tyr/Cys=1.66-2.89; ORAA99-Tyr/Phe=1.40; 95% CIAA99-Tyr/Phe=1.09-1.82) and HLA-A-aa-
site-145 (Paa-Combined=1.41x10
-4; ORAA145-Arg/His=1.64; 95% CIAA145-Arg/His=1.27-2.12) to 
be deleterious or damaging variants (Table 4.4, Appendix G-I). The corresponding SNP 
for HLA-A-aa-site-99 is rs1136697 (PSNP-Combined=3.79x10
-8 ; ORrs1136697-A/G=2.19; 95% 
CIrs1136697-A/G=1.66-2.89; ORrs1136697-A/T=1.40; 95% CIrs1136697-A/T=1.09-1.82) and HLA-
A-aa-site-145 is rs1059520 (PSNP-Combined=1.41x10
-4 ; OR=1.64; 95% CI=1.27-2.12). 
The HLA-A-99Tyr reference amino acid tyrosine (Tyr, Y) is substituted for cysteine 
(Cys, C) when rs1136697-A is substituted for G. The HLA-A-145Arg reference amino 
acid arginine (Arg, R) is substituted for histidine when rs1059520-G is substituted for –
A. The remaining amino acid variants, though showing association signals in both 
amino acid and SNP variants were benign or tolerated variants (Table 4.4, Appendix I). 
To establish if the association of HLA-A-99 and HLA-A-145 is independent or due to 
LD with HLA-A alleles, logistic regression controlling for effects of HLA-A*02:07 was 
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done. This is because HLA-A-99, HLA-A-145 and HLA-A*02:07 show a susceptible 
genetic effect. Controlling for HLA-A*02:07 reduced the effects of HLA-A-99Tyr/Cys 
and rs1136697-A/G (Padjusted=1) and HLA-A-145Arg/His and rs1059520 
(Padjusted=8.04x10
-2) and vice versa (Appendix E-F, Appendix J-K). These results 
indicated that effects of HLA-A-99Tyr/Cys and HLA-A-145Arg/His to be driven by 
and correlated with HLA-A*02:07. 
 
4.1.5 Regulatory functions of NPC associated HLA-A SNP variants 
HaploReg was used to predict potential epigenetic signatures in the NPC 
associated HLA-A SNP variants. The search only focused on 5’-UTR region of the 
HLA-A. Epigenetic data was limited to those of the B-cell lymphoblastoid cell lines as 
we focus on epigenetic signatures related to immune-response function. HaploReg data 
indicated that rs9260067, rs9260072, rs9260077, rs41545520, rs9260120 and 
rs114945359 may regulate transcription of HLA-A as the SNP variants intersect histone 
modification sites and/or DNase I hypersensitivity sites, suggesting promoter or 
enhancer activity. The variants also influence binding of transcription factors and/or a 
regulatory motif (Table 4.5). The 6 SNPs with potential epigenetic function are 
correlated with HLA-A*11:01. Controlling for effects of HLA-A*11:01 diminished the 
association of the 6 SNPs (extreme Padjusted_ A*11:01 10
-3-10-2) (Appendix E). The 
association of HLA-A*11:01 also diminished after controlling against effects of the 6 
SNPs (PA*11:01_unadjusted  4.63x10
-7; extreme PA*11:01_index 10
-1) (Appendix F).  
SNP rs41545520 is of particular interest as it influence change in strength of 
motif binding for activating transcription factor 3 (ATF3). ATF3 binds the cAMP 
response element (CRE), repressing transcription by stabilizing the binding of inhibitory 
cofactors at the promoter (Gilchrist et al., 2006). Genotype data of rs41545520 was 
corroborated with eQTL data from Genevar Database to investigate effects of SNP 
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genotypes on HLA-A expression. Though not listed in the Genevar Database, 
rs41545520 is tightly linked to rs2860580 (r2=0.84). The eQTL expression profiles of 
rs2860580 is more consistent with HaploReg predictions of strengthened motif binding 
for repressor ATF3 in reference allele rs41545520-G (rs2860580-G), resulting in lower 
HLA-A expression. The alternate allele rs41545520-T (rs2860580-A) shows weakened 
binding of ATF3, resulting in higher HLA-A expression (Table 4.5; Figure 4.7). 
rs41545520-T also defines HLA-A*11:01, with the higher HLA-A*11:01 expression 
implying a protective effect towards NPC. The epigenetic influence of rs9260077 is not 
discussed as the predicted transcription factor, HDAC2, does not directly bind DNA but 
is tethered against other transcription factors (Ropero & Esteller, 2010), thus strength of 
motif binding is not directly influenced by change in rs9260077 alleles. Further 
examination in NPC cell lines to replicate effects of HLA-A 5’-UTR SNP variants on 
transcriptional regulation and gene expression would be necessary. 
 
4.1.6 Association signals from previous NPC GWAS studies  
Previously reported association signals from Ng et al. 2009a, Tse et al. 2009, 
Bei et al. 2010 and Tang et al. 2012 were genotyped (Appendix L). Our results 
replicated the associations reported in the HLA-A region (including adjacent GABBR1, 
HLA-F and HCG9). Controlling for HLA-A*11:01 reduced the association strength of 
GABBR1, HLA-F, HLA-A and HCG9 where the extreme NPC association is reduced 
from 1.73x10-9-0.01 to 1.0x10-4-0.51 (Appendix E). The association of HLA-A*11:01 
also diminished after controlling against effects of the NPC SNPs (PA*11:01  4.84x10
-
7;extreme PA*11:01_index 10
-1) (Appendix F). The results suggest the HLA-A region 








Figure 4.6: NPC association plot of amino acid variants mapped from HLA-A alleles. The false positive rates are expressed in –log10 Paa-Combined (y-
axis) according to the HLA-A amino acid residue position (x-axis). Coloured markers signify corresponding function of amino acid positions, be it for 
β2-microglobulin binding, CD8 receptor binding, T-cell receptor binding, Natural killer cell receptor binding KIR3DL or antigenic peptide binding 






SNP rs2860580     
Reference allele : G   
Variant allele  : A       
Major allele  : G LD r2=0.84 with rs41545520-G ATF3 LOD 11.6 
Minor allele  : A LD r2=0.84 with rs41545520-T ATF3 LOD 8.6 
Ensemble Gene ID : ENSG00000206503   
Gene Name  : HLA-A   
 
Figure 4.7: GeneVar eQTL analysis of HLA-A flanking SNP rs41545520 using MuTHER resource datasets (Nica et al., 2011) as well as 





Table 4.4: HLA-A amino acid variants association and function prediction by PROVEAN, SIFT and Polyphen-2. 
 
No Amino acid Paa-Combined SNP PSNP-Combined Codon Change Residue Change PROVEAN SIFT Polyphen-2 
1 AA-15 1.37 x 10-5 rs1143146 1.37 x 10-5 C/G Leu>Val Neutral Tol Benign 
2 AA9 5.36 x 10-5 rs1136659 1.46 x 10-1 T/A Phe>Ile Neutral Dmg Benign 
  
 rs2075684 6.98 x 10-6 T/A/C Phe>Tyr/Ser Neutral/Neutral Tol/Tol Benign/Benign 
3 AA62 2.10 x 10-9 rs1059455 3.74 x 10-5 C/G Gln>Glu Neutral Tol Benign 
     rs1064588 1.29 x 10-6 A/G/T Gln>Arg/Leu Neutral/Del Tol/Tol Benign/Benign 
4 AA66 5.60 x 10-5 rs199474436 5.60 x 10-5 T/A Asn>Lys Neutral Tol Benign 
5 AA70 3.01 x 10-8 rs78306866 3.01 x 10-8 G/C Gln>His Neutral Tol Benign 
6 AA74 2.20 x 10-4 rs1136683 2.20 x 10-4 G/C Asp>His Neutral Tol Pos Dmg 
7 AA90 7.73 x 10-7 rs1136692 7.73 x 10-7 C/A Ala>Asp Del Tol Benign 
8 AA95 1.21E-07 rs1071743 1.21 x 10-7 A/C/G Ile>Leu/Val Neutral/Neutral Tol/Tol Benign/Benign 
9 AA97 2.44 x 10-9 rs199474485 4.65 x 10-5 T/G Ile>Arg Neutral Tol Benign 
     rs1136695 1.95 x 10-8 A/G Ile>Met Neutral Tol Benign 
10 AA99 3.79 x 10-8 rs1136697 3.79 x 10-8 A/G/T Tyr>Cys/Phe Del/Del Dmg/Tol Prob Dmg/Benign 
11 AA105 7.06 x 10-7 rs1136700 7.06 x 10-7 T/C Ser>Pro Neutral Tol Benign 
12 AA107 9.61 x 10-5 rs1136702 9.61 x 10-5 G/T Gly>Trp Del Tol Prob Dmg 
13 AA114 2.78 x 10-9 rs3173420 4.60 x 10-8 G/A Arg>Gln Neutral Tol Pos Dmg 
     rs12721717 7.00 x 10-8 G/A/C Arg Neutral/Neutral Tol/Tol N/A 
14 AA116 7.00 x 10-8 rs3173419 7.00 x 10-8 G/C/T Asp>His/Tyr Neutral/Neutral Tol/Tol Benign/Benign 
15 AA127 5.24 x 10-5 rs1059509 5.24 x 10-5 C/A Asn>Lys Del Tol Benign 
16 AA142 1.41 x 10-4 rs1059516 1.41 x 10-4 T/C Ile>Thr Del Tol Prob Dmg 
17 AA145 1.41 x 10-4 rs1059520 1.41 x 10-4 G/A Arg>His Del Tol Prob Dmg 
18 AA152 6.64 x 10-8 rs9256983 6.64 x 10-8 A/T/C/G Glu>Val/Ala/Gly Neutral/Neutral/Neutral Tol/Tol/Dmg Benign/Benign/Benign 
19 AA163 1.66 x 10-7 rs3129017 2.82 x 10-7 A/C Thr>Pro Neutral Tol Pos Dmg 
     rs3129018 2.82 x 10-7 C/G Thr>Arg Neutral Tol Benign 
20 AA184 7.94 x 10-5 rs1136741 7.94 x 10-5 C/G Pro>Ala Del Tol Prob Dmg 
21 AA193 7.42 x 10-7 rs1059563 1.09 x 10-6 C/G Pro>Ala Del Tol Prob Dmg 
     rs1059564 8.14 x 10-5 C/G/T Pro Neutral/Neutral Tol/Tol N/A 
22 AA194 7.42 x 10-7 rs9260179 7.42 x 10-7 A/G Ile>Val Neutral Tol Benign 
23 AA207 7.42 x 10-7 rs9260180 7.42 x 10-7 G/A Gly>Ser Del Tol Pos Dmg 
24 AA253 7.42 x 10-7 rs2231095 7.42 x 10-7 G/C Glu>Gln Neutral Tol Pos Dmg 
25 AA276 2.11 x 10-8 rs1136903 1.95 x 10-8 T/C Leu>Pro Neutral Tol Benign 
     rs1136917 5.28 x 10-1 G/A Leu Neutral Tol N/A 




Table 4.4, continued. 
          
No Amino acid Paa-Combined SNP PSNP-Combined Codon Change Residue Change PROVEAN SIFT Polyphen-2 
27 AA321 1.95 x 10-8 rs2231119 1.95 x 10-8 A/T Thr>Ser Neutral Tol Benign 
 
Paa-Combined=amino acid association in combined cohort; PSNP-Combined=SNP association in combined cohort;  
Tol=Tolerated, Dmg=Damaging; Del=Deleterious; Prob Dmg= Probably Damaging; Pos Dmg= Possibly damaging 
 
 
Table 4.5: HaploReg prediction of 5'-UTR HLA-A SNP variants. 
 






marks bDNAse cProteins bound dMotifs changed RefSeq genes 
6 rs9260067 29908649 T A,C,G None 
State 5 
Strong 
enhancer None None None 
1.6kb 5' of 
HLA-A 
6 rs9260072 29908838 G C None 
State 4 
Strong 
enhancer None None None 
1.4kb 5' of 
HLA-A 
6 rs9260077 29908954 G A None 
State 4 
Strong 
enhancer Present None HDAC2,Pax-5 












RefLOD 11.6; AltLOD 8.6 
5' of HLA-A 






None 5' of HLA-A 






LF-A1 5' of HLA-A 
 
aRegulatory chromatin states follows the 15-state definition of Ernst et al., 2011 
bRegion where chromatin is hypersensitive to Dnase I enzyme cleavage (ENCODE data) 
cProtein binding regions assayed by ChIP-seq (ENCODE data) 
dMotif change as predicted by TRANSFAC, JASPAR and protein-binding microarray experiments 
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4.2 Results for meta-analysis of NPC GWAS 
The initial meta-analysis across GWAS included a total of 2,152 cases and 3,740 
controls. Results from the meta-analysis are summarized in Appendix M. As described 
in the Materials and Methods section, 43 SNPs were identified for replication based on 
the GWAS meta-analysis. For the Malaysian study, the results from the GWAS and 
replication efforts were combined. No SNP was associated at the genome-wide level 
(P<5.0x10-08) (Table 4.6). The more prominent associations reported were SNPs near 
ITGA9 (OR=2; P=1.22x10-04) and MECOM (OR=1.37; P=1.34x10-04) (Table 4.6). 
When merged with GWAS and replication data from other NPC study groups, ITGA9 
association was not replicated (OR=1.02; P=8.30x10-01) while MECOM showed 
consistent association (OR=0.84; P=1.50x10-12) (Table 4.7).    
In replication efforts performed across four studies, the strongest association 
with NPC was observed for rs31489 (ORrep=0.79; Prep=4.3x10
-11), an intronic SNP 
within CLPTM1L in the CLPTM1L/TERT region (chr.5p15.33). This represents a locus 
not reported in previously published NPC GWAS. Findings for this SNP were 
consistent in the mainland Chinese and two Taiwanese replication studies and absent 
from the Malaysian replication study, the smallest of the replication efforts (Figure 4.8). 
A second SNP within the CLPTM1L/TERT locus (rs2853668; r2 = 0.108 and D' = 0.917 
with rs31489 among controls in our replication studies) was also associated with NPC 
in the replication phase (OR=1.11; P=5.2x10−4), but the association was no longer 
statistically significant in analyses that conditioned on rs31489 (OR=1.05; P=0.15). 
 In analyses that combined the GWAS and replication studies, findings for 
rs31489 were strengthened (OR across GWA+replication studies = 0.81; P-value = 
6.3x10−13; Table 4.7). Some evidence for heterogeneity across studies was observed (P-
heterogeneity = 0.035). Additional associations (P≤ 1x10−7) were observed in our 
combined GWA plus replication studies meta-analysis for rs6774494 (P=1.5x10-12; 
 
73 
MECOM gene region), rs9510787 (P=5.0x10-10; TNFRSF19 gene region), rs1412829, 
rs4977756, and rs1063192 (P=2.8x10-8, P=7.0x10-7, and P=8.4x10-7, respectively; 
























Table 4.6: Results for 43 SNPs in Malaysian Chinese combining GWAS and replication samples. 
 
        
GWAS Replication study Combined 








allele OR P OR P OR P 
rs31489 CLPTM1L/TERT 5 1342714 2 0.22 C A 1.04 7.55x10-01 1.11 5.09x10-01 1.07 4.96x10-01 
rs6774494 MECOM 3 169082633 2 0.36 A G 0.76 1.29x10-02 0.69 4.11x10-03 1.37 1.34x10-04 
rs9510787 TNFRSF19 13 24205195 2 0.35 A G 1.23 5.33x10-02 1.04 7.35x10-01 1.14 1.01x10-01 
rs1412829 CDKN2A/2B 9 22043926 1 0.11 T C 0.8 1.78x10-01 1.15 4.79x10-01 1.07 5.94x10-01 
rs4977756 CDKN2A/2B 9 22068652 1 0.22 A G 0.85 2.02x10-01 1.31 6.76x10-02 1.02 8.13x10-01 
rs1063192 CDKN2A/2B 9 22003367 1 0.17 T C 0.89 3.97x10-01 1.1 5.73x10-01 1.03 7.98x10-01 
rs2853668 CLPTM1L/TERT 5 1300025 2 0.31 C A 1.09 5.13x10-01 1.02 8.98x10-01 1.05 5.70x10-01 
rs3731239 C9orf53,CDKN2A 9 21974218 1 0.13 T C 0.92 5.88x10-01 1.03 8.62x10-01 1.03 7.70x10-01 
rs1572072 TNFRSF19 13 24127210 2 0.26 G T 1.02 8.49x10-01 1.15 2.94x10-01 1.08 4.10x10-01 
rs3109384 LOC646388 11 40118598 1 0.26 C T 0.9 3.95x10-01 0.84 1.77x10-01 1.15 1.10x10-01 
rs9928448 ALDOA,PPP4C 16 30072530 2 0.41 T C 1.05 6.26x10-01 1.14 2.62x10-01 1.09 2.57x10-01 
rs10120688 RP11-145E5.4 9 22056499 2 0.28 A G 0.9 3.51x10-01 0.8 7.78x10-02 1.17 6.63x10-01 
rs2877822 MUC13 3 124645034 2 0.04 C T 0.72 1.80x10-01 1.58 9.22x10-02 1.03 8.79x10-01 
rs6671127 LOC100133029, 
GPR177 
1 68571220 1 0.37 A C 1.07 5.20x10-01 1.06 6.40x10-01 1.07 4.29x10-01 
rs10796139 FRMD4A 10 13892298 1 0.36 A G 0.82 8.72x10-02 0.95 6.65x10-01 1.14 1.26x10-01 
rs1331627 NTNG2 9 135091879 1 0.42 C T 0.84 9.95x10-02 0.97 7.56x10-01 1.12 1.63x10-01 
rs11672613 C3 19 6705246 1 0.42 T C 0.87 1.91x10-01 0.9 3.58x10-01 1.13 1.12x10-01 
rs6468749 YWHAZ 8 102008828 1 0.37 T C 1.04 7.20x10-01 1.17 1.97x10-01 1.1 2.61x10-01 
rs12577139 BARX2 11 129301284 2 0.15 C T 0.91 5.51x10-01 0.82 2.44x10-01 1.15 1.98x10-01 
rs7119879 BARX2 11 129305687 2 0.16 G A 0.84 2.21x10-01 0.88 4.24x10-01 1.17 1.50x10-01 
rs1991007 N/A 5 55968018 1 0.08 C A 1.63 1.16x10-02 0.59 2.10x10-02 1.09 5.76x10-01 
rs12570170 HK1 10 70801833 1 0.37 G A 1.13 2.67x10-01 0.94 5.68x10-01 1.04 6.23x10-01 
rs2886189 ZBTB16 11 113501655 1 0.3 T C 0.95 6.67x10-01 1.02 8.56x10-01 1.02 8.34x10-01 
rs9820110 N/A 3 70469958 1 0.29 G T 1.24 6.61x10-02 1.09 4.74x10-01 1.17 7.04x10-02 
rs17801001 EPHA3 3 89414555 1 0.12 A C 1.56 5.69x10-03 0.88 4.75x10-01 1.21 1.15x10-01 
rs11209216 LOC100133029, 
GPR177 
1 68571431 1 0.44 C T 1.05 6.67x10-01 1.06 5.98x10-01 1.05 5.03x10-01 
rs6795074 EPHA3 3 89516652 1 0.1 T C 1.36 8.06x10-02 0.7 8.19x10-02 1.02 8.56x10-01 
rs9538032 N/A 13 58985847 1 0.25 T C 1.18 1.99x10-01 1.1 4.99x10-01 1.14 1.57x10-01 
rs3181088 VCAM1 1 101198708 2 0.11 C T 1.1 5.91x10-01 1.08 6.63x10-01 1.09 4.87x10-01 




           
Table 4.6, continued. 
           
        GWAS Replication study Combined 








allele OR P OR P OR P 
rs6800118 MIRN138-1, 
hsa-mir-138-1 
3 44141157 2 0.28 A G 0.99 9.19x10-01 0.72 1.08x10-02 1.16 7.71x10-02 
rs7702277 N/A 5 14020756 1 0.12 G T 1.58 3.87x10-03 0.99 9.49x10-01 1.28 3.44x10-02 
rs1296284 N/A 5 55934938 1 0.33 G A 1.29 6.84x10-02 1.13 3.14x10-01 1.2 5.12x10-02 
rs2802402 ITM2B 13 47685360 1 0.16 C T 0.85 2.30x10-01 1.04 8.01x10-01 1.08 4.64x10-01 
rs695207 MIR3134,ROD1 9 114056169 1 0.27 T G 1.14 2.29x10-01 0.89 3.66x10-01 1.02 8.07x10-01 
rs189897 ITGA9 3 37518545 2 0.04 A T 2.52 4.13x10-06 1.23 5.15x10-01 2 1.22x10-04 
rs2158250 ITGB8 7 20425446 2 0.41 A G 0.97 7.72x10-01 0.92 4.65x10-01 1.06 4.93x10-01 
rs1286041 N/A 6 6839192 1 0.17 A G 1.41 1.36x10-02 0.7 2.84x10-02 1.05 6.63x10-01 
rs4714505 LOC100130606, 
TFEB 
6 41648147 1 0.11 C T 0.7 3.79x10-02 1.13 4.99x10-01 1.13 3.16x10-01 
rs7014115 ASPH 8 62649567 1 0.12 T G 1.63 3.84x10-03 1.01 9.55x10-01 1.3 3.15x10-02 
rs4936612 N/A 11 121203120 1 0.4 A G 0.92 4.30x10-01 0.97 8.01x10-01 1.06 4.50x10-01 
rs11637457 AGBL1 15 87572506 1 0.16 C T 0.88 4.21x10-01 1.34 5.17x10-02 1.1 3.97x10-01 
rs1324103b N/A 6 93901016 1 0.42 A G 0.84 1.10x10-01 0.75 1.57x10-02 1.25 3.84x10-03 
rs9924017 HS3ST4 16 25849321 1 0.36 A G 1.1 4.17x10-05 1.09 4.63x10-01 1.09 2.70x10-01 
 
a1=Selected based on GWAS meta-analysis results; 2= Selected as an additional candidate based on a-priori literature. 













Table 4.7: Results from GWAS meta-analysis and replication study for 43 SNPs selected for replication (Bei et al., 2016). 
 
        
GWAS 
meta-analysis Replication study Combined 








allele OR P OR P OR P 
rs31489 CLPTM1L/TERT 5 1342714 2 0.22 C A 0.85 1.80x10-03 0.79 4.30x10-11 0.81 6.30x10-13 
rs6774494 MECOM 3 169082633 2 0.36 A G 0.81 4.00x10-07 0.86 3.40x10-07 0.84 1.50x10-12 
rs9510787 TNFRSF19 13 24205195 2 0.35 A G 1.2 1.90x10-05 1.14 4.10x10-06 1.16 5.00x10-10 
rs1412829 CDKN2A/2B 9 22043926 1 0.11 T C 0.72 2.80x10-06 0.85 4.20x10-04 0.8 2.80x10-08 
rs4977756 CDKN2A/2B 9 22068652 1 0.22 A G 0.8 9.70x10-06 0.9 2.70x10-03 0.87 7.00x10-07 
rs1063192 CDKN2A/2B 9 22003367 1 0.17 T C 0.77 2.40x10-06 0.9 6.00x10-03 0.86 8.40x10-07 
rs2853668 CLPTM1L/TERT 5 1300025 2 0.31 C A 1.15 1.70x10-03 1.11 5.20x10-04 1.12 3.60x10-06 
rs3731239 C9orf53,CDKN2A 9 21974218 1 0.13 T C 0.77 6.30x10-05 0.87 1.60x10-03 0.84 1.30x10-06 
rs1572072 TNFRSF19 13 24127210 2 0.26 G T 0.89 1.3x10-02 0.92 1.10x10-02 0.91 4.80x10-04 
rs3109384 LOC646388 11 40118598 1 0.26 C T 0.83 3.30x10-05 0.93 1.80x10-02 0.89 1.60x10-05 
rs9928448 ALDOA,PPP4C 16 30072530 2 0.41 T C 1.17 1.50x10-04 1.07 2.40x10-02 1.1 6.50x10-05 
rs10120688 RP11-145E5.4 9 22056499 2 0.28 A G 0.84 1.80x10-04 0.94 4.30x10-02 0.91 1.50x10-04 
rs2877822 MUC13 3 124645034 2 0.04 C T 0.68 1.10x10-04 1.14 5.40x10-02 0.96 5.20x10-01 
rs6671127 LOC100133029, 
GPR177 
1 68571220 1 0.37 A C 1.2 1.60x10-05 1.05 8.50x10-02 1.1 1.20x10-04 
rs10796139 FRMD4A 10 13892298 1 0.36 A G 0.82 1.30x10-05 0.96 1.20x10-01 0.91 2.10x10-04 
rs1331627 NTNG2 9 135091879 1 0.42 C T 0.84 4.70x10-05 1.04 1.30x10-01 0.98 2.90x10-01 
rs11672613 C3 19 6705246 1 0.42 T C 0.83 1.10x10-05 0.96 1.50x10-01 0.92 2.40x10-04 
rs6468749 YWHAZ 8 102008828 1 0.37 T C 1.21 1.00x10-05 1.04 1.50x10-01 1.09 2.20x10-04 
rs12577139 BARX2 11 129301284 2 0.15 C T 0.84 2.10x10-03 1.06 1.50x10-01 0.98 5.70x10-01 
rs7119879 BARX2 11 129305687 2 0.16 G A 0.84 1.60x10-03 1.05 1.90x10-01 0.98 4.80x10-01 
rs1991007 N/A 5 55968018 1 0.08 C A 1.38 2.50x10-05 1.05 3.20x10-01 1.15 1.30x10-03 
rs12570170 HK1 10 70801833 1 0.37 G A 1.19 5.30x10-05 1.03 3.50x10-01 1.08 2.10x10-03 
rs2886189 ZBTB16 11 113501655 1 0.3 T C 0.83 4.30x10-05 0.97 3.80x10-01 0.93 2.40x10-03 
rs9820110 N/A 3 70469958 1 0.29 G T 1.24 2.60x10-06 1.03 3.80x10-01 1.09 7.10x10-04 
rs17801001 EPHA3 3 89414555 1 0.12 A C 1.32 7.70x10-06 1.03 4.40x10-01 1.11 1.70x10-03 
rs11209216 LOC100133029, 
GPR177 
1 68571431 1 0.44 C T 1.18 5.50x10-05 1.02 4.90x10-01 1.07 4.60x10-03 
rs6795074 EPHA3 3 89516652 1 0.1 T C 1.38 3.30x10-06 1.03 5.10x10-01 1.13 1.70x10-03 
rs9538032 N/A 13 58985847 1 0.25 T C 1.21 5.50x10-05 0.98 5.10x10-01 1.05 8.20x10-02 




              
              
Table 4.7, continued 
 
        GWAS 
meta-analysis 
Replication study Combined 








allele OR P OR P OR P 
rs6800118 MIRN138-1, 
hsa-mir-138-1 
3 44141157 2 0.28 A G 0.84 1.20x10-04 1.02 6.20x10-01 0.96 8.00x10-02 
rs7702277 N/A 5 14020756 1 0.12 G T 1.39 8.00x10-08 0.98 6.60x10-01 1.1 6.50x10-03 
rs1296284 N/A 5 55934938 1 0.33 G A 1.21 2.90x10-05 1.01 7.00x10-01 1.07 7.90x10-03 
rs2802402 ITM2B 13 47685360 1 0.16 C T 0.77 2.90x10-06 0.99 8.10x10-01 0.91 4.40x10-03 
rs695207 MIR3134,ROD1 9 114056169 1 0.27 T G 1.2 7.30x10-05 0.99 8.20x10-01 1.06 3.50x10-02 
rs189897 ITGA9 3 37518545 2 0.04 A T N/A N/A 1.02 8.30x10-01 1.02 8.30x10-01 
rs2158250 ITGB8 7 20425446 2 0.41 A G 0.86 4.80x10-04 1 8.70x10-01 0.95 3.70x10-02 
rs1286041 N/A 6 6839192 1 0.17 A G 1.26 3.10x10-05 1.01 8.90x10-01 1.08 1.40x10-02 
rs4714505 LOC100130606, 
TFEB 
6 41648147 1 0.11 C T 0.71 1.70x10-07 1 9.30x10-01 0.9 4.30x10-03 
rs7014115 ASPH 8 62649567 1 0.12 T G 1.33 6.10x10-06 1 9.50x10-01 1.09 1.30x10-02 
rs4936612 N/A 11 121203120 1 0.4 A G 0.85 6.30x10-05 1 9.50x10-01 0.95 2.70x10-02 
rs11637457 AGBL1 15 87572506 1 0.16 C T 0.8 7.70x10-05 1 9.50x10-01 0.93 3.10x10-02 
rs1324103b N/A 6 93901016 1 0.42 A G 0.84 1.40x10-05 1 9.60x10-01 0.94 1.20x10-02 
rs9924017 HS3ST4 16 25849321 1 0.36 A G 1.19 4.70x10-05 1 9.70x10-01 1.06 2.20x10-02 
 
a1=Selected based on GWAS meta-analysis results; 2= Selected as an additional candidate based on a-priori literature. 








A. rs31489        B. rs1063192 
 
   
P-heterogeneity across studies: 0.035    P-heterogeneity across studies: 0.097 
 
C. rs1412829        D. rs4977756 
 
   
P-heterogeneity across studies: 0.25     P-heterogeneity across studies: 0.039 
 







E. rs6774494        F. rs9510787 
   
P-heterogeneity across studies: 0.0093    P-heterogeneity across studies: 0.016 
 












4.3 Results for integrated pathway analysis of NPC 
4.3.1 GWAS and gene expression data 
The PCA indicated that NPC patients and controls were genetically matched, 
with minimal evidence of population stratification (Figure 4.9; Figure 4.10). Total of 
6,702,151 autosomal SNPs overlapping Illumina HumanHap 550K and Illumina Human 
OmniExpress_12 v1.1 were retained post-imputation after quality control measures 
were applied (Figure 4.11). SNP association P-values have been adjusted for age, 
gender and population structure. Quantile–quantile plot analysis detected a small 
inflation factor (λgc) of 1.03, indicating minimal inflation of the genome-wide 
association due to population structure (Figure 4.12). Post-imputation SNPs were 
mapped to 20,273 genes. Total of 18,905 gene scores were calculated out of 20,273 
genes and were used for GSEA. The remaining 1,368 genes were removed either due to 
lack of a gene score or were situated in the MHC region. Gene scores calculation have 
been adjusted for confounding factors. 
Differential gene expression analysis was performed on GSE12452 data (31 
nasopharyngeal carcinomas; 10 non-NPC nasopharynx tissues) from a Taiwanese case 
control cohort using GEO2R employing a Student’s t-test, adjusted for log2 fold-
change. Total of 21,586 genes were evaluated, of which 5,680 genes showed differential 
expression, PGEO2R<0.05. All 21,586 P-values from GEO2R were used as gene level P-
values for GSEA analysis, screening 2,757 pathways across BioCarta, GO, Ingenuity, 
KEGG, Panther and Reactome databases. 
Pathways identified through joint GWAS and published gene expression data 
GSE12452 were replicated in a separate cohort of 10 NPC and 7 non-NPC nasopharynx 
tissues (Table 4.8; Table 4.9). Sample details are listed in Table 4.10. Whole genome 
gene expression analysis was performed using the Ion AmpliSeq™ Transcriptome 
Human Gene Expression Kit. Total of 3,218 genes showing normalized read counts <10 
 
81 
were removed from analysis. PCA plot (Figure 4.13), heatmap of sample-to-sample 
distance (Figure 4.14) all showed consistent clustering and demarcation of sample 
phenotypes. Differential expression analysis for remaining 17,595 genes was performed 
in DESeq2, and P-values for genes that form the target replication pathways were used 













Figure 4.9: PCA plot of HumanOmniExpress_12 v1.1 and HumanHap550K samples after outlier removal. Overlapping SNPs were pruned (r2<0.2) 
and first 2 principal components (PC1 vs PC2) plotted. Blue markers signify OMNI chip cases (NPC patients), orange markers signify OMNI chip 





















Figure 4.10: PCA plot of HumanOmniExpress_12 v1.1 and HumanHap550K against Hapmap CHB and JPN samples after outlier removal. 
Overlapping SNPs were pruned (r2<0.2) and first 2 principal components plotted. Blue markers signify OMNI chip cases (NPC patients), orange 
markers signify OMNI chip controls (healthy controls), black markers signify 550K chip cases (NPC patients), white markers signify 550K chip 






















Figure 4.11: Manhattan plot of HumanOmniExpress_12 v1.1, HumanHap550K and all imputated SNPs. Only SNPs showing P<0.01 are shown. The 










Figure 4.12: QQ plot of merged HumanOmniExpress_12 v1.1 and HumanHap550K post imputation. Red markers signify unadjusted P-values and 









Figure 4.13: PCA plot. The 10 NPC and 7 non-NPC tissues clustered across their first 
two principal components based on regularized log (rlog) of expression data from Ion 






Figure 4.14: Sample-to-sample distances. Heatmap showing the Euclidean distances 
between the samples as calculated from the regularized log transformation count data 





















Table 4.8: Pathways associated with NPC in a Malaysian Chinese cohort. 
 




cPCombined dPBonf-Combined eAmpliSeq 
GSEA 
Gene Ontology Axonemal dynein complex 12 0.0198 1.27x10-24 1.50x10-24 4.15x10-21 6.56x10-4 
Gene Ontology Chromosome, centromeric region 46 0.0235 3.54x10-8 1.82x10-8 5.02x10-5 0.95 
 
aNominal GSEA calculated by MAGENTA 
bNominal GSEA calculated by GSA-SNP 
cCombination P-values of nominal MAGENTA and GSA-SNP P-values using Fisher’s method  
dBonferroni corrected combination P-values 





Table 4.9: List of genes in pathways associated with NPC. 
 










Axonemal dynein complex 12 1767 DNAH5 1.30x10-2 3.07x10-7 -2.64 1.28x10-6 -2.82 
 1769 DNAH8 8.22x10-1 7.4X10-1 -0.05 2.08x10-2 -2.14 
 1770 DNAH9 3.80x10-2 6.79X10-8 -2.16 5.60x10-6 -3.59 
 7802 DNALI1 4.23x10-1 4.24X10-9 -3.05 4.31x10-24 -5.60 
 8632 DNAH17 3.74x10-1 3.34X10-1 -0.11 3.81x10-4 2.51 
 8701 DNAH11 4.37x10-1 5.37X10-6 -0.64 2.52x10-4 -2.31 
 10126 DNAL4 6.03X10-1 7.65X10-3 -0.45 3.05x10-1 0.35 
 25981 DNAH1 9.07X10-1 3.14X10-7 -0.59 3.66x10-5 -1.83 
 55567 DNAH3 4.85X10-2 2.82X10-8 -0.99 2.84x10-6 -4.40 
 56171 DNAH7 1.62X10-1 1.83X10-7 -1.72 1.19x10-5 -3.33 
 64446 DNAI2 4.64X10-1 3.04X10-7 -2.48 1.96x10-16 -6.81 




Table 4.9, continued.         
         










Chromosomal, centromeric region 46 332 BIRC5 1.38X10-2 1.05x10-5 1.56 1.39x10-4 1.58 
 1058 CENPA 8.96X10-1 1.68x10-4 1.27 5.78x10-4 1.46 
 1059 CENPB 5.82X10-1 3.96x10-2 0.22 3.70x10-1 0.27 
 1062 CENPE 7.34X10-1 4.25x10-5 1.18 3.21x10-2 1.17 
  1063 CENPF 6.65X10-1 3.73x10-6 1.51 1.14x10-4 1.66 
  2491 CENPI N/A 3.97x10-4 0.83 1.06x10-3 1.28 
  3070 HELLS 3.17X10-1 7.11x10-8 2 6.98x10-4 1.13 
  3619 INCENP 8.51X10-1 2.76x10-1 -0.1 4.63x10-1 0.26 
  4288 MKI67 1.27X10-1 2.79x10-5 0.94 3.29x10-2 1.06 
  5515 PPP2CA 6.48X10-1 4.14x10-1 0.20 4.40x10-1 0.31 
  5516 PPP2CB 8.28X10-1 1.22x10-1 -0.22 1.35x10-1 0.45 
  5518 PPP2R1A 4.54X10-1 7.12x10-1 -0.08 5.43x10-1 0.15 
  5525 PPP2R5A 7.31X10-1 2.41x10-3 -0.55 6.88x10-5 -1.12 
  5527 PPP2R5C 1.38X10-1 7.45x10-2 -0.54 1.26x10-6 -1.49 
  5663 PSEN1 7.42X10-2 1.00x10-1 -0.13 2.53x10-1 -0.27 
  6839 SUV39H1 N/A 5.37x10-1 0.08 5.09x10-2 0.45 
  8690 JRKL 7.10X10-1 1.16x10-1 -0.14 8.26x10-1 -0.09 
  10403 NDC80 5.16X10-1 4.00x10-6 1.97 3.09x10-2 0.97 
  10664 CTCF 2.33x10-1 4.59x10-2 -0.31 8.95x10-2 -0.51 
  10951 CBX1 1.40X10-1 6.32x10-3 0.82 1.06x10-7 2.28 
  11004 KIF2C 1.81X10-1 1.19x10-4 0.90 1.29x10-4 1.57 
  11339 OIP5 5.11X10-1 1.87x10-4 1.48 3.72x10-5 1.82 
  23421 ITGB3BP 6.04X10-1 1.89x10-4 0.77 3.89x10-2 0.78 
  27309 ZNF330 6.76X10-1 4.27x10-1 -0.13 3.56x10-1 0.25 
  54069 MIS18A 6.65x10-1 6.51x10-4 1.16 2.30x10-4 0.83 
  55143 CDCA8 5.31X10-1 2.32x10-2 0.38 1.79x10-3 1.19 




Table 4.9, continued.         
         










  55320 MIS18BP1 7.29x10-1 1.23x10-2 0.55 1.66x10-1 -0.40 
  55355 HJURP 3.85X10-1 1.52x10-3 0.63 6.63x10-4 1.33 
  55920 RCC2 6.02X10-1 6.13x10-3 0.47 1.74x10-3 1.05 
  79075 DSCC1 4.31X10-1 4.95x10-6 1.49 1.33x10-3 1.57 
  79723 SUV39H2 2.83X10-2 8.58x10-4 1.27 1.73x10-6 1.80 
  81789 TIGD6 4.09X10-3 9.65x10-1 0.01 8.56x10-1 -0.11 
  83540 NUF2 1.67X10-2 2.75x10-5 2.06 1.94x10-4 1.47 
  84948 TIGD5 5.23X10-1 1.65x10-1 0.21 4.03x10-3 0.78 
  91151 TIGD7 3.95X10-1 5.48x10-2 -0.56 4.33x10-1 -0.67 
  91687 CENPL 6.66X10-1 1.06x10-3 0.65 2.21x10-3 1.13 
  151246 SGOL2 4.34X10-2 3.59x10-3 0.88 1.45x10-2 0.82 
  151648 SGOL1 1.89X10-1 1.02x10-2 0.22 5.26x10-4 1.30 
  166815 TIGD2 5.61X10-1 1.21x10-2 0.64 3.56x10-2 0.56 
  200765 TIGD1 9.12X10-1 1.29x10-1 0.61 2.72x10-2 -0.59 
  201254 STRA13 4.17X10-2 3.00x10-1 0.27 2.84x10-1 0.37 
  201798 TIGD4 6.68X10-1 1.31x10-1 -0.19 N/A N/A 
  220359 TIGD3 3.69X10-1 1.94x10-1 -0.14 4.06x10-1 -0.81 
  378708 APITD1 5.39X10-1 6.94x10-1 0.12 2.97x10-1 0.48 
  387103 CENPW 8.99X10-1 1.04x10-2 0.97 1.85x10-5 1.71 
 
aGene P-val assigned using best SNP association; 10kb UTR 2kb DTR 
bGene differential expression calculated by GEO2R (limma package) adjusting for log2 fold change 
cLog2 fold change calculated in the direction of NPC cases vs non-NPC nasopharynx tissue 
dGene differential expression calculated by DESeq2 from 10 NPC and 7 non-NPC nasopharynx tissues from a Malaysian cohort 







Table 4.10: Sample details of NPC and non-NPC nasopharynx tissues from a Malaysian cohort used in gene expression analysis. 
 
Sample ID Phenotype Gender Ethnic group Histology 
non-NPC1 non-NPC Male Bajau lymphoid tissue with 40% normal epithelial 
non-NPC2 non-NPC Female Other Malaysian lymphoid tissue with 30% epithelial 
non-NPC3 non-NPC Female Bajau lymphoid tissue with 20% normal epithelial 
non-NPC4 non-NPC Female Kadazan Dusun lymphoid tissue with 30% epithelial 
non-NPC5 non-NPC Male Indian lymphoid tissue with 20% epithelial 
non-NPC6 non-NPC Female Malay lymphoid tissue with 20% epithelial 
non-NPC7 non-NPC Male Malay lymphoid tissue with 40% epithelial 
NPC1 NPC Male Other Malaysian 80% cancer cells 
NPC2 NPC Male Bajau 80% cancer cells 
NPC3 NPC Female Kadazan Dusun 80% cancer cells 
NPC4 NPC Male Kadazan Dusun 80-90% cancer cells 
NPC5 NPC Female Other Malaysian 80% cancer cells 
NPC6 NPC Male Other Malaysian 80-90% cancer cells 
NPC7 NPC Female Kadazan Dusun 80% cancer cells 
NPC8 NPC Male Kadazan Dusun 90% cancer cells 
NPC9 NPC Male Malay 90% cancer cells 








4.3.2 GWAS and Gene Expression Pathway analysis 
For GSEA of both GWAS and gene expression data, 2,757 pathways was 
screened with gene sizes of 10-100 genes across BioCarta, GO, Ingenuity, KEGG, 
Panther and Reactome databases. GSEA of GWAS data in MAGENTA identified 92 
pathways associated with NPC, showing nominal PGWAS-GSEA<0.05 (Appendix N). 
GSEA of gene expression data in GSA-SNP identified 312 pathways associated with 
NPC, with a similar threshold of nominal PEXPR-GSEA<0.05 (Appendix N). A total of 8 
overlapping pathways were identified across the two platforms, assuming the nominal 
threshold of P<0.05 (Appendix O). We used Fisher’s method to integrate the GSEA P-
values from GWAS and gene expression data. 
Two pathways were identified to be associated with NPC, namely the GO 








-5) pathway (Table 4.8; Appendix P). Upon 
replication using NPC and non-NPC nasopharynx tissues, only the Gene Ontology (GO) 
axonemal dynein complex association was replicated (PAmpliSeq-GSEA=6.56x10
-4) while 
the chromosomal centromic region association was not replicated (PAmpliSeq-GSEA=0.95) 
(Table 4.8). Of the 12 genes that form this axonemal dynein complex pathway, 2 genes 
showed nominal significance in both GWAS and gene expression data with log2 fold-
change ≤ -2, namely DNAH5 (PDNAH5-GWAS=1.30x10-2; PDNAH5-exp=3.07x10-7; log2FC=-
2.64) and DNAH9 (PDNAH9-GWAS=3.8x10
-2; PDNAH9-exp=6.79x10
-8; log2FC=-2.16) (Table 
4.9). The difference in gene expression of DNAH5 and DNAH9 between NPC and non-
NPC nasopharynx tissues was replicated (DESeq2 FDR-corrected Wald test P<0.05, 
log2FC≤-2) in our replication cohort (PDNAH5-AmpliSeq=7.75x10-5, log2FC=-2.44; PDNAH9-
AmpliSeq=4.50x10
-6, log2FC=-3.67) (Table 4.9). These results implicate key genes in the 
axonemal dynein complex pathway driving NPC development.  
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CHAPTER 5: DISCUSSION 
 
5.1 Discussion for NPC GWAS study 
This study describes a NPC GWAS of the Malaysian Chinese population, with 
emphasis on the HLA-A region. NPC GWAS studies to date have consistently 
implicated the HLA-A as a strongly associated locus towards NPC (Bei et al., 2010; 
Tang et al., 2012; Tse et al., 2009). In this study, strong SNP and amino acid 
association signals were detected, driven by both susceptible HLA-A allele HLA-
A*02:07 and protective HLA-A*11:01. Controlling for effects of HLA-A*02:07 reduced 
the associations of both damaging variants, HLA-A-99Tyr/Cys-rs1136697-A/G and 
HLA-A-145Arg/His-rs1059520 while controlling for effects of HLA-A*11:01 reduced 
the associations of HLA-A 5’-UTR SNPs and adjacent GABBR1, HLA-F and HCG9 loci 
(Appendix E-F, Appendix J-K). Thus, HLA-A association is largely driven by effects of 
HLA-A*02:07 and HLA-A*11:01, with internal and adjacent SNPs and amino acid 
variants acting as proxies. 
 HLA-A alleles display diverse occurrence across different populations. The 
HLA-A*02:07 allele shows a frequency ranging from 6% to 13% among Southern Han 
Chinese individuals, including those of Hong Kong, Taiwan, Singapore and Malaysia 
(González-Galarza et al., 2015).  In stark contrast, HLA-A*02:07  is rare in Japan, with 
only frequency of less than 1% (González-Galarza et al., 2015). The HLA-A*11:01 
allele shows an even more striking contrast between Southern Han Chinese individuals 
and Japanese individuals with frequencies of approximately 30% in Southern Han 
Chinese while it is reported to be only 5% in the Japanese population (Nakaoka & 
Inoue, 2015). As HLA-A alleles are linked to NPC occurrence, its diverse distribution 
could be a factor in  the distinct distribution of NPC incidence.    
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In our present study, in silico methods of PROVEAN (Choi et al., 2012), SIFT 
(Kumar et al., 2009) and Polyphen-2 (Adzhubei et al., 2010) predicted damaging 
variants for HLA-A-99Tyr (pocket groove binding) and HLA-A-145Arg (T-cell 
receptor binding site). HLA-A-99Tyr is a residue for pocket A, B, C and D binding. The 
stability of pocket B is critical as it is the binding groove for anchor position 2 of HLA-
A associated peptides (Matsui et al., 1993). From our study, multi-allelic variants are 
observed for HLA-A-aa-site-99, namely HLA-A-99Phe and HLA-A-99Cys. However, 
HLA-A-99Phe is predicted to be a benign or tolerated variant (Table 3.4). Thus, the 
damaging variant HLA-A-99Cys could possibly be influencing the peptide loading 
ability of HLA-A, and subsequently altering the cytotoxic T lymphocyte (CTL) 
recognition of the MHC-peptide complex. The stability of cell-mediated immune 
responses is also modulated by the T-cell receptors. In HLA-A molecules, the T-cell 
receptor acts to bind and stabilize the cytotoxic T-cells-MHC-peptide complex, while 
the CTL elicits an apoptotic response to destroy the infected cell (Salter et al., 1990). A 
damaging variant on HLA-A-145Arg was detected. It is a T-cell receptor binding site of 
the HLA-A molecule. This variant is located in the α3 domain encoded by exon 3 of the 
HLA-A gene, the binding site of the CD8 co-receptor (Salter et al., 1990). Despite not 
being the main contact point for the CD8 receptor (residue 223-229), it is possible that 
mutation in HLA-A-145Arg could de-stabilize the T-cell receptor binding to the MHC-
peptide complex, disrupting the antigen-specific activation. Although HLA-A variants 
have been identified to be associated with NPC in this study, the results fail to exclude 
the influence of EBV in NPC development. This limitation is because EBV data such as 
serology or DNA viral load is not available for our samples.  
EBV genotypes have been found to be unique for specific tissue types (Chen et 
al., 1996) as well as ethnicity (Zhou et al., 2008). EBV genotypes show distinct BZLF 
gene variation in blood and tissue samples (Chen et al., 1996). In Southern China, the 
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type C EBV variant is more prevalent. This variant shows a loss of a BamHI site 
between the BamHl Wl* and I1* regions. In addition, an “f” variant  harboring an extra 
BamHI site in the BamHI F region is also detected (Lung et al., 1990). The type C 
variant is less prevalent in non-endemic regions, as observed in NPC cases in Japan 
whereby EBV type A is the more prevalent genotype (Zhou et al., 2008). The different 
EBV genotypes are speculated to influence NPC development differently. However, 
most reports merely document association and correlation. No studies thus far have 
reported on how the EBV genotype influences NPC occurrence. 
The high SNP exclusion rate from our GWAS could possibly result in lower 
power of detection. The excluded SNPs were cross-checked against the National 
Human Genome Research Institute (NHGRI) Catalog of Published Genome-Wide 
Association Studies (GWAS) Catalog (Welter et al., 2014), the Catalogue of Somatic 
Mutations (COSMIC) (Forbes et al., 2011) and the Genetic Association Database 
(GAD) (Becker et al., 2004). No previous GWAS and COSMIC loci were found among 
our excluded SNPs. As for the GAD database, there were potential NPC associated 
genes that were implicated such as ABCB1, GSTM1, MDM2, MMP2, NAT2, NQO1, 
TLR10 and TLR4 and these loci were excluded due to low genotyping rate (call rates < 
99%) or rare minor alleles (MAF < 1%). In addition, removal of sample outliers 
showing abnormal population structure or cryptic relatedness is important to avoid false 
positives. Samples of different ethnicity would introduce a bias and skew the SNP 
frequencies, affecting the association analysis. Similarly, presence of relatives would 
inflate the frequencies of SNP alleles and affect the association analysis as well. In 
GWAS studies, the common practice would be to remove all unexpected relatedness, 
including 4th and 5th degree relatives. This would minimize the effect of cryptic 




5.2 Discussion for meta-analysis of NPC GWAS 
This study presents results from a meta-analysis of NPC GWAS followed by 
replication studies across three regions in Asia. A novel association was observed 
within the CLPTM1L/TERT locus. This finding is of note given that SNPs in this region 
were reported from GWAS conducted for numerous other cancers, including lung, 
bladder, pancreas, testis, and central nervous system (Mocellin et al., 2012). A recent 
meta-analysis of 85 studies including over 490,000 subjects that evaluated 67 
TERT/CLPTM1L locus polymorphisms and 24 tumor types identified 11 SNPs with 
strong cumulative evidence for an association with at least one cancer type. rs31489 
was one of these SNPs and was found to have strong cumulative evidence for 
association with testicular cancer among Caucasians and moderate cumulative evidence 
for association with Asian lung cancer (Mocellin et al., 2012). Furthermore, a review of 
the literature identified candidate gene studies (two that evaluated SNPs and a third that 
evaluated a microsatellite marker) that reported an association between polymorphisms 
within the CLPTM1L/TERT locus and NPC (Fachiroh et al., 2012; Yee Ko et al., 2014; 
Zhang et al., 2011). Two of the three SNPs evaluated in these studies are in LD with 
rs31489 (rs401681 r2=0.427 in 1 kG ASN and 0.512 in 1 kG CHB; rs402710 r2=0.433 
in 1 kG ASN and 0.569 in 1 kG CHB). The third SNP is not in LD with rs31489, 
suggesting the possibility for the existence of greater than one independent 
susceptibility variant within the CLPTM1L/TERT locus (rs2736098 r2=0.016 in 1 kG 
ASN and 0.049 in 1 kG CHB). Our findings in the CLPTM1L/TERT locus gain added 
significance given the role of TERT in telomere length regulation (Bellon & Nicot, 
2008), the finding that telomerase overexpression is observed in NPC (Cheng et al., 
1998), and that the EBV protein LMP1, a protein frequently expressed in NPC, 
activates TERT expression and enhances telomerase activity (Mei et al., 2006; Terrin et 
al., 2008). There was evidence for possible heterogeneity in effect observed for rs31489 
 
96 
across study populations (Phet=0.035). The evidence for heterogeneity was of marginal 
statistical significance and was driven primarily by the two Malaysian studies included 
in this study. It is unclear at this time whether our findings reflect true heterogeneity. 
This observation deserves further consideration in future studies. 
Additional associations (P≤ 1x10-7) were observed in our combined GWA plus 
replication studies meta-analysis for rs6774494 (P=1.5x10-12; MECOM gene region), 
rs9510787 (P=5.0x10-10; TNFRSF19 gene region), rs1412829, rs4977756, and 
rs1063192 (P=2.8x10−8, P=7.0x10-7, and P=8.4x10-7, respectively; CDKN2A/2B gene 
region; Table 4.3 and Figure 4.1). These associations were previously reported from the 
Mainland China NPC GWAS and their potential biological implications discussed (Bei 
et al., 2010); the study data provide support for these associations. 
Strengths of the study include the fact that it evaluated associations with NPC 
across multiple GWAS and the large size of its replication effort. Limitations include 
the inability to further investigate potential heterogeneity of effects by exposure status 
or geographic/ethnic groups. This study also did not identify functional variants of the 
CLPTM1L/TERT locus. This aspect is important considering cells with mutated TERT 
promoters have elongated telomeres, with the possibility of promoting immortalization 
and tumorigenesis of cancer cells (Chiba et al., 2015). Future studies should explore the 










5.3 Discussion for integrated pathway analysis of NPC 
This work reports an integrated approach of investigating pathway associations 
towards NPC. Using this study design that combines GWAS and gene expression data, 
the joint contributions of genomic variants and differential gene expression towards 
NPC development can be identified. Also, focusing on pathway-based associations 
removes the need to adhere to strict multiple testing thresholds commonly practiced in 
GWAS studies, enabling inclusion of moderate to small effect loci. GSEA was chosen 
for pathway analysis of both GWAS and gene expression data to standardize the 
pathway analysis methodology and avoid discrepancies brought upon by other pathway 
analysis methods. The choice is strongly influenced by MAGENTA and its ability to 
account for confounding factors on the association scores of genes for GWAS data, a 
feature not available for other GSEA methods (Segre et al., 2010).  
GWAS and gene expression data used in this study are from independent 
sources. Also, the epigenetic effect is not addressed in this study. These are possible 
reasons leading to low concordance of gene association strength and differential gene 
expression. Nonetheless, the results identified a link between the axonemal dynein 
complex and NPC. This association was also replicated in a separate cohort of NPC and 
non-NPC tissues, further strengthening our findings. 
Axonemal dynein complex are critical components in the ciliated cells. The 
axonemal dynein complex functions in mucociliary clearance, failure of which would 
lead to infection in the upper and lower respiratory tract (Palmblad et al., 1984).  
Ciliated cells line the upper and lower respiratory tract, the nasopharynx included. 
Coordinated movement of the cilia sweeps mucus out of the upper and lower respiratory 
tract, acting as a primary defense mechanism of the airways (Knowles & Boucher, 
2002). Seeing that NPC is a viral cancer caused by EBV infection as well as 
nasopharynx exposure to carcinogens, the implications of impaired mucociliary 
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clearance, in particular in the upper respiratory tract, are highly relevant to NPC. 
Two genes grouped under the axonemal dynein complex, namely DNAH5 and 
DNAH9 showed consistent association to NPC across both genomic and gene 
expression data. DNAH5 codes for a heavy chain of the dynein complex. Mutations in 
DNAH5 have been linked to cilia immotility (Olbrich et al., 2002). DNAH9 co-exists 
with DNAH5, but is localized in a distal position of the cilia. It also codes for a heavy 
chain of the dynein complex and functions to drive beating of the cilia. Both DNAH5 
(GEO2R log2FC=-2.64; AmpliSeq log2FC= log2FC=-2.44) and DNAH9 (GEO2R 
log2FC=-2.16; AmpliSeq log2FC=-3.67) are lowly expressed in NPC tissues, suggesting 
a loss of function. This study was unable to investigate any links of EBV genes to host 
gene expression due to lack of EBV genes expression data. In addition, there has been 
no previous reports documenting the influence of EBV genes in modulating expression 
of axonemal dynein genes. 
This study is not without its limitations. The association of the axonemal 
dyenein gene set is largely driven by the expression data. In addition, although DNAH5 
and DNAH9 are lowly expressed in NPC tissues, there is no data available indicating 
direct impairment of cilia function. The results are also unable to identify the main 
reason behind the dysregulation of the axonemal dyenein gene set. Other probable 
causes include epigenetic signatures, in particular methylation. There is no paired 
epigenetic data to corroborate this hypothesis. Likewise, the absence of paired genomic 
data also hinders identifying genomic variants that directly correlate with gene 










CHAPTER 6: CONCLUSION 
 
 
The advent of high throughput GWAS studies have accelerated the discovery of 
potential susceptible variants in our genome. The amount of data generated is 
unprecedented, and have led to better understanding of disease etiology. Despite the 
wealth of data available, GWAS studies remains at best, an epidemiological study. 
Despite our best efforts, we have yet to translate our findings to the clinic. Correlation 
does not imply causation. The challenge remains to identify disease causing genomic 
variants with direct consequence to disease. Current limitations include the high cost of  
next  generation sequencing technologies to enable large scale sequencing of samples, 
generating even more detailed maps of our genome. This can be corroborated with other 
data, for example transcriptomics, proteomics and epigenomics to construct a more 
wholistic representation of the dynamics of disease onset. 
In the case of NPC, there is no doubt it displays a multi-factorial etiology. NPC 
onset can range from environmental factors such as diet, lifestyle habits, viral infection 
or even genetics. The challenge moving forward would be to identify functional variants 
of NPC. To unravel the complex etiology of NPC, high throughput platforms will play a 
crucial role in accelerating the search for prospective therapeutic candidates. This 
coupled with the emergence of machine learning or artificial intelligence will shape the 
future direction of cancer research in our never ending quest to understand and combat 
cancer. 
The antigen presentation mechanism of the HLA-A is a complex process, 
instrumented by the peptide loading complex (PLC) that consists of a myriad of 
assembly molecules (Purcell & Elliott, 2008). Polymorphisms in the HLA-A gene only 
constitute a small portion of the processes involved in HLA-A-peptide presentation. Any 
defect in the cascade of processes, starting from the formation of the nascent class I 
heavy chain until the final stage of transporting the MHC-peptide complex to the cell 
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surface, would result in a defective MHC-peptide complex. Not forgetting, the EBV 
virus through the EBNA-1 is capable of eluding the cells immune-surveillance by 
expressing a Gly-Ala repeat sequence, thus preventing its proteosomal breakdown 
(Young & Rickinson, 2004). Solving the genetic predisposition of NPC remains a 
challenging task. Nevertheless, the plethora of genomic data available would greatly 
facilitate exploring the functional basis of NPC development, in particular, the HLA-A 
region. 
The GWAS meta-analysis and replication effort has identified an additional 
susceptibility locus for NPC within the CLPTM1L/TERT region of chromosome 
5p15.33 and provides support for several previously reported NPC susceptibility loci. 
However, heterogeneity does exists across studies, as evidenced by the lack of 
association of the Malaysian NPC loci, ITGA9 in other NPC studies. 
The integrated approach of investigating pathway associations towards NPC, 
utilizing joint contributions of genomic variants and differential gene expression data. 
The results uncovered a pathway with possible influence on NPC development. The 
limited concordance between GWAS association data and differential gene expression 
levels put forth the challenges of adopting a multi-platform approach in identifying 
aberrant or dysregulated pathways in NPC. An eQTL approach analyzing correlation of 
genomic variants to gene expression of a common cohort could enhance the resolution 
of pathway-based GWAS approaches and enable us to drill down to the key pathways 
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  Appendix A: OmniExpress NPC GWAS analysis showing top 20 association signals. 	  
No SNP CHR Position Risk Panel Case, RAF Control, RAF P-val OR 
      b36 allele         (95% CI) 
1 rs3869062 6 30042870 G Cohort 1 (GWAS) 0.81  0.66  2.61E-06 2.57 (1.73-3.81) 
  1/2=A/G       Cohort 2 (Replication) 0.80  0.68  3.51E-04 2.11 (1.4-3.17) 
          Combined 0.80  0.67  1.73E-09 2.37 (1.79-3.14) 
2 rs2735085 6 30035073 C Cohort 1 (GWAS) 0.79  0.66  7.16E-06 2.41 (1.64-3.53) 
 1/2=T/C    Cohort 2 (Replication) 0.79  0.65  1.95E-04 2.12 (1.43-3.14) 
     Combined 0.79  0.65  1.92E-09 2.31 (1.76-3.03) 
3 rs7747253 6 30027757 A Cohort 1 (GWAS) 0.75  0.62  1.58E-05 2.2 (1.54-3.15) 
  1/2=C/A       Cohort 2 (Replication) 0.75  0.60  8.44E-05 2.14 (1.47-3.14) 
          Combined 0.75  0.61  2.08E-09 2.21 (1.71-2.86) 
4 rs2893999 6 30051811 T Cohort 1 (GWAS) 0.81  0.66  1.73E-06 2.63 (1.77-3.9) 
 1/2=C/T    Cohort 2 (Replication) 0.79  0.67  8.12E-04 1.98 (1.33-2.95) 
     Combined 0.80  0.67  2.61E-09 2.32 (1.76-3.07) 
5 rs9260734 6 30040644 G Cohort 1 (GWAS) 0.79  0.65  8.25E-06 2.39 (1.63-3.5) 
  1/2=A/G       Cohort 2 (Replication) 0.79  0.66  2.35E-04 2.1 (1.41-3.12) 
          Combined 0.79  0.65  2.96E-09 2.29 (1.74-3) 
6 rs2860580 6 30014669 C Cohort 1 (GWAS) 0.75  0.79  7.28E-06 2.23 (1.57-3.17) 
 1/2=T/C    Cohort 2 (Replication) 0.73  0.79  1.29E-03 1.8 (1.26-2.58) 
     Combined 0.74  0.79  1.86E-08 2.04 (1.59-2.62) 
7 rs16896044 6 30089729 G Cohort 1 (GWAS) 0.85  0.73  2.40E-05 2.45 (1.62-3.72) 
  1/2=A/G       Cohort 2 (Replication) 0.85  0.77  5.23E-03 1.83 (1.2-2.79) 
          Combined 0.85  0.75  2.07E-07 2.17 (1.62-2.91) 
8 rs2286404 6 30081598 A Cohort 1 (GWAS) 0.85  0.73  2.40E-05 2.45 (1.62-3.72) 
 1/2=G/A    Cohort 2 (Replication) 0.85  0.77  5.23E-03 1.83 (1.2-2.79) 
     Combined 0.85  0.75  2.07E-07 2.17 (1.62-2.91) 
9 rs3202637 6 30045875 A Cohort 1 (GWAS) 0.78  0.64  4.06E-06 2.41 (1.66-3.51) 
  1/2=G/A       Cohort 2 0.75  0.65  2.36E-02 1.52 (1.06-2.19) 
	            Combined 0.76  0.64  5.07E-07 1.93 (1.49-2.5) 
10 rs2844804 6 30050105 C Cohort 1 (GWAS) 0.56  0.44  4.20E-05 2.06 (1.46-2.9) 
 1/2=A/C    Cohort 2 (Replication) 0.55  0.48  3.98E-02 1.42 (1.02-1.98) 
     Combined 0.56  0.46  7.40E-06 1.72 (1.36-2.18) 
11 rs16896923 6 30108665 T Cohort 1 (GWAS) 0.85  0.73  2.44E-05 2.45 (1.61-3.71) 
  1/2=C/T       Cohort 2 (Replication) 0.84  0.77  1.49E-01 1.51 (0.86-2.64) 
          Combined 0.85  0.75  1.46E-05 2.07 (1.49-2.87) 
12 rs10484549 6 30134268 T Cohort 1 (GWAS) 0.85  0.73  2.44E-05 2.45 (1.61-3.71) 
 1/2=C/T    Cohort 2 (Replication) 0.84  0.77  1.49E-01 1.51 (0.86-2.64) 
     Combined 0.85  0.75  1.46E-05 2.07 (1.49-2.87) 
13 rs1165165 6 25970445 A Cohort 1 (GWAS) 0.21  0.13  9.35E-06 3.18 (1.91-5.29) 
  1/2=A/G       Cohort 2 (Replication) 0.22  0.18  1.59E-01 1.48 (0.86-2.56) 
          Combined 0.21  0.15  2.75E-05 2.11 (1.49-2.99) 
14 rs1165159 6 25972604 G Cohort 1 (GWAS) 0.21  0.13  9.35E-06 3.18 (1.91-5.29) 
 1/2=G/A    Cohort 2 (Replication) 0.22  0.18  1.59E-01 1.48 (0.86-2.56) 
     Combined 0.21  0.15  2.75E-05 2.11 (1.49-2.99) 
15 rs2523946 6 30049922 T Cohort 1 (GWAS) 0.57  0.44  3.27E-05 2.06 (1.47-2.9) 
  1/2=T/C       Cohort 2 (Replication) 0.54  0.48  4.39E-01 1.18 (0.77-1.8) 
          Combined 0.56  0.46  9.67E-05 1.67 (1.29-2.17) 
16 rs1324087 6 25949387 A Cohort 1 (GWAS) 0.17  0.12  3.09E-05 3.26 (1.87-5.68) 
 1/2=A/G    Cohort 2 (Replication) 0.19  0.16  2.30E-01 1.43 (0.8-2.57) 
     Combined 0.18  0.14  1.09E-04 2.11 (1.44-3.07) 
17 rs10432590 2 118759781 T Cohort 1 (GWAS) 0.19  0.10  2.06E-05 2.89 (1.77-4.7) 
  1/2=T/C       Cohort 2 (Replication) 0.13  0.12  7.57E-01 1.08 (0.66-1.77) 
          Combined 0.15  0.11  7.19E-04 1.79 (1.28-2.51) 
18 rs10862694 12 82487317 C Cohort 1 (GWAS) 0.50  0.38  3.17E-05 2.16 (1.5-3.11) 
 1/2=C/A    Cohort 2 (Replication) 0.45  0.44  9.05E-01 0.97 (0.63-1.5) 
     Combined 0.48  0.41  1.98E-03 1.53 (1.17-2) 
19 rs6062957 20 60821530 T Cohort 1 (GWAS) 0.77  0.70  3.48E-05 2.38 (1.58-3.58) 
  1/2=C/T       Cohort 2 (Replication) 0.72  0.74  6.29E-01 0.88 (0.54-1.45) 
	            Combined 0.75  0.72  2.74E-03 1.59 (1.17-2.16) 
20 rs13426 1 32028673 A Cohort 1 (GWAS) 0.62  0.48  1.06E-05 2.24 (1.57-3.21) 
 1/2=G/A    Cohort 2 (Replication) 0.58  0.57  7.84E-01 0.96 (0.7-1.31) 
          Combined 0.60  0.53  2.92E-03 1.41 (1.13-1.78) 	  
1=minor allele; 2=major allele; RAF=Risk allele frequency; P-val=Logistic regression P-value adjusting for age, gender and PC1; OR=Odds ratio; 95% CI= 95% confidence interval 
Cohort 1 (GWAS): Cases, n=184; Controls, n=236; Total, n=420 
Cohort 2: Cases, n=260; Controls, n=245; Total, n=505 
Combined: Cases, n=444; Controls, n=481; Total, n=925 
GWAS total SNPs tested: 575,247 

























	  Appendix B: Association results of HLA-A flanking SNPs imputated by Hapmap 2, Hapmap 3 and 1000 genomes. 
 
Hapmap 2   
No SNP ID CHR Position Position Risk allele Panel Case, RAF Control, RAF P-val OR 
      b36 b37           (95% CI) 
1 rs2517723 6 30023247 29915268 A Cohort 1 (GWAS) 0.75  0.62  1.12E-05 2.24 (1.56-3.2) 
  1/2=G/A         Cohort 2 0.74  0.61  2.46E-04 2 (1.38-2.9) 
            Combined 0.75  0.62  4.99E-09 2.15 (1.66-2.78) 
2 rs1632882 6 30024347 29916368 C Cohort 1 (GWAS) 0.78  0.63  3.85E-06 2.42 (1.66-3.52) 
 1/2=A/C     Cohort 2 0.75  0.64  6.02E-04 1.95 (1.33-2.86) 
      Combined 0.76  0.64  6.26E-09 2.19 (1.68-2.85) 
3 rs417162 6 30024484 29916505 A Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
  1/2=G/A         Cohort 2 0.75  0.62  4.94E-04 1.96 (1.34-2.85) 
            Combined 0.75  0.62  6.89E-09 2.16 (1.66-2.8) 
4 rs2517713 6 30026078 29918099 A Cohort 1 (GWAS) 0.76  0.61  6.68E-06 2.31 (1.6-3.32) 
 1/2=C/A     Cohort 2 0.74  0.63  2.25E-03 1.78 (1.23-2.57) 
      Combined 0.75  0.62  3.46E-08 2.06 (1.6-2.67) 
5 rs2975042 6 30028515 29920536 A Cohort 1 (GWAS) 0.76  0.62  6.68E-06 2.31 (1.6-3.32) 
  1/2=C/A         Cohort 2 0.74  0.63  2.25E-03 1.78 (1.23-2.57) 
            Combined 0.75  0.63  3.46E-08 2.06 (1.6-2.67) 
6 rs9260599 6 30030632 29922653 C Cohort 1 (GWAS) 0.76  0.62  7.18E-06 2.3 (1.6-3.31) 
 1/2=A/C     Cohort 2 0.75  0.62  2.37E-04 2.04 (1.4-2.99) 
      Combined 0.75  0.62  3.27E-09 2.2 (1.7-2.86) 
7 rs7767668 6 30031002 29923023 T Cohort 1 (GWAS) 0.75  0.62  1.10E-05 2.24 (1.56-3.2) 
  1/2=C/T         Cohort 2 0.75  0.61  2.00E-04 2.03 (1.4-2.95) 
            Combined 0.75  0.62  3.76E-09 2.17 (1.68-2.81) 
8 rs9260632 6 30031269 29923290 G Cohort 1 (GWAS) 0.77  0.63  6.49E-06 2.33 (1.61-3.37) 
 1/2=T/G     Cohort 2 0.76  0.63  4.32E-04 1.95 (1.35-2.83) 
      Combined 0.76  0.63  6.13E-09 2.16 (1.67-2.81) 
9 rs3873283 6 30040979 29933000 T Cohort 1 (GWAS) 0.79  0.65  4.89E-06 2.46 (1.67-3.61) 
	    1/2=C/T         Cohort 2 0.79  0.66  2.59E-04 2.09 (1.41-3.11) 
            Combined 0.79  0.66  1.91E-09 2.32 (1.76-3.05) 
10 rs7754245 6 30046457 29938478 G Cohort 1 (GWAS) 0.77  0.63  7.95E-06 2.34 (1.61-3.4) 
 1/2=A/G     Cohort 2 0.75  0.65  1.62E-02 1.56 (1.09-2.24) 
      Combined 0.76  0.64  5.17E-07 1.93 (1.49-2.5) 
11 rs9260794 6 30047656 29939677 T Cohort 1 (GWAS) 0.80  0.66  2.87E-06 2.54 (1.72-3.76) 
  1/2=A/T         Cohort 2 0.79  0.67  7.79E-04 1.97 (1.33-2.93) 
            Combined 0.79  0.67  4.69E-09 2.28 (1.73-3) 
12 rs5009448 6 30048467 29940488 C Cohort 1 (GWAS) 0.75  0.60  8.04E-06 2.28 (1.59-3.27) 
 1/2=T/C     Cohort 2 0.74  0.62  4.68E-03 1.68 (1.17-2.41) 
      Combined 0.75  0.61  8.97E-08 1.99 (1.55-2.57) 
13 rs2394249 6 30048765 29940786 A Cohort 1 (GWAS) 0.81  0.66  1.76E-06 2.62 (1.77-3.9) 
  1/2=T/A         Cohort 2 0.80  0.67  4.33E-04 2.05 (1.38-3.07) 
            Combined 0.80  0.67  1.50E-09 2.36 (1.79-3.12) 
14 rs9260816 6 30049790 29941811 A Cohort 1 (GWAS) 0.81  0.65  1.79E-06 2.67 (1.78-4) 
 1/2=C/A     Cohort 2 0.79  0.67  1.31E-03 1.91 (1.29-2.82) 
      Combined 0.79  0.66  6.09E-09 2.28 (1.73-3.01) 
15 rs2232236 6 30050170 29942191 G Cohort 1 (GWAS) 0.80  0.66  2.96E-06 2.54 (1.72-3.76) 
  1/2=T/G         Cohort 2 0.79  0.67  5.91E-04 2.01 (1.35-3) 
            Combined 0.80  0.67  3.49E-09 2.3 (1.75-3.04) 
16 rs3823359 6 30050272 29942293 C Cohort 1 (GWAS) 0.79  0.64  1.81E-06 2.51 (1.72-3.66) 
 1/2=G/C     Cohort 2 0.75  0.66  9.43E-03 1.62 (1.13-2.34) 
      Combined 0.77  0.65  7.81E-08 2.04 (1.57-2.64) 
17 rs2394251 6 30051667 29943688 C Cohort 1 (GWAS) 0.80  0.65  5.63E-06 2.46 (1.67-3.62) 
  1/2=G/C         Cohort 2 0.78  0.67  9.98E-04 1.93 (1.3-2.85) 
            Combined 0.79  0.66  9.99E-09 2.23 (1.69-2.92) 
18 rs3873291 6 30056920 29948941 C Cohort 1 (GWAS) 0.85  0.72  1.55E-05 2.51 (1.65-3.8) 
 1/2=T/C     Cohort 2 0.84  0.76  4.94E-03 1.82 (1.2-2.77) 
      Combined 0.84  0.74  1.73E-07 2.17 (1.62-2.9) 
19 rs2275854 6 30084817 29976838 C Cohort 1 (GWAS) 0.84  0.72  7.13E-05 2.19 (1.49-3.23) 
	    1/2=T/C         Cohort 2 0.83  0.76  2.97E-02 1.54 (1.04-2.28) 
            Combined 0.83  0.74  5.21E-06 1.88 (1.43-2.47) 
20 rs16896970 6 30140896 30032917 A Cohort 1 (GWAS) 0.85  0.73  2.40E-05 2.45 (1.62-3.72) 
 1/2=C/A     Cohort 2 0.85  0.77  2.85E-03 1.94 (1.25-2.99) 
            Combined 0.85  0.75  1.20E-07 2.23 (1.66-2.99) 
           Hapmap 3  
No SNP ID CHR Position Position Risk allele Panel Case, RAF Control, RAF P-val OR 
      b36 b37           (95% CI) 
1 rs376646 6 30022356 29914377 C Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=T/C     Cohort 2 0.74  0.63  6.11E-04 1.93 (1.32-2.81) 
            Combined 0.75  0.62  8.52E-09 2.15 (1.65-2.78) 
           1000 Genomes  
No SNP ID CHR Position Position Risk allele Panel Case, RAF Control, RAF P-val OR 
      b36 b37           (95% CI) 
1 rs62388798 6 30013936 29905957 C Cohort 1 (GWAS) 0.78  0.64  1.81E-05 2.28 (1.56-3.32) 
  1/2=T/C         Cohort 2 0.76  0.65  7.54E-04 1.92 (1.31-2.82) 
            Combined 0.77  0.65  4.09E-08 2.1 (1.61-2.74) 
2 rs2517731 6 30014028 29906049 A Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=C/A     Cohort 2 0.74  0.63  1.45E-03 1.82 (1.26-2.63) 
      Combined 0.75  0.62  2.35E-08 2.08 (1.61-2.69) 
3 rs62388799 6 30014005 29906026 A Cohort 1 (GWAS) 0.78  0.64  1.81E-05 2.28 (1.56-3.32) 
  1/2=G/A         Cohort 2 0.76  0.65  7.54E-04 1.92 (1.31-2.82) 
            Combined 0.77  0.65  4.09E-08 2.1 (1.61-2.74) 
4 rs428081 6 30014491 29906512 T Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=C/T     Cohort 2 0.74  0.63  1.45E-03 1.82 (1.26-2.63) 
      Combined 0.75  0.62  2.35E-08 2.08 (1.61-2.69) 
5 rs56147022 6 30014512 29906533 C Cohort 1 (GWAS) 0.78  0.64  1.05E-05 2.33 (1.6-3.39) 
  1/2=T/C         Cohort 2 0.76  0.66  1.91E-03 1.82 (1.25-2.66) 
            Combined 0.77  0.65  5.64E-08 2.08 (1.6-2.71) 
6 rs62388801 6 30014536 29906557 A Cohort 1 (GWAS) 0.78  0.64  1.05E-05 2.33 (1.6-3.39) 
	   1/2=C/A     Cohort 2 0.76  0.66  1.91E-03 1.82 (1.25-2.66) 
      Combined 0.77  0.65  5.64E-08 2.08 (1.6-2.71) 
7 rs367077 6 30014543 29906564 C Cohort 1 (GWAS) 0.76  0.62  6.24E-06 2.33 (1.61-3.36) 
  1/2=A/C         Cohort 2 0.75  0.63  7.43E-04 1.92 (1.31-2.8) 
            Combined 0.75  0.62  9.86E-09 2.15 (1.65-2.79) 
8 rs414215 6 30014751 29906772 T Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=C/T     Cohort 2 0.75  0.61  8.57E-05 2.08 (1.44-2.99) 
      Combined 0.75  0.62  1.44E-09 2.21 (1.71-2.86) 
9 rs9260029 6 30015222 29907243 A Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
  1/2=G/A         Cohort 2 0.75  0.61  8.57E-05 2.08 (1.44-2.99) 
            Combined 0.75  0.62  1.44E-09 2.21 (1.71-2.86) 
10 rs9260032 6 30015265 29907286 T Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=C/T     Cohort 2 0.74  0.63  1.45E-03 1.82 (1.26-2.63) 
      Combined 0.75  0.62  2.35E-08 2.08 (1.61-2.69) 
11 rs9260033 6 30015277 29907298 G Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
  1/2=A/G         Cohort 2 0.75  0.61  8.57E-05 2.08 (1.44-2.99) 
            Combined 0.75  0.62  1.44E-09 2.21 (1.71-2.86) 
12 rs3132690 6 30015310 29907331 G Cohort 1 (GWAS) 0.78  0.63  4.07E-06 2.41 (1.66-3.51) 
 1/2=A/G     Cohort 2 0.76  0.64  4.61E-04 1.98 (1.35-2.9) 
      Combined 0.77  0.64  4.20E-09 2.21 (1.7-2.88) 
13 rs116395083  6 30015465 29907486 A Cohort 1 (GWAS) 0.77  0.64  2.34E-05 2.21 (1.53-3.19) 
  1/2=G/A         Cohort 2 0.76  0.66  9.46E-04 1.91 (1.3-2.81) 
            Combined 0.77  0.65  4.36E-08 2.09 (1.6-2.72) 
14 rs9260036 6 30015473 29907494 G Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=C/G     Cohort 2 0.75  0.62  2.46E-04 2.05 (1.4-3.02) 
      Combined 0.75  0.62  3.41E-09 2.21 (1.7-2.88) 
15 rs9260038 6 30015523 29907544 G Cohort 1 (GWAS) 0.76  0.62  9.33E-06 2.27 (1.58-3.27) 
  1/2=T/G         Cohort 2 0.74  0.63  4.09E-04 2 (1.36-2.94) 
            Combined 0.75  0.62  7.95E-09 2.17 (1.67-2.82) 
16 rs387850 6 30015675 29907696 C Cohort 1 (GWAS) 0.76  0.62  9.97E-06 2.27 (1.58-3.26) 
	   1/2=T/C     Cohort 2 0.74  0.63  3.33E-04 2.02 (1.38-2.96) 
      Combined 0.75  0.62  7.04E-09 2.17 (1.67-2.82) 
17 rs366907 6 30015734 29907755 A Cohort 1 (GWAS) 0.76  0.62  6.36E-06 2.31 (1.61-3.33) 
  1/2=C/A         Cohort 2 0.75  0.63  3.90E-04 1.98 (1.36-2.89) 
            Combined 0.75  0.62  4.70E-09 2.18 (1.68-2.83) 
18 rs62388802 6 30015803 29907824 T Cohort 1 (GWAS) 0.78  0.64  1.10E-05 2.32 (1.59-3.38) 
 1/2=C/T     Cohort 2 0.76  0.66  1.91E-03 1.82 (1.25-2.66) 
      Combined 0.77  0.65  5.79E-08 2.08 (1.6-2.71) 
19 rs9260046 6 30016023 29908044 G Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
  1/2=A/G         Cohort 2 0.74  0.62  1.34E-03 1.83 (1.26-2.64) 
            Combined 0.75  0.62  2.16E-08 2.09 (1.61-2.7) 
20 rs1655921 6 30016168 29908189 G Cohort 1 (GWAS) 0.78  0.63  5.38E-06 2.38 (1.64-3.45) 
 1/2=A/G     Cohort 2 0.76  0.64  5.35E-04 1.96 (1.34-2.88) 
      Combined 0.77  0.64  6.43E-09 2.19 (1.68-2.85) 
21 rs9260056 6 30016219 29908240 G Cohort 1 (GWAS) 0.77  0.62  3.90E-06 2.4 (1.66-3.49) 
  1/2=A/G         Cohort 2 0.75  0.63  1.84E-04 2.08 (1.42-3.04) 
            Combined 0.76  0.63  1.45E-09 2.27 (1.74-2.95) 
22 rs9260067 6 30016628 29908649 G Cohort 1 (GWAS) 0.77  0.62  3.90E-06 2.4 (1.66-3.49) 
 1/2=T/G     Cohort 2 0.75  0.63  1.84E-04 2.08 (1.42-3.04) 
      Combined 0.76  0.63  1.45E-09 2.27 (1.74-2.95) 
23 rs9260072 6 30016817 29908838 C Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
  1/2=G/C         Cohort 2 0.75  0.63  4.76E-04 1.97 (1.35-2.89) 
            Combined 0.75  0.62  6.50E-09 2.17 (1.67-2.82) 
24 rs9260077 6 30016933 29908954 T Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) 
 1/2=C/T     Cohort 2 0.75  0.63  4.58E-04 1.97 (1.35-2.89) 
      Combined 0.75  0.62  6.06E-09 2.17 (1.67-2.82) 
25 rs376253 6 30022512 29914533 C Cohort 1 (GWAS) 0.77  0.63  4.37E-06 2.4 (1.65-3.49) 
  1/2=T/C         Cohort 2 0.76  0.64  6.55E-04 1.93 (1.32-2.83) 
            Combined 0.77  0.64  6.64E-09 2.18 (1.68-2.84) 
26 rs2571385 6 30022746 29914767 A Cohort 1 (GWAS) 0.77  0.63  4.37E-06 2.4 (1.65-3.49) 
	   1/2=G/A     Cohort 2 0.76  0.64  6.55E-04 1.93 (1.32-2.83) 
      Combined 0.77  0.64  6.64E-09 2.18 (1.68-2.84) 
27 rs56171155 6 30023096 29915117 C Cohort 1 (GWAS) 0.78  0.64  1.05E-05 2.33 (1.6-3.39) 
  1/2=G/C         Cohort 2 0.76  0.65  4.40E-04 2 (1.36-2.94) 
            Combined 0.77  0.65  1.07E-08 2.18 (1.67-2.85) 
28 rs9260288 6 30024138 29916159 C Cohort 1 (GWAS) 0.78  0.64  1.16E-05 2.32 (1.59-3.38) 
 1/2=A/C     Cohort 2 0.76  0.65  6.79E-04 1.96 (1.33-2.89) 
      Combined 0.77  0.65  1.87E-08 2.16 (1.65-2.82) 
29 rs62390518 6 30024330 29916351 C Cohort 1 (GWAS) 0.78  0.64  1.16E-05 2.32 (1.59-3.38) 
  1/2=T/C         Cohort 2 0.76  0.66  6.79E-04 1.96 (1.33-2.89) 
            Combined 0.77  0.65  1.87E-08 2.16 (1.65-2.82) 
30 rs56369124 6 30025106 29917127 C Cohort 1 (GWAS) 0.77  0.64  2.06E-05 2.23 (1.54-3.22) 
 1/2=T/C     Cohort 2 0.77  0.64  1.18E-04 2.15 (1.46-3.18) 
      Combined 0.77  0.64  5.01E-09 2.21 (1.69-2.88) 
31 rs56232426 6 30025484 29917505 C Cohort 1 (GWAS) 0.78  0.64  1.20E-05 2.31 (1.59-3.37) 
  1/2=A/C         Cohort 2 0.77  0.65  2.82E-04 2.09 (1.4-3.11) 
            Combined 0.77  0.65  7.68E-09 2.22 (1.69-2.91) 
32 rs62390555 6 30027199 29919220 T Cohort 1 (GWAS) 0.77  0.64  2.07E-05 2.23 (1.54-3.22) 
 1/2=G/T     Cohort 2 0.76  0.66  5.09E-04 1.99 (1.35-2.94) 
      Combined 0.77  0.65  2.20E-08 2.13 (1.64-2.78) 
33 rs9260623 6 30031119 29923140 T Cohort 1 (GWAS) 0.77  0.63  3.13E-05 2.16 (1.5-3.11) 
  1/2=C/T         Cohort 2 0.76  0.63  4.05E-04 1.96 (1.35-2.84) 
            Combined 0.76  0.63  2.40E-08 2.08 (1.61-2.7) 
34 rs62392214 6 30031468 29923489 T Cohort 1 (GWAS) 0.80  0.65  9.31E-07 2.69 (1.81-3.99) 
 1/2=A/T     Cohort 2 0.78  0.66  1.82E-03 1.84 (1.26-2.71) 
      Combined 0.79  0.66  4.76E-09 2.26 (1.72-2.96) 
35 rs436003 6 30031920 29923941 T Cohort 1 (GWAS) 0.80  0.65  9.31E-07 2.69 (1.81-3.99) 
  1/2=A/T         Cohort 2 0.78  0.67  1.82E-03 1.84 (1.26-2.71) 
            Combined 0.79  0.66  4.76E-09 2.26 (1.72-2.96) 
36 rs117485380 6 30033260 29925281 C Cohort 1 (GWAS) 0.81  0.66  2.32E-06 2.58 (1.74-3.83) 
	   1/2=G/C     Cohort 2 0.80  0.68  6.93E-04 1.99 (1.34-2.96) 
      Combined 0.80  0.67  3.34E-09 2.3 (1.75-3.04) 
37 rs62392216 6 30033856 29925877 G Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
  1/2=A/G         Cohort 2 0.80  0.68  5.68E-04 2 (1.35-2.98) 
            Combined 0.80  0.67  2.96E-09 2.31 (1.75-3.04) 
38 rs115200927 6 30034368 29926389 G Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
 1/2=A/G     Cohort 2 0.79  0.68  7.64E-04 1.97 (1.33-2.93) 
      Combined 0.80  0.67  4.30E-09 2.29 (1.74-3.01) 
39  rs115280716 6 30034394 29926415 C Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
  1/2=A/C         Cohort 2 0.79  0.68  7.41E-04 1.98 (1.33-2.93) 
            Combined 0.80  0.67  4.05E-09 2.29 (1.74-3.02) 
40 rs114905642 6 30034993 29927014 A Cohort 1 (GWAS) 0.81  0.66  2.32E-06 2.58 (1.74-3.83) 
 1/2=C/A     Cohort 2 0.79  0.68  7.41E-04 1.98 (1.33-2.93) 
      Combined 0.80  0.67  3.72E-09 2.3 (1.74-3.03) 
41 rs2394246 6 30035147 29927168 G Cohort 1 (GWAS) 0.79  0.66  8.97E-06 2.38 (1.62-3.48) 
  1/2=T/G         Cohort 2 0.79  0.66  2.54E-04 2.08 (1.41-3.08) 
            Combined 0.79  0.66  3.34E-09 2.27 (1.73-2.99) 
42 rs2735083 6 30035442 29927463 C Cohort 1 (GWAS) 0.79  0.66  9.74E-06 2.37 (1.62-3.47) 
 1/2=A/C     Cohort 2 0.79  0.66  2.04E-04 2.12 (1.43-3.15) 
      Combined 0.79  0.66  2.82E-09 2.29 (1.74-3.01) 
43 rs2517695 6 30035608 29927629 C Cohort 1 (GWAS) 0.79  0.66  8.97E-06 2.38 (1.62-3.48) 
  1/2=T/C         Cohort 2 0.79  0.66  2.54E-04 2.08 (1.41-3.08) 
            Combined 0.79  0.66  3.34E-09 2.27 (1.73-2.99) 
44 rs55897388 6 30036167 29928188 G Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
 1/2=A/G     Cohort 2 0.79  0.68  1.10E-03 1.93 (1.3-2.86) 
      Combined 0.80  0.67  7.01E-09 2.26 (1.71-2.98) 
45 rs116174003 6 30036536 29928557 G Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
  1/2=A/G         Cohort 2 0.79  0.68  8.93E-04 1.95 (1.31-2.89) 
            Combined 0.80  0.67  5.04E-09 2.27 (1.73-3) 
46 rs17179992 6 30037303 29929324 T Cohort 1 (GWAS) 0.80  0.66  3.33E-06 2.5 (1.7-3.69) 
	   1/2=C/T     Cohort 2 0.79  0.67  6.45E-04 1.99 (1.34-2.95) 
      Combined 0.80  0.67  4.04E-09 2.28 (1.73-3) 
47 rs17180006 6 30037339 29929360 A Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
  1/2=G/A         Cohort 2 0.80  0.68  6.08E-04 2.01 (1.35-3) 
            Combined 0.80  0.67  2.98E-09 2.32 (1.76-3.06) 
48 rs62388660 6 30038381 29930402 T Cohort 1 (GWAS) 0.81  0.66  2.98E-06 2.55 (1.72-3.79) 
 1/2=C/T     Cohort 2 0.79  0.68  6.47E-04 1.99 (1.34-2.96) 
      Combined 0.80  0.67  4.30E-09 2.29 (1.73-3.01) 
49 rs62388661 6 30038439 29930460 T Cohort 1 (GWAS) 0.81  0.66  2.32E-06 2.58 (1.74-3.83) 
  1/2=C/T         Cohort 2 0.80  0.68  6.57E-04 1.99 (1.34-2.95) 
            Combined 0.80  0.67  3.32E-09 2.3 (1.75-3.03) 
50 rs56262516 6 30038918 29930939 G Cohort 1 (GWAS) 0.81  0.66  2.83E-06 2.56 (1.73-3.8) 
 1/2=A/G     Cohort 2 0.79  0.68  9.74E-04 1.95 (1.31-2.91) 
      Combined 0.80  0.67  6.28E-09 2.27 (1.72-3) 
51 rs56052321 6 30039625 29931646 T Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
  1/2=C/T         Cohort 2 0.80  0.68  5.07E-04 2.02 (1.36-2.99) 
            Combined 0.80  0.67  2.51E-09 2.32 (1.76-3.05) 
52 rs17180093 6 30043976 29935997 A Cohort 1 (GWAS) 0.81  0.66  2.48E-06 2.57 (1.73-3.8) 
 1/2=C/A     Cohort 2 0.80  0.68  7.54E-04 1.97 (1.33-2.93) 
      Combined 0.80  0.67  3.88E-09 2.29 (1.74-3.02) 
53 rs17180107 6 30044085 29936106 A Cohort 1 (GWAS) 0.81  0.66  2.05E-06 2.59 (1.75-3.83) 
  1/2=C/A         Cohort 2 0.79  0.68  5.91E-04 2.01 (1.35-3) 
            Combined 0.80  0.67  2.54E-09 2.32 (1.76-3.06) 
54 rs6939037 6 30045950 29937971 T Cohort 1 (GWAS) 0.81  0.66  3.57E-06 2.53 (1.71-3.75) 
 1/2=C/T     Cohort 2 0.80  0.67  3.38E-04 2.06 (1.39-3.07) 
      Combined 0.80  0.67  2.35E-09 2.32 (1.76-3.06) 
55 rs17186566 6 30046272 29938293 A Cohort 1 (GWAS) 0.81  0.66  3.67E-06 2.51 (1.7-3.7) 
  1/2=T/A         Cohort 2 0.79  0.67  4.55E-04 2.04 (1.37-3.04) 
            Combined 0.80  0.67  3.46E-09 2.3 (1.74-3.03) 
56 rs17180227 6 30046715 29938736 C Cohort 1 (GWAS) 0.81  0.66  2.58E-06 2.57 (1.73-3.81) 
	   1/2=T/C     Cohort 2 0.80  0.68  6.07E-04 2 (1.34-2.96) 
      Combined 0.80  0.67  3.23E-09 2.3 (1.75-3.03) 
57 rs56289102 6 30048990 29941011 C Cohort 1 (GWAS) 0.81  0.66  1.52E-06 2.64 (1.78-3.93) 
  1/2=T/C         Cohort 2 0.79  0.68  7.96E-04 1.97 (1.32-2.92) 
            Combined 0.80  0.67  2.77E-09 2.31 (1.75-3.05) 
58 rs9260810 6 30049617 29941638 C Cohort 1 (GWAS) 0.79  0.65  2.61E-06 2.51 (1.71-3.69) 
 1/2=G/C     Cohort 2 0.78  0.66  5.10E-04 2.01 (1.36-2.98) 
      Combined 0.79  0.65  2.54E-09 2.29 (1.74-3.01) 
59 rs62388723 6 30050468 29942489 C Cohort 1 (GWAS) 0.81  0.66  1.84E-06 2.63 (1.77-3.9) 
  1/2=T/C         Cohort 2 0.79  0.68  7.68E-04 1.98 (1.33-2.94) 
            Combined 0.80  0.67  2.84E-09 2.32 (1.76-3.06) 
60 rs3823368 6 30051885 29943906 A Cohort 1 (GWAS) 0.81  0.66  1.68E-06 2.63 (1.77-3.9) 
 1/2=G/A     Cohort 2 0.79  0.68  6.72E-04 2.01 (1.34-3) 
            Combined 0.80  0.67  2.56E-09 2.33 (1.77-3.08) 
 
1=minor allele; 2=major allele; RAF=Risk allele frequency; P-val=Logistic regression additive model P-value adjusting for age, gender and PC1; OR=Odds ratio; 95% CI= 95% 
confidence interval 
GWAS: Cases, n=184; Controls, n=236; Total, n=420 
Replication: Cases, n=260; Controls, n=245; Total, n=505 












	  Appendix C: Association of Bi-allelic HLA-A SNPs to NPC susceptibility in Malaysian Chinese. 
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T Cohort 1 (GWAS) 0.77 0.62 8.84E-06 2.34 (1.61-3.41) 
  
1/2=C/T 
   
Cohort 2 0.74 0.63 1.52E-03 1.89 (1.27-2.79) 
      
Combined 0.75 0.62 3.38E-08 2.13 (1.63-2.78) 
     






T Cohort 1 (GWAS) 0.77 0.62 8.84E-06 2.34 (1.61-3.41) 
    1/2=A/T       Cohort 2 0.74 0.63 1.52E-03 1.89 (1.27-2.79) 
            Combined 0.75 0.62 3.38E-08 2.13 (1.63-2.78) 
                      
                      






G Cohort 1 (GWAS) 0.78 0.64 1.70E-05 2.32 (1.58-3.4) 
  
1/2=T/G 
   
Cohort 2 0.76 0.65 1.69E-03 1.89 (1.27-2.81) 
      
Combined 0.77 0.65 7.91E-08 2.11 (1.61-2.77) 






G Cohort 1 (GWAS) 0.78 0.64 1.70E-05 2.32 (1.58-3.4) 
    1/2=C/G       Cohort 2 0.76 0.65 1.69E-03 1.89 (1.27-2.81) 
            Combined 0.77 0.65 7.91E-08 2.11 (1.61-2.77) 
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G Cohort 1 (GWAS) 0.78 0.64 1.70E-05 2.32 (1.58-3.4) 
  
1/2=C/G 
   
Cohort 2 0.76 0.65 1.69E-03 1.89 (1.27-2.81) 
      
Combined 0.77 0.65 7.91E-08 2.11 (1.61-2.77) 
           









G Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
    1/2=T/G       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
                      
                      







C Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
  
1/2=G/C 
   
Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
     
	  A*24:03,A*24:07,A*24:08,A*24:10,A*24:20,A*26:01,
A*29:01,A*31:01,A*32:01,A*33:03 









G Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
    1/2=A/G       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
                      
                      









C Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
  
1/2=G/C 
   
Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
     







C Cohort 1 (GWAS) 0.75 0.62 3.34E-05 2.18 (1.51-3.14) 
    1/2=G/C       Cohort 2 0.74 0.61 4.43E-04 2.01 (1.36-2.97) 
            Combined 0.75 0.61 3.01E-08 2.12 (1.62-2.76) 
                      
                      









C Cohort 1 (GWAS) 0.79 0.64 1.48E-05 2.33 (1.59-3.41) 
  
1/2=G/C 
   
Cohort 2 0.76 0.65 1.32E-03 1.92 (1.29-2.85) 
      
Combined 0.77 0.65 5.88E-08 2.12 (1.62-2.79) 
           









G Cohort 1 (GWAS) 0.79 0.64 1.48E-05 2.33 (1.59-3.41) 
    1/2=A/G       Cohort 2 0.76 0.65 1.32E-03 1.92 (1.29-2.85) 
            Combined 0.77 0.65 5.88E-08 2.12 (1.62-2.79) 
                      









C Cohort 1 (GWAS) 0.79 0.64 1.48E-05 2.33 (1.59-3.41) 
  
1/2=T/C 
   
Cohort 2 0.76 0.65 1.32E-03 1.92 (1.29-2.85) 
      
Combined 0.77 0.65 5.88E-08 2.12 (1.62-2.79) 






G Cohort 1 (GWAS) 0.77 0.62 5.67E-06 2.38 (1.64-3.45) 
    1/2=A/G       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 1.95E-08 2.15 (1.65-2.81) 
                      
                      
15 6 rs3173420 29911114 Exon 3 rs3173420-G: A Cohort 1 (GWAS) 0.77 0.62 1.44E-05 2.27 (1.57-3.29) 









Cohort 2 0.74 0.62 1.43E-03 1.88 (1.28-2.78) 
      
Combined 0.75 0.62 4.60E-08 2.1 (1.61-2.74) 
     






A Cohort 1 (GWAS) 0.39 0.28 1.06E-03 1.86 (1.28-2.7) 
    1/2=A/G       Cohort 2 0.39 0.30 9.79E-02 1.35 (0.95-1.92) 
            Combined 0.39 0.29 1.41E-04 1.61 (1.25-2.08) 
                      
                      









G Cohort 1 (GWAS) 0.78 0.63 5.68E-06 2.41 (1.65-3.53) 
  
1/2=A/G 
   
Cohort 2 0.75 0.64 3.18E-03 1.8 (1.22-2.65) 
      
Combined 0.76 0.64 5.94E-08 2.1 (1.61-2.75) 
           









A Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
    1/2=G/A       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
                      
                      









C Cohort 1 (GWAS) 0.79 0.63 3.88E-06 2.45 (1.67-3.58) 
  
1/2=T/C 
   
Cohort 2 0.75 0.64 3.18E-03 1.8 (1.22-2.65) 
      
Combined 0.76 0.64 4.28E-08 2.12 (1.62-2.77) 
           









C Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
    1/2=T/C       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
                      
                      






C Cohort 1 (GWAS) 0.77 0.62 5.67E-06 2.38 (1.64-3.45) 
  
1/2=T/C 
   
Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.75 0.62 1.95E-08 2.15 (1.65-2.81) 
     





T Cohort 1 (GWAS) 0.77 0.62 5.67E-06 2.38 (1.64-3.45) 
    1/2=C/T       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 1.95E-08 2.15 (1.65-2.81) 
                      
                      
	  A*26:01,A*29:01,A*31:01,A*32:01,A*33:03 









G Cohort 1 (GWAS) 0.79 0.64 1.03E-05 2.36 (1.61-3.46) 
  
1/2=A/G 
   
Cohort 2 0.76 0.65 1.32E-03 1.92 (1.29-2.85) 
      
Combined 0.77 0.65 4.27E-08 2.14 (1.63-2.81) 
           









C Cohort 1 (GWAS) 0.79 0.64 1.03E-05 2.36 (1.61-3.46) 
    1/2=A/C       Cohort 2 0.76 0.65 1.32E-03 1.92 (1.29-2.85) 
            Combined 0.77 0.65 4.27E-08 2.14 (1.63-2.81) 
                      









G Cohort 1 (GWAS) 0.77 0.62 5.07E-06 2.39 (1.64-3.47) 
  
1/2=T/G 
   
Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.75 0.62 1.80E-08 2.16 (1.65-2.82) 
     






C Cohort 1 (GWAS) 0.77 0.62 5.67E-06 2.38 (1.64-3.45) 
    1/2=T/C       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 1.95E-08 2.15 (1.65-2.81) 
                      
                      






T Cohort 1 (GWAS) 0.77 0.62 5.67E-06 2.38 (1.64-3.45) 
  
1/2=A/T 
   
Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.75 0.62 1.95E-08 2.15 (1.65-2.81) 
     
           









A Cohort 1 (GWAS) 0.77 0.62 5.07E-06 2.39 (1.64-3.47) 
    1/2=G/A       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
            Combined 0.75 0.62 1.80E-08 2.16 (1.65-2.82) 
                      
                      
            









C Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
  
1/2=T/C 
   
Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
     
           






A Cohort 1 (GWAS) 0.77 0.62 7.55E-06 2.35 (1.62-3.42) 
    1/2=G/A       Cohort 2 0.74 0.62 1.21E-03 1.91 (1.29-2.82) 
	            A*02:01,A*02:03,A*02:06,A*02:07,A*02:10,A*24:02,
A*24:03,A*24:07,A*24:08,A*24:10,A*24:20,A*26:01,
A*29:01,A*31:01,A*32:01,A*33:03 
  Combined 0.75 0.62 2.56E-08 2.14 (1.64-2.8) 
                      
                      






C Cohort 1 (GWAS) 0.78 0.64 1.53E-05 2.33 (1.59-3.42) 
  
1/2=G/C 
   
Cohort 2 0.76 0.65 1.45E-03 1.91 (1.28-2.84) 
      
Combined 0.77 0.65 6.17E-08 2.13 (1.62-2.79) 







C Cohort 1 (GWAS) 0.78 0.63 5.81E-06 2.42 (1.65-3.54) 
    1/2=T/C       Cohort 2 0.75 0.64 3.45E-03 1.79 (1.21-2.65) 
            Combined 0.76 0.64 6.07E-08 2.11 (1.61-2.76) 
                      
                      
 
aSNPs forming HLA-A alleles identified in our study are denoted accordingly. 
SNP position on HLA-A gene is also denoted as 5'-UTR, Exon, Intron or 3'-UTR. Positions were according to HLA-A sequence data from NCBI dbMHC database  
(http://www.ncbi.nlm.nih.gov/projects/gv/mhc/main.fcgi?cmd=init) 
1=minor allele; 2=major allele; RAF=Risk allele frequency;  P-val=Logistic regression additive model P-value adjusting for age, gender and PC1; OR=Odds ratio; 95% CI= 95% 
confidence interval 
Cohort 1 (GWAS): Cases, n=184; Controls, n=236; Total, n=420 
Cohort 2: Cases, n=260; Controls, n=245; Total, n=505 















	  Appendix D: Association of Multi-allelic HLA-A SNPs to NPC susceptibility in Malaysian Chinese. 
 
No SNP ID Pos b37 aHLA-A alleles Major Panel 
P-val 
(FET) OR (95% CI) 
        Allele   
 
A C G T 












Cohort 2 1.56E-05 REF ALLELE NONE 0.52 (0.39-0.70) 0.59 (0.41-0.85) 
    
Combined 2.07E-09 REF ALLELE NONE 0.50 (0.41-0.63) 0.71 (0.54-0.93) 
      







A Cohort 1 (GWAS) 1.43E-03 REF ALLELE NONE 2.12 (1.38-3.25) 1.36 (0.94-1.96)
    Exon 3    Cohort 2 3.93E-05 REF ALLELE NONE 2.18 (1.52-3.13) 1.49 (1.04-2.14) 
        Combined 3.79E-08 REF ALLELE NONE 2.18 (1.65-2.87) 1.41 (1.09-1.82) 
                    
                    
                    











Cohort 2 4.44E-05 0.37 (0.08-1.78) 1.69 (1.31-2.18) REF ALLELE NONE 
    
Combined 7.00E-08 0.67 (0.23-1.93) 1.70 (1.40-2.05) REF ALLELE NONE 
      







G Cohort 1 (GWAS) 3.88E-04 NONE 1.30 (0.29-5.88) REF ALLELE 1.72 (1.30-2.29) 
    Exon 3    Cohort 2 4.44E-05 NONE 0.37 (0.08-1.78) REF ALLELE 1.69 (1.31-2.18) 
        Combined 7.00E-08 NONE 0.67 (0.23-1.93) REF ALLELE 1.70 (1.40-2.05) 
                    
                    
                    
5 rs9256983 6:29911228 rs9256983-A: A*02:03,A*03:01, A*26:01 










Cohort 2 1.02E-03 0.98 (0.64-1.50) 0.60 (0.45-0.80) 0.24 (0.05-1.17) REF ALLELE 
    
Combined 6.64E-08 0.84 (0.62-1.15) 0.53 (0.43-0.66) 0.41 (0.14-1.20) REF ALLELE 
                    
                    
Association calculation was performed using Fisher Exact Test using 2x3 table testing affection status (Case or Control) against the respective allelic frequencies. 
Odds ratio were calculated using the major allele as a reference allele (denoted as 'REF ALLELE') on which Odds ratios of other alleles were calculated. Alleles not found in a 
particular SNP were denoted as 'NONE' 
	  Appendix E: Multivariate logistic regression of HLA-A single SNPs and previous NPC associated SNPs adjusted for effects of HLA-A*02:06, HLA-
A*02:07 and HLA-A*11:01. 
 
SNP1 b37 pos Gene P-value SNP2 
        A*02:06 A*02:07 A*11:01 
1,3rs2267633 29570841 GABBR1 1.72E-02 3.61E-02 9.58E-02 4.12E-01 
1rs2076483 29571545 GABBR1 1.69E-02 3.55E-02 9.47E-02 4.24E-01 
1rs29230 29576393 GABBR1 1.78E-02 3.55E-02 9.47E-02 4.24E-01 
1rs29232 29576393 GABBR1 2.64E-04 5.13E-05 3.55E-02 2.55E-01 
1rs3129055 29670261 HLA-F 3.40E-02 1.87E-02 6.89E-01 5.12E-01 
1rs9258122 29671740 HLA-F 2.67E-02 1.46E-02 6.30E-01 4.50E-01 
rs62388798 29905957 HLA-A 5'-UTR 4.09E-08 1.97E-07 8.57E-06 4.25E-02 
rs62388799 29906026 HLA-A 5'-UTR 4.09E-08 1.97E-07 8.57E-06 4.25E-02 
rs2517731 29906049 HLA-A 5'-UTR 2.35E-08 1.42E-07 5.56E-06 1.93E-02 
rs428081 29906512 HLA-A 5'-UTR 2.35E-08 1.42E-07 5.56E-06 1.93E-02 
rs56147022 29906533 HLA-A 5'-UTR 5.64E-08 2.66E-07 1.12E-05 5.74E-02 
rs62388801 29906557 HLA-A 5'-UTR 5.64E-08 2.66E-07 1.12E-05 5.74E-02 
rs367077 29906564 HLA-A 5'-UTR 9.86E-09 5.47E-08 3.23E-06 8.72E-03 
2rs2860580 29906691 HLA-A 5'-UTR 1.86E-08 1.45E-07 6.01E-06 2.22E-02 
rs414215 29906772 HLA-A 5'-UTR 1.44E-09 9.80E-09 4.54E-07 2.04E-03 
rs9260029 29907243 HLA-A 5'-UTR 1.44E-09 9.80E-09 4.54E-07 2.04E-03 
rs9260032 29907286 HLA-A 5'-UTR 2.35E-08 1.42E-07 5.56E-06 1.93E-02 
rs9260033 29907298 HLA-A 5'-UTR 1.44E-09 9.80E-09 4.54E-07 2.04E-03 
rs3132690 29907331 HLA-A 5'-UTR 4.20E-09 2.83E-08 8.79E-07 2.38E-03 
rs116395083  29907486 HLA-A 5'-UTR 4.36E-08 2.11E-07 1.18E-05 6.27E-02 
rs9260036 29907494 HLA-A 5'-UTR 3.41E-09 2.15E-08 9.10E-07 3.29E-03 
rs9260038 29907544 HLA-A 5'-UTR 7.95E-09 4.73E-08 1.79E-06 9.32E-03 
rs387850 29907696 HLA-A 5'-UTR 7.04E-09 4.19E-08 1.65E-06 6.78E-03 
rs366907 29907755 HLA-A 5'-UTR 4.70E-09 2.87E-08 1.66E-06 7.12E-03 
rs62388802 29907824 HLA-A 5'-UTR 5.79E-08 2.72E-07 1.14E-05 5.84E-02 
rs9260046 29908044 HLA-A 5'-UTR 2.16E-08 1.32E-07 5.18E-06 1.79E-02 
rs1655921 29908189 HLA-A 5'-UTR 6.43E-09 4.19E-08 1.36E-06 4.38E-03 
rs9260056 29908240 HLA-A 5'-UTR 1.45E-09 8.67E-09 4.12E-07 1.01E-03 
rs9260067 29908649 HLA-A 5'-UTR 1.45E-09 8.67E-09 4.12E-07 1.01E-03 
rs9260072 29908838 HLA-A 5'-UTR 6.50E-09 4.09E-08 1.97E-06 5.62E-03 
rs9260077 29908954 HLA-A 5'-UTR 6.06E-09 3.75E-08 1.72E-06 4.18E-03 
	  rs9260118 29910176 HLA-A 5'-UTR 3.38E-08 1.00E-07 4.74E-06 2.75E-02 
rs9260119 29910189 HLA-A 5'-UTR 3.38E-08 1.00E-07 4.74E-06 2.75E-02 
rs41545520 29910265 HLA-A 5'-UTR 7.91E-08 1.96E-07 9.72E-06 8.41E-02 
rs9260120 29910277 HLA-A 5'-UTR 7.91E-08 1.96E-07 9.72E-06 8.41E-02 
rs114945359 29910324 HLA-A 5'-UTR 7.91E-08 1.96E-07 9.72E-06 8.41E-02 
rs9260125 29910457 HLA-A Intron 1 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs9260127 29910478 HLA-A Intron 1 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
*rs9256980-A/G 29910484 HLA-A Intron 1 1.64E-06 3.35E-06 6.26E-04 8.79E-02 
rs9260129 29910508 HLA-A Intron 1 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs9260130 29910522 HLA-A Intron 1 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs78306866 29910742 HLA-A Exon 2 3.01E-08 9.29E-08 4.31E-06 3.39E-02 
rs41540614 29910865 HLA-A Intron 2 5.88E-08 1.47E-07 7.44E-06 8.56E-02 
rs41547618 29911005 HLA-A Intron 2 5.88E-08 1.47E-07 7.44E-06 8.56E-02 
rs41562213 29911011 HLA-A Intron 2 5.88E-08 1.47E-07 7.44E-06 8.56E-02 
rs1136695 29911064 HLA-A Exon 3 1.95E-08 5.81E-08 2.55E-06 2.54E-02 
*rs1136697-A/G 29911070 HLA-A Exon 3 2.32E-03 6.41E-04 1 1.45E-01 
rs3173420 29911114 HLA-A Exon 3 4.60E-08 1.37E-07 5.74E-06 5.72E-02 
*rs12721717-C/G 29911118 HLA-A Exon 3 6.92E-05 2.21E-04 9.60E-03 5.75E-01 
*rs3173419-T/G 29911121 HLA-A Exon 3 6.92E-05 2.21E-04 9.60E-03 5.75E-01 
rs1059520 29911207 HLA-A Exon 3 1.41E-04 9.29E-04 8.04E-02 1.72E-01 
*rs9256983-C/T 29911233 HLA-A Exon 3 1.23E-08 3.96E-08 2.30E-06 6.67E-02 
rs3132687 29911356 HLA-A Intron 3 5.94E-08 1.60E-07 7.26E-06 7.74E-02 
rs79222956 29911538 HLA-A Intron 3 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs9260164 29911684 HLA-A Intron 3 4.28E-08 1.15E-07 5.03E-06 7.31E-02 
rs29028878 29911727 HLA-A Intron 3 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs1136903 29912280 HLA-A Exon 5 1.95E-08 5.81E-08 2.55E-06 2.54E-02 
rs1141891 29912368 HLA-A Exon 5 1.95E-08 5.81E-08 2.55E-06 2.54E-02 
rs41551619 29912410 HLA-A Intron 5 4.27E-08 1.06E-07 5.19E-06 8.13E-02 
rs41545117 29912614 HLA-A Intron 5 4.27E-08 1.06E-07 5.19E-06 8.13E-02 
rs9260201 29912668 HLA-A Intron 5 1.80E-08 5.37E-08 2.47E-06 2.59E-02 
rs1137296 29912852 HLA-A Exon 6 1.95E-08 5.81E-08 2.55E-06 2.54E-02 
rs2231119 29912856 HLA-A Exon 6 1.95E-08 5.81E-08 2.55E-06 2.54E-02 
rs2975057 29913171 HLA-A Intron 7 1.80E-08 5.37E-08 2.47E-06 2.59E-02 
rs2975055 29913191 HLA-A Intron 7 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs9260210 29913192 HLA-A Intron 7 2.56E-08 7.69E-08 3.68E-06 2.83E-02 
rs41545022 29913386 HLA-A 3'-UTR 6.17E-08 1.54E-07 7.89E-06 8.05E-02 
	  rs62390509 29913430 HLA-A 3'-UTR 6.07E-08 1.63E-07 7.51E-06 7.15E-02 
rs376646 29914377 HLA-A 3'-UTR 8.52E-09 5.85E-08 2.46E-06 1.04E-02 
rs376253 29914533 HLA-A 3'-UTR 6.64E-09 3.81E-08 1.50E-06 6.33E-03 
rs2571385 29914767 HLA-A 3'-UTR 6.64E-09 3.81E-08 1.50E-06 6.33E-03 
rs56171155 29915117 HLA-A 3'-UTR 1.07E-08 5.10E-08 2.63E-06 8.74E-03 
rs2517723 29915268 HLA-A 3'-UTR 4.99E-09 3.65E-08 1.83E-06 7.03E-03 
rs9260288 29916159 HLA-A 3'-UTR 1.87E-08 8.78E-08 4.22E-06 2.20E-02 
rs62390518 29916351 HLA-A 3'-UTR 1.87E-08 8.78E-08 4.22E-06 2.20E-02 
rs1632882 29916368 HLA-A 3'-UTR 6.26E-09 3.80E-08 1.81E-06 8.97E-03 
3rs417162 29916505 HLA-A 3'-UTR 6.89E-09 4.31E-08 1.88E-06 5.54E-03 
rs56369124 29917127 HLA-A 3'-UTR 5.01E-09 2.51E-08 1.20E-06 5.80E-03 
rs56232426 29917505 HLA-A 3'-UTR 7.68E-09 3.67E-08 1.57E-06 9.67E-03 
1,3rs2517713 29918099 HLA-A 3'-UTR 3.46E-08 2.14E-07 8.81E-06 2.68E-02 
rs62390555 29919220 HLA-A 3'-UTR 2.20E-08 1.23E-07 3.90E-06 1.74E-02 
rs7747253 29919779 HLA-A 3'-UTR 2.08E-09 1.62E-08 7.79E-07 2.79E-03 
1rs2975042 29920536 HLA-A 3'-UTR 3.46E-08 2.14E-07 8.81E-06 2.68E-02 
rs9260599 29922653 HLA-A 3'-UTR 3.27E-09 1.96E-08 8.70E-07 4.11E-03 
rs7767668 29923023 HLA-A 3'-UTR 3.76E-09 2.76E-08 1.34E-06 4.61E-03 
rs9260623 29923140 HLA-A 3'-UTR 2.40E-08 1.55E-07 6.57E-06 2.65E-02 
rs9260632 29923290 HLA-A 3'-UTR 6.13E-09 4.22E-08 1.99E-06 7.97E-03 
rs62392214 29923489 HLA-A 3'-UTR 4.76E-09 2.27E-08 1.05E-06 1.89E-03 
rs436003 29923941 HLA-A 3'-UTR 4.76E-09 2.27E-08 1.05E-06 1.89E-03 
rs117485380 29925281 HLA-A 3'-UTR 3.34E-09 1.22E-08 7.19E-07 2.36E-03 
rs62392216 29925877 HLA-A 3'-UTR 2.96E-09 1.07E-08 5.29E-07 1.44E-03 
rs115200927 29926389 HLA-A 3'-UTR 4.30E-09 1.59E-08 9.24E-07 3.61E-03 
rs115280716 29926415 HLA-A 3'-UTR 4.05E-09 1.49E-08 9.01E-07 3.58E-03 
rs114905642 29927014 HLA-A 3'-UTR 3.72E-09 1.39E-08 8.49E-07 3.32E-03 
rs2735085 29927095 HLA-A 3'-UTR 1.92E-09 9.58E-09 4.96E-07 1.34E-03 
rs2394246 29927168 HLA-A 3'-UTR 3.34E-09 1.50E-08 9.21E-07 2.97E-03 
rs2735083 29927463 HLA-A 3'-UTR 2.82E-09 1.67E-08 5.33E-07 1.21E-03 
rs2517695 29927629 HLA-A 3'-UTR 3.34E-09 1.50E-08 9.21E-07 2.97E-03 
rs55897388 29928188 HLA-A 3'-UTR 7.01E-09 2.84E-08 1.37E-06 3.60E-03 
rs116174003 29928557 HCG9 5'-UTR 5.04E-09 1.86E-08 1.07E-06 3.67E-03 
rs17179992 29929324 HCG9 5'-UTR 4.04E-09 1.57E-08 9.62E-07 4.01E-03 
rs17180006 29929360 HCG9 5'-UTR 2.98E-09 1.08E-08 6.70E-07 3.32E-03 
rs62388660 29930402 HCG9 5'-UTR 4.30E-09 1.57E-08 7.68E-07 1.88E-03 
	  rs62388661 29930460 HCG9 5'-UTR 3.32E-09 1.24E-08 6.42E-07 2.10E-03 
rs56262516 29930939 HCG9 5'-UTR 6.28E-09 2.78E-08 8.97E-07 2.74E-03 
rs56052321 29931646 HCG9 5'-UTR 2.51E-09 1.02E-08 4.96E-07 1.42E-03 
1,3rs9260734 29932666 HCG9 5'-UTR 2.96E-09 1.27E-08 5.78E-07 1.31E-03 
rs3873283 29933000 HCG9 5'-UTR 1.91E-09 8.90E-09 4.62E-07 9.24E-04 
1rs3869062 29934891 HCG9 5'-UTR 1.73E-09 7.55E-09 2.59E-07 1.14E-03 
rs17180093 29935997 HCG9 5'-UTR 3.88E-09 1.39E-08 7.20E-07 3.59E-03 
rs17180107 29936106 HCG9 5'-UTR 2.54E-09 9.58E-09 4.95E-07 2.69E-03 
rs6939037 29937971 HCG9 5'-UTR 2.35E-09 8.85E-09 4.66E-07 1.50E-03 
rs17186566 29938293 HCG9 5'-UTR 3.46E-09 1.30E-08 7.58E-07 4.20E-03 
rs17180227 29938736 HCG9 5'-UTR 3.23E-09 1.18E-08 6.88E-07 2.24E-03 
rs9260794 29939677 HCG9 5'-UTR 4.69E-09 1.92E-08 9.18E-07 2.53E-03 
1,3rs5009448 29940488 HCG9 5'-UTR 8.97E-08 5.29E-07 2.44E-05 1.66E-02 
rs2394249 29940786 HCG9 5'-UTR 1.50E-09 5.63E-09 2.69E-07 9.57E-04 
rs56289102 29941011 HCG9 5'-UTR 2.77E-09 1.03E-08 4.04E-07 1.08E-03 
rs9260810 29941638 HCG9 5'-UTR 2.54E-09 1.03E-08 4.96E-07 9.06E-04 
rs9260816 29941811 HCG9 5'-UTR 6.09E-09 2.94E-08 1.34E-06 2.86E-03 
rs2232236 29942191 HCG9 5'-UTR 3.49E-09 1.30E-08 5.73E-07 2.05E-03 
rs62388723 29942489 HCG9 5'-UTR 2.84E-09 1.18E-08 5.12E-07 2.47E-03 
rs2394251 29943688 HCG9 Intron 9.99E-09 3.78E-08 1.67E-06 3.84E-03 
rs2893999 29943832 HCG9 Intron 2.61E-09 1.06E-08 5.11E-07 1.11E-03 
rs3823368 29943906 HCG9 Intron 2.56E-09 1.02E-08 4.49E-07 2.55E-03 
1rs16896923 30000687 ZNRD1-AS1 1.25E-05 3.76E-05 1.94E-04 2.28E-02 
2rs2894207 31263751 HLA-C 5'-UTR 2.00E-01 2.71E-01 4.17E-01 2.60E-01 
2rs28421666 32592737 HLA-DQA1 5'-UTR 7.91E-03 3.88E-03 2.27E-02 5.18E-02 
 
Multiallelic SNPs are denoted by (*). Linkage disequilibrium and logistic regression calculations for multiallelic SNPs were done only using allelic combinations showing the 
strongest association to NPC.  
SNPs reported in previous NPC GWAS are highlighted in grey with the superscript number referring to the corresponding publication. SNPs identified in this study with potential 
epigenetic influence are highlighted in grey without superscript numbers.  
SNP1 is adjusted against effects of SNP2 assuming an additive model. Results are also adjusted for age, gender and principal component 1 (PC1). Reduction in association strength 
is expressed in log10 values. 
References: 1. Tse, K-P. et al. 2009. The American Journal of Human Genetics 85:194-203; 2. Bei, J-X. et al. 2010. Nature genetics 42: 599-603; 3. Tang, M.Z. et al. 2012. PLOS 
Genetics 8(11) 
 
	  Appendix F: Multivariate logistic regression of HLA-A*02:06, HLA-A*02:07 and HLA-A*11:01 adjusted for the effects of HLA-A single SNPs and 
previous NPC associated SNPs. 
 
  b37 pos Gene SNP1 
SNP2     A*02:06 A*02:07 A*11:01 
P-value 
  
6.22E-03 7.71E-05 4.84E-07 
1,3rs2267633 29570841 GABBR1 1.81E-02 8.15E-03 4.70E-04 
1rs2076483 29571545 GABBR1 1.82E-02 8.10E-03 4.97E-04 
1rs29230 29576393 GABBR1 1.82E-02 8.10E-03 4.97E-04 
1rs29232 29576393 GABBR1 1.42E-03 7.40E-03 1.13E-04 
1rs3129055 29670261 HLA-F 4.95E-03 1.74E-02 2.93E-04 
1rs9258122 29671740 HLA-F 4.96E-03 1.65E-02 2.87E-04 
rs62388798 29905957 HLA-A 5'-UTR 2.35E-02 1.83E-02 5.57E-01 
rs62388799 29906026 HLA-A 5'-UTR 2.35E-02 1.83E-02 5.57E-01 
rs2517731 29906049 HLA-A 5'-UTR 3.28E-02 1.89E-02 3.75E-01 
rs428081 29906512 HLA-A 5'-UTR 3.28E-02 1.89E-02 3.75E-01 
rs56147022 29906533 HLA-A 5'-UTR 2.65E-02 1.66E-02 5.12E-01 
rs62388801 29906557 HLA-A 5'-UTR 2.65E-02 1.66E-02 5.12E-01 
rs367077 29906564 HLA-A 5'-UTR 6.11E-02 1.67E-02 5.44E-01 
2rs2860580 29906691 HLA-A 5'-UTR 3.17E-02 1.95E-02 2.09E-01 
rs414215 29906772 HLA-A 5'-UTR 3.56E-02 2.41E-02 6.85E-01 
rs9260029 29907243 HLA-A 5'-UTR 3.56E-02 2.41E-02 6.85E-01 
rs9260032 29907286 HLA-A 5'-UTR 3.28E-02 1.89E-02 3.75E-01 
rs9260033 29907298 HLA-A 5'-UTR 3.56E-02 2.41E-02 6.85E-01 
rs3132690 29907331 HLA-A 5'-UTR 3.25E-02 2.85E-02 9.50E-01 
rs116395083  29907486 HLA-A 5'-UTR 2.74E-02 1.24E-02 4.53E-01 
rs9260036 29907494 HLA-A 5'-UTR 5.40E-02 2.74E-02 7.27E-01 
rs9260038 29907544 HLA-A 5'-UTR 5.32E-02 2.57E-02 4.48E-01 
rs387850 29907696 HLA-A 5'-UTR 5.23E-02 2.44E-02 5.29E-01 
rs366907 29907755 HLA-A 5'-UTR 3.36E-02 1.58E-02 5.31E-01 
rs62388802 29907824 HLA-A 5'-UTR 2.64E-02 1.64E-02 5.11E-01 
rs9260046 29908044 HLA-A 5'-UTR 3.30E-02 1.92E-02 3.87E-01 
rs1655921 29908189 HLA-A 5'-UTR 3.07E-02 2.60E-02 9.09E-01 
rs9260056 29908240 HLA-A 5'-UTR 3.19E-02 2.80E-02 9.35E-01 
rs9260067 29908649 HLA-A 5'-UTR 3.19E-02 2.80E-02 9.35E-01 
rs9260072 29908838 HLA-A 5'-UTR 2.95E-02 2.07E-02 6.35E-01 
	  rs9260077 29908954 HLA-A 5'-UTR 3.00E-02 2.26E-02 6.99E-01 
rs9260118 29910176 HLA-A 5'-UTR 3.60E-02 1.73E-02 4.69E-01 
rs9260119 29910189 HLA-A 5'-UTR 3.60E-02 1.73E-02 4.69E-01 
rs41545520 29910265 HLA-A 5'-UTR 2.90E-02 1.46E-02 6.01E-01 
rs9260120 29910277 HLA-A 5'-UTR 2.90E-02 1.46E-02 6.01E-01 
rs114945359 29910324 HLA-A 5'-UTR 2.90E-02 1.46E-02 6.01E-01 
rs9260125 29910457 HLA-A Intron 1 3.28E-02 1.89E-02 4.47E-01 
rs9260127 29910478 HLA-A Intron 1 3.28E-02 1.89E-02 4.47E-01 
*rs9256980-A/G 29910484 HLA-A Intron 1 1.22E-01 5.75E-03 3.56E-01 
rs9260129 29910508 HLA-A Intron 1 3.28E-02 1.89E-02 4.47E-01 
rs9260130 29910522 HLA-A Intron 1 3.28E-02 1.89E-02 4.47E-01 
rs78306866 29910742 HLA-A Exon 2 3.73E-02 2.62E-02 3.47E-01 
rs41540614 29910865 HLA-A Intron 2 2.64E-02 1.61E-02 5.80E-01 
rs41547618 29911005 HLA-A Intron 2 2.64E-02 1.61E-02 5.80E-01 
rs41562213 29911011 HLA-A Intron 2 2.64E-02 1.61E-02 5.80E-01 
rs1136695 29911064 HLA-A Exon 3 3.57E-02 2.36E-02 4.61E-01 
*rs1136697-A/G 29911070 HLA-A Exon 3 3.10E-03 1 7.66E-05 
rs3173420 29911114 HLA-A Exon 3 3.52E-02 2.11E-02 3.24E-01 
*rs12721717-C/G 29911118 HLA-A Exon 3 3.67E-02 1.76E-02 8.01E-05 
*rs3173419-T/G 29911121 HLA-A Exon 3 3.67E-02 1.76E-02 8.01E-05 
rs1059520 29911207 HLA-A Exon 3 4.52E-02 2.98E-02 5.51E-05 
*rs9256983-C/T 29911233 HLA-A Exon 3 5.52E-02 1.13E-01 3.31E-01 
rs3132687 29911356 HLA-A Intron 3 2.86E-02 1.51E-02 4.40E-01 
rs79222956 29911538 HLA-A Intron 3 3.28E-02 1.89E-02 4.47E-01 
rs9260164 29911684 HLA-A Intron 3 2.98E-02 1.74E-02 4.40E-01 
rs29028878 29911727 HLA-A Intron 3 3.28E-02 1.89E-02 4.47E-01 
rs1136903 29912280 HLA-A Exon 5 3.57E-02 2.36E-02 4.61E-01 
rs1141891 29912368 HLA-A Exon 5 3.57E-02 2.36E-02 4.61E-01 
rs41551619 29912410 HLA-A Intron 5 2.76E-02 1.85E-02 5.82E-01 
rs41545117 29912614 HLA-A Intron 5 2.76E-02 1.85E-02 5.82E-01 
rs9260201 29912668 HLA-A Intron 5 3.43E-02 2.18E-02 4.50E-01 
rs1137296 29912852 HLA-A Exon 6 3.57E-02 2.36E-02 4.61E-01 
rs2231119 29912856 HLA-A Exon 6 3.57E-02 2.36E-02 4.61E-01 
rs2975057 29913171 HLA-A Intron 7 3.43E-02 2.18E-02 4.50E-01 
rs2975055 29913191 HLA-A Intron 7 3.28E-02 1.89E-02 4.47E-01 
rs9260210 29913192 HLA-A Intron 7 3.28E-02 1.89E-02 4.47E-01 
	  rs41545022 29913386 HLA-A 3'-UTR 3.04E-02 1.47E-02 6.00E-01 
rs62390509 29913430 HLA-A 3'-UTR 3.30E-02 1.38E-02 4.61E-01 
rs376646 29914377 HLA-A 3'-UTR 3.21E-02 2.37E-02 4.77E-01 
rs376253 29914533 HLA-A 3'-UTR 2.80E-02 2.55E-02 8.42E-01 
rs2571385 29914767 HLA-A 3'-UTR 2.80E-02 2.55E-02 8.42E-01 
rs56171155 29915117 HLA-A 3'-UTR 2.89E-02 1.60E-02 9.98E-01 
rs2517723 29915268 HLA-A 3'-UTR 3.40E-02 2.23E-02 5.22E-01 
rs9260288 29916159 HLA-A 3'-UTR 2.65E-02 1.75E-02 7.79E-01 
rs62390518 29916351 HLA-A 3'-UTR 2.65E-02 1.75E-02 7.79E-01 
rs1632882 29916368 HLA-A 3'-UTR 2.83E-02 2.04E-02 7.11E-01 
3rs417162 29916505 HLA-A 3'-UTR 3.15E-02 2.40E-02 6.41E-01 
rs56369124 29917127 HLA-A 3'-UTR 2.76E-02 2.84E-02 9.42E-01 
rs56232426 29917505 HLA-A 3'-UTR 4.53E-02 2.69E-02 9.67E-01 
1,3rs2517713 29918099 HLA-A 3'-UTR 2.83E-02 1.70E-02 3.18E-01 
rs62390555 29919220 HLA-A 3'-UTR 2.93E-02 2.63E-02 8.14E-01 
rs7747253 29919779 HLA-A 3'-UTR 4.12E-02 3.68E-02 6.32E-01 
1rs2975042 29920536 HLA-A 3'-UTR 2.83E-02 1.70E-02 3.18E-01 
rs9260599 29922653 HLA-A 3'-UTR 3.46E-02 2.54E-02 6.05E-01 
rs7767668 29923023 HLA-A 3'-UTR 3.16E-02 2.21E-02 6.30E-01 
rs9260623 29923140 HLA-A 3'-UTR 2.77E-02 1.48E-02 5.02E-01 
rs9260632 29923290 HLA-A 3'-UTR 2.83E-02 1.99E-02 7.54E-01 
rs62392214 29923489 HLA-A 3'-UTR 2.67E-02 1.48E-02 5.47E-01 
rs436003 29923941 HLA-A 3'-UTR 2.67E-02 1.48E-02 5.47E-01 
rs117485380 29925281 HLA-A 3'-UTR 2.57E-02 1.51E-02 6.47E-01 
rs62392216 29925877 HLA-A 3'-UTR 2.55E-02 1.92E-02 7.50E-01 
rs115200927 29926389 HLA-A 3'-UTR 2.47E-02 1.41E-02 5.70E-01 
rs115280716 29926415 HLA-A 3'-UTR 2.48E-02 1.36E-02 5.68E-01 
rs114905642 29927014 HLA-A 3'-UTR 2.50E-02 1.39E-02 5.76E-01 
rs2735085 29927095 HLA-A 3'-UTR 2.99E-02 2.93E-02 6.22E-01 
rs2394246 29927168 HLA-A 3'-UTR 2.74E-02 1.52E-02 4.69E-01 
rs2735083 29927463 HLA-A 3'-UTR 3.07E-02 3.19E-02 6.80E-01 
rs2517695 29927629 HLA-A 3'-UTR 2.74E-02 1.52E-02 4.69E-01 
rs55897388 29928188 HLA-A 3'-UTR 2.14E-02 1.45E-02 5.72E-01 
rs116174003 29928557 HCG9 5'-UTR 2.57E-02 1.44E-02 5.84E-01 
rs17179992 29929324 HCG9 5'-UTR 2.59E-02 1.45E-02 5.15E-01 
rs17180006 29929360 HCG9 5'-UTR 2.46E-02 1.39E-02 5.43E-01 
	  rs62388660 29930402 HCG9 5'-UTR 2.28E-02 1.88E-02 7.40E-01 
rs62388661 29930460 HCG9 5'-UTR 2.51E-02 1.77E-02 6.69E-01 
rs56262516 29930939 HCG9 5'-UTR 2.75E-02 2.68E-02 6.44E-01 
rs56052321 29931646 HCG9 5'-UTR 2.56E-02 1.96E-02 7.48E-01 
1,3rs9260734 29932666 HCG9 5'-UTR 2.86E-02 2.30E-02 5.81E-01 
rs3873283 29933000 HCG9 5'-UTR 2.48E-02 2.01E-02 6.30E-01 
1rs3869062 29934891 HCG9 5'-UTR 2.82E-02 3.04E-02 7.58E-01 
rs17180093 29935997 HCG9 5'-UTR 2.45E-02 1.82E-02 5.04E-01 
rs17180107 29936106 HCG9 5'-UTR 2.58E-02 1.96E-02 5.71E-01 
rs6939037 29937971 HCG9 5'-UTR 2.57E-02 1.93E-02 7.30E-01 
rs17186566 29938293 HCG9 5'-UTR 2.59E-02 1.56E-02 4.87E-01 
rs17180227 29938736 HCG9 5'-UTR 2.57E-02 1.52E-02 6.58E-01 
rs9260794 29939677 HCG9 5'-UTR 2.43E-02 2.13E-02 5.28E-01 
1,3rs5009448 29940488 HCG9 5'-UTR 3.22E-02 1.97E-02 3.77E-02 
rs2394249 29940786 HCG9 5'-UTR 2.40E-02 2.11E-02 7.89E-01 
rs56289102 29941011 HCG9 5'-UTR 2.32E-02 2.55E-02 7.86E-01 
rs9260810 29941638 HCG9 5'-UTR 2.69E-02 2.56E-02 6.11E-01 
rs9260816 29941811 HCG9 5'-UTR 2.02E-02 1.60E-02 5.07E-01 
rs2232236 29942191 HCG9 5'-UTR 2.61E-02 2.74E-02 5.62E-01 
rs62388723 29942489 HCG9 5'-UTR 2.59E-02 1.99E-02 5.78E-01 
rs2394251 29943688 HCG9 Intron 2.43E-02 1.85E-02 4.10E-01 
rs2893999 29943832 HCG9 Intron 2.75E-02 2.47E-02 8.22E-01 
rs3823368 29943906 HCG9 Intron 4.60E-02 2.00E-02 5.94E-01 
1rs16896923 30000687 ZNRD1-AS1 2.35E-02 2.98E-02 8.43E-02 
2rs2894207 31263751 HLA-C 5'-UTR 1.05E-02 1.14E-04 6.87E-07 
2rs28421666 32592737 HLA-DQA1 5'-UTR 9.60E-03 1.80E-04 1.10E-06 
 
Multiallelic SNPs are denoted by (*). Linkage disequilibrium and logistic regression calculations for multiallelic SNPs were done only using allelic combinations showing the 
strongest association to NPC.  
SNPs reported in previous NPC GWAS are highlighted in grey with the superscript number referring to the corresponding publication. SNPs identified in this study with potential 
epigenetic influence are highlighted in grey without superscript numbers.  
SNP1 is adjusted against effects of SNP2 assuming an additive model. Results are also adjusted for age, gender and principal component 1 (PC1). Reduction in association strength 
is expressed in log10 values. 
References: 1. Tse, K-P. et al. 2009. The American Journal of Human Genetics 85:194-203; 2. Bei, J-X. et al. 2010. Nature genetics 42: 599-603; 3. Tang, M.Z. et al. 2012. PLOS 
Genetics 8(11) 
 
	  Appendix G: Association of HLA-A amino acid residues to NPC in Malaysian Chinese (Bi-allelic variants) 
 
Amino 
acid pos Exon 
HLA-A 
function HLA-A alleles A1 A2 Risk Panel Case, AAF Ctrl, AAF P-val Odds ratio 
            AA   1 2 1 2   (95% CI) 







Leu Val Val Cohort 1 (GWAS) 0.40 0.60 0.53 0.47 1.80E-03 1.75 (1.23-2.48) 
      
Cohort 2 0.40 0.60 0.55 0.45 5.34E-03 1.63 (1.15-2.29) 
      
Combined 0.40 0.60 0.54 0.46 1.37E-05 1.71 (1.34-2.18) 






Leu Ser Leu Cohort 1 (GWAS) 0.16 0.84 0.15 0.85 2.20E-02 2.01 (1.11-3.64) 
      
Cohort 2 0.14 0.86 0.18 0.82 8.54E-01 1.04 (0.67-1.63) 
      
Combined 0.15 0.85 0.16 0.84 1.69E-01 1.28 (0.9-1.8) 






His Gln His Cohort 1 (GWAS) 0.01 0.99 0.00 1.00 6.83E-01 1.63 (0.16-16.9) 
            Cohort 2 0.00 1.00 0.00 1.00 3.89E-01 9.11 (0.06-1389) 
            Combined 0.01 0.99 0.00 1.00 4.75E-01 2.12 (0.27-16.68) 
                          






Ser Arg Arg Cohort 1 (GWAS) 0.01 0.99 0.01 0.99 7.76E-01 1.27 (0.24-6.63) 
      
Cohort 2 0.00 1.00 0.01 0.99 1.22E-01 5.15 (0.64-41.22) 
      
Combined 0.01 0.99 0.01 0.99 1.75E-01 2.39 (0.68-8.42) 






Lys Glu Glu Cohort 1 (GWAS) 0.02 0.98 0.05 0.95 5.77E-02 2.58 (0.97-6.88) 
      
Cohort 2 0.04 0.96 0.04 0.96 7.96E-01 0.88 (0.35-2.24) 
      
Combined 0.03 0.97 0.05 0.95 1.96E-01 1.53 (0.8-2.91) 






Lys Arg Arg Cohort 1 (GWAS) 0.00 1.00 0.01 0.99 2.08E-01 4.17 (0.45-38.34) 
            Cohort 2 0.01 0.99 0.01 0.99 1.90E-01 0.29 (0.05-1.85) 
            Combined 0.01 0.99 0.01 0.99 8.03E-01 1.18 (0.32-4.36) 
                          
AA56 2 Non-binding AA56_Arg: A*3001,A*3101 
AA56_Gly: 
A*0101,A*0201,A*0203,A*0206,A*0207, 
Arg Gly Gly Cohort 1 (GWAS) 0.01 0.99 0.03 0.97 1.97E-01 2.3 (0.65-8.12) 
            Cohort 2 0.01 0.99 0.02 0.98 3.57E-01 1.9 (0.48-7.46) 
            Combined 0.01 0.99 0.03 0.97 9.33E-02 2.2 (0.88-5.53) 
	        
A*0210,A*0218,A*0301,A*0302,A*1101,A*1102, 
A*2402,A*2403,A*2407,A*2408,A*2410,A*2420, 
A*2446,A*2601, A*2901,A*3201,A*3303                     












   
Cohort 2 0.17 0.83 0.13 0.87 5.27E-01 1.17 (0.72-1.89) 
      
Combined 0.18 0.82 0.15 0.85 4.83E-01 1.13 (0.81-1.57) 







Lys Asn Lys Cohort 1 (GWAS) 0.42 0.58 0.55 0.45 6.78E-04 1.85 (1.3-2.63) 
            Cohort 2 0.56 0.44 0.43 0.57 4.36E-02 1.42 (1.01-1.99) 
            Combined 0.57 0.43 0.44 0.56 5.60E-05 1.64 (1.29-2.09) 
                          






Met Val Val Cohort 1 (GWAS) 0.00 1.00 0.01 0.99 2.08E-01 4.17 (0.45-38.34) 
      
Cohort 2 0.01 0.99 0.01 0.99 1.90E-01 0.29 (0.05-1.85) 
      
Combined 0.01 0.99 0.01 0.99 8.03E-01 1.18 (0.32-4.36) 









Gln His His Cohort 1 (GWAS) 0.25 0.75 0.38 0.62 3.34E-05 2.18 (1.51-3.14) 
            Cohort 2 0.26 0.74 0.39 0.61 4.43E-04 2.01 (1.36-2.97) 
            Combined 0.25 0.75 0.39 0.61 3.01E-08 2.12 (1.62-2.76) 
                          






Ile Thr Ile Cohort 1 (GWAS) 0.15 0.85 0.14 0.86 4.84E-02 1.84 (1-3.39) 
      
Cohort 2 0.14 0.86 0.15 0.85 3.89E-01 1.23 (0.77-1.94) 
      
Combined 0.14 0.86 0.15 0.85 8.32E-02 1.37 (0.96-1.97) 








His Asp His Cohort 1 (GWAS) 0.39 0.61 0.28 0.72 1.14E-03 1.87 (1.28-2.73) 
    Pocket C,F binding       Cohort 2 0.39 0.61 0.30 0.70 9.79E-02 1.35 (0.95-1.92) 
            Combined 0.39 0.61 0.29 0.71 2.20E-04 1.62 (1.25-2.09) 
                          
AA79 2 KIR3DL1 binding AA79_Arg: A*24:02,A*24:03,A*24:07,A*24:08, 
A*24:10,A*24:20, A*32:01 
Arg Gly Arg Cohort 1 (GWAS) 0.20 0.80 0.17 0.83 5.82E-01 1.14 (0.72-1.8) 
  
KIR3DL2 binding 
   
Cohort 2 0.17 0.83 0.13 0.87 5.62E-01 1.15 (0.71-1.86) 







   
Combined 0.18 0.82 0.15 0.85 4.38E-01 1.14 (0.82-1.59) 






Ile Thr Ile Cohort 1 (GWAS) 0.20 0.80 0.17 0.83 5.82E-01 1.14 (0.72-1.8) 
    KIR3DL2 binding       Cohort 2 0.17 0.83 0.13 0.87 5.62E-01 1.15 (0.71-1.86) 
    Pocket F binding       Combined 0.18 0.82 0.15 0.85 4.38E-01 1.14 (0.82-1.59) 
                          







Ala Leu Ala Cohort 1 (GWAS) 0.20 0.80 0.17 0.83 5.82E-01 1.14 (0.72-1.8) 
  
KIR3DL2 binding 
   
Cohort 2 0.17 0.83 0.13 0.87 5.62E-01 1.15 (0.71-1.86) 
  
Pocket F binding 
   
Combined 0.18 0.82 0.15 0.85 4.38E-01 1.14 (0.82-1.59) 







Leu Arg Leu Cohort 1 (GWAS) 0.20 0.80 0.17 0.83 5.82E-01 1.14 (0.72-1.8) 
    KIR3DL2 binding       Cohort 2 0.17 0.83 0.13 0.87 5.62E-01 1.15 (0.71-1.86) 
    
T-cell receptor 
binding       Combined 0.18 0.82 0.15 0.85 4.38E-01 1.14 (0.82-1.59) 
                          







Arg Gly Arg Cohort 1 (GWAS) 0.20 0.80 0.17 0.83 5.82E-01 1.14 (0.72-1.8) 
  
KIR3DL2 binding 
   
Cohort 2 0.17 0.83 0.13 0.87 5.62E-01 1.15 (0.71-1.86) 
      
Combined 0.18 0.82 0.15 0.85 4.38E-01 1.14 (0.82-1.59) 





Asp Ala Ala Cohort 1 (GWAS) 0.25 0.75 0.39 0.61 3.32E-06 2.4 (1.66-3.47) 
            Cohort 2 0.29 0.71 0.37 0.63 3.74E-02 1.48 (1.02-2.14) 
            Combined 0.27 0.73 0.38 0.62 7.73E-07 1.91 (1.48-2.47) 
                          






His Asp Asp Cohort 1 (GWAS) 0.01 0.99 0.00 1.00 4.69E-01 0.34 (0.02-6.44) 
      
Cohort 2 0.00 1.00 0.02 0.98 9.98E-01 NA 
      
Combined 0.00 1.00 0.01 0.99 3.23E-01 2.32 (0.44-12.25) 




Pro Ser Ser Cohort 1 (GWAS) 0.24 0.76 0.39 0.61 5.03E-06 2.36 (1.63-3.41) 
            Cohort 2 0.29 0.71 0.38 0.62 2.61E-02 1.51 (1.05-2.18) 
            Combined 0.27 0.73 0.39 0.61 7.06E-07 1.91 (1.48-2.46) 
                          
	  A*24:03A*24:07,A*24:08,A*24:10,A*24:20, 
A*29:01,A*30:01A*31:01,A*32:01,A*33:03 







Trp Gly Trp Cohort 1 (GWAS) 0.39 0.61 0.28 0.72 9.09E-04 1.9 (1.3-2.78) 
            Cohort 2 0.39 0.61 0.29 0.71 5.88E-02 1.41 (0.99-2.02) 
            Combined 0.39 0.61 0.29 0.71 9.61E-05 1.67 (1.29-2.16) 






Leu Phe Phe Cohort 1 (GWAS) 0.00 1.00 0.00 1.00 9.99E-01 NA 
            Cohort 2 0.00 1.00 0.01 0.99 9.99E-01 NA 
            Combined 0.00 1.00 0.00 1.00 3.59E-01 3.25 (0.26-40.36) 
                          






Asn Lys Lys Cohort 1 (GWAS) 0.41 0.59 0.55 0.45 5.71E-04 1.86 (1.31-2.64) 
            Cohort 2 0.44 0.56 0.57 0.43 4.36E-02 1.42 (1.01-1.99) 
            Combined 0.43 0.57 0.56 0.44 5.24E-05 1.65 (1.29-2.09) 
                          






Lys Met None Cohort 1 (GWAS) 0.01 0.99 0.00 1.00 9.99E-01 NA 
      
Cohort 2 0.00 1.00 0.00 1.00 1.00E+00 NA 
      
Combined 0.00 1.00 0.00 1.00 9.99E-01 NA 








Thr Ile Thr Cohort 1 (GWAS) 0.39 0.61 0.28 0.72 8.51E-04 1.89 (1.3-2.75) 
      
Cohort 2 0.39 0.61 0.30 0.70 7.96E-02 1.38 (0.96-1.96) 
      
Combined 0.39 0.61 0.29 0.71 1.41E-04 1.64 (1.27-2.12) 







Gln Lys Gln Cohort 1 (GWAS) 0.19 0.81 0.18 0.82 9.51E-02 1.58 (0.92-2.71) 
      
Cohort 2 0.18 0.82 0.21 0.79 4.70E-01 1.17 (0.77-1.78) 
      
Combined 0.18 0.82 0.20 0.80 1.63E-01 1.26 (0.91-1.74) 






His Arg His Cohort 1 (GWAS) 0.39 0.61 0.28 0.72 8.51E-04 1.89 (1.3-2.75) 
            Cohort 2 0.39 0.61 0.30 0.70 7.96E-02 1.38 (0.96-1.96) 
            Combined 0.39 0.61 0.29 0.71 1.41E-04 1.64 (1.27-2.12) 














Thr Ala Thr Cohort 1 (GWAS) 0.11 0.89 0.11 0.89 8.02E-01 0.93 (0.54-1.61) 
            Cohort 2 0.11 0.89 0.09 0.91 4.27E-01 1.26 (0.71-2.23) 
            Combined 0.11 0.89 0.10 0.90 7.04E-01 1.08 (0.73-1.6) 
                          











   
Cohort 2 0.01 0.99 0.01 0.99 1.92E-01 0.29 (0.05-1.86) 
      
Combined 0.01 0.99 0.01 0.99 7.98E-01 1.19 (0.32-4.38) 









Arg His Arg Cohort 1 (GWAS) 0.17 0.83 0.16 0.84 4.22E-02 1.82 (1.02-3.23) 
            Cohort 2 0.14 0.86 0.19 0.81 7.91E-01 0.94 (0.61-1.46) 










Val Ala Ala Cohort 1 (GWAS) 0.00 1.00 0.01 0.99 2.07E-01 4.18 (0.45-38.45) 
      
Cohort 2 0.01 0.99 0.01 0.99 1.92E-01 0.29 (0.05-1.86) 
      
Combined 0.01 0.99 0.01 0.99 7.98E-01 1.19 (0.32-4.38) 






Asp Glu Asp Cohort 1 (GWAS) 0.00 1.00 0.00 1.00 4.41E-01 4.07 (0.11-145.5) 
            Cohort 2 0.01 0.99 0.01 0.99 7.82E-01 1.31 (0.19-9.01) 
            Combined 0.00 1.00 0.00 1.00 4.87E-01 1.79 (0.35-9.3) 
                          







Arg Thr Thr Cohort 1 (GWAS) 0.25 0.75 0.40 0.60 4.87E-06 2.36 (1.63-3.42) 
    
T-cell receptor 
binding       Cohort 2 0.29 0.71 0.38 0.62 3.08E-02 1.5 (1.04-2.17) 
            Combined 0.27 0.73 0.39 0.61 7.95E-07 1.91 (1.48-2.47) 
                          








Asp Glu Asp Cohort 1 (GWAS) 0.20 0.80 0.18 0.82 8.77E-01 1.04 (0.66-1.63) 
      
Cohort 2 0.18 0.82 0.13 0.87 3.07E-01 1.28 (0.8-2.07) 
      
Combined 0.18 0.82 0.15 0.85 4.35E-01 1.14 (0.82-1.58) 
                    
	  A*11:02A*24:03,A*24:10,A*26:01,A*29:01, 
A*30:01,A*31:01 A*32:01,A*33:03 







Gly Trp Gly Cohort 1 (GWAS) 0.20 0.80 0.18 0.82 8.77E-01 1.04 (0.66-1.63) 
    
T-cell receptor 
binding       Cohort 2 0.18 0.82 0.13 0.87 3.07E-01 1.28 (0.8-2.07) 
            Combined 0.18 0.82 0.15 0.85 4.35E-01 1.14 (0.82-1.58) 
                          
                          






Ala Pro Ala Cohort 1 (GWAS) 0.43 0.57 0.31 0.69 9.79E-04 1.86 (1.29-2.69) 
      
Cohort 2 0.43 0.57 0.34 0.66 4.21E-02 1.44 (1.01-2.06) 
      
Combined 0.43 0.57 0.33 0.67 7.94E-05 1.67 (1.29-2.15) 







Pro Ala Ala Cohort 1 (GWAS) 0.42 0.58 0.55 0.45 3.07E-05 2.13 (1.49-3.05) 
            Cohort 2 0.43 0.57 0.51 0.49 7.64E-03 1.63 (1.14-2.34) 
            Combined 0.43 0.57 0.53 0.47 7.42E-07 1.89 (1.47-2.43) 
                          
                          







Ile Val Val Cohort 1 (GWAS) 0.42 0.58 0.55 0.45 3.07E-05 2.13 (1.49-3.05) 
      
Cohort 2 0.43 0.57 0.51 0.49 7.64E-03 1.63 (1.14-2.34) 
      
Combined 0.43 0.57 0.53 0.47 7.42E-07 1.89 (1.47-2.43) 
       







Gly Ser Ser Cohort 1 (GWAS) 0.42 0.58 0.55 0.45 3.07E-05 2.13 (1.49-3.05) 
            Cohort 2 0.44 0.56 0.51 0.49 7.64E-03 1.63 (1.14-2.34) 
            Combined 0.43 0.57 0.53 0.47 7.42E-07 1.89 (1.47-2.43) 
                          
                          







Ser Ala Ser Cohort 1 (GWAS) 0.19 0.81 0.17 0.83 7.12E-02 1.67 (0.96-2.9) 
      
Cohort 2 0.17 0.83 0.20 0.80 2.58E-01 1.28 (0.84-1.95) 
      
Combined 0.18 0.82 0.18 0.82 7.13E-02 1.35 (0.97-1.88) 
       
             AA253 4 Non-binding AA253_Glu: 
A*0101,A*0301,A*0302,A*1101,A*1102,A*2402, 
A*2403,A*2407,A*2408,A*2410,A*2420,A*2446, 
Glu Gln Gln Cohort 1 (GWAS) 0.42 0.58 0.55 0.45 3.07E-05 2.13 (1.49-3.05) 
            Cohort 2 0.43 0.57 0.51 0.49 7.64E-03 1.63 (1.14-2.34) 
            Combined 0.43 0.57 0.53 0.47 7.42E-07 1.89 (1.47-2.43) 




                    
                          






Leu Pro Pro Cohort 1 (GWAS) 0.23 0.77 0.38 0.62 7.51E-06 2.35 (1.62-3.42) 
            Cohort 2 0.26 0.74 0.38 0.62 1.02E-03 1.93 (1.3-2.85) 
            Combined 0.25 0.75 0.38 0.62 2.11E-08 2.15 (1.65-2.82) 
                          
                          







Val Ile Val Cohort 1 (GWAS) 0.19 0.81 0.17 0.83 7.97E-01 1.06 (0.67-1.7) 
            Cohort 2 0.17 0.83 0.13 0.87 5.45E-01 1.16 (0.72-1.88) 
            Combined 0.18 0.82 0.15 0.85 5.47E-01 1.11 (0.79-1.55) 
                          
                          






Leu Phe Phe Cohort 1 (GWAS) 0.42 0.58 0.55 0.45 2.63E-05 2.15 (1.51-3.08) 
            Cohort 2 0.43 0.57 0.51 0.49 7.64E-03 1.63 (1.14-2.34) 
            Combined 0.43 0.57 0.53 0.47 6.58E-07 1.9 (1.47-2.44) 
                          
                          






Met Val Val Cohort 1 (GWAS) 0.00 1.00 0.00 1.00 9.99E-01 NA 
      
Cohort 2 0.00 1.00 0.01 0.99 9.99E-01 NA 
      
Combined 0.00 1.00 0.00 1.00 3.62E-01 3.23 (0.26-40.08) 






Phe Ile Phe Cohort 1 (GWAS) 0.16 0.84 0.15 0.85 2.29E-02 2 (1.1-3.62) 
            Cohort 2 0.14 0.86 0.18 0.82 8.75E-01 1.04 (0.66-1.62) 
            Combined 0.15 0.85 0.16 0.84 1.79E-01 1.27 (0.9-1.79) 






Ala Thr Ala Cohort 1 (GWAS) 0.19 0.81 0.17 0.83 5.44E-02 1.73 (0.99-3.03) 
      
Cohort 2 0.17 0.83 0.20 0.80 2.58E-01 1.28 (0.84-1.95) 
      
Combined 0.18 0.82 0.18 0.82 5.96E-02 1.37 (0.99-1.91) 





Arg Met Arg Cohort 1 (GWAS) 0.16 0.84 0.15 0.85 2.29E-02 2 (1.1-3.62) 
      
Cohort 2 0.14 0.86 0.18 0.82 8.75E-01 1.04 (0.66-1.62) 
      
Combined 0.15 0.85 0.16 0.84 1.79E-01 1.27 (0.9-1.79) 
             
	  A*3001 







Asn Lys Asn Cohort 1 (GWAS) 0.19 0.81 0.17 0.83 7.97E-01 1.06 (0.67-1.7) 
      
Cohort 2 0.17 0.83 0.13 0.87 5.45E-01 1.16 (0.72-1.88) 
      
Combined 0.18 0.82 0.15 0.85 5.47E-01 1.11 (0.79-1.55) 






Thr Ser Ser Cohort 1 (GWAS) 0.23 0.77 0.38 0.62 5.67E-06 2.38 (1.64-3.45) 
      
Cohort 2 0.26 0.74 0.38 0.62 1.21E-03 1.91 (1.29-2.82) 
      
Combined 0.25 0.75 0.38 0.62 1.95E-08 2.15 (1.65-2.81) 
       







Met Val Met Cohort 1 (GWAS) 0.19 0.81 0.17 0.83 5.44E-02 1.73 (0.99-3.03) 
            Cohort 2 0.17 0.83 0.20 0.80 2.58E-01 1.28 (0.84-1.95) 
            
Combined 0.18 0.82 0.18 0.82 5.96E-02 1.37 (0.99-1.91) 
 
A1=amino acid 1; A2=amino acid 2; Risk AA=risk amino acid; AAF=amino acid frequency; P-val=Logistic regression additive model P-value adjusting for age, gender and PC1; 
95% CI= 95% Confidence Interval  
























(GWAS) Cohort 2 Combined 
Cohort 1 
(GWAS) Cohort 2 Combined 
Cohort 1 
(GWAS) Cohort 2 Combined 
















Phe 0.36 0.27 0.37 0.30 0.37 0.29 2.00 1.47  1.69  7.68E-04 3.08E-02 5.36E-05 
   Exon 2 
β2-
microglobulin 
binding Ser 0.20 0.18 0.17 0.14 0.19 0.16 1.72 1.44  1.54        
      Thr 0.16 0.15 0.14 0.17 0.15 0.16 1.62 0.98  1.23        
      Tyr 0.27 0.41 0.32 0.38 0.30 0.39 - - -       
                                




















binding Gln 0.23 0.40 0.27 0.39 0.25 0.40 - - - 
   
   
Glu 0.19 0.17 0.17 0.13 0.18 0.15 1.97 1.88  1.88 
   
   
Leu 0.01 0.00 0.00 0.02 0.00 0.01 6.70 0.08 0.52 
   
   
Gly 0.39 0.28 0.39 0.30 0.39 0.29 2.39  1.91 2.11 
             













Asn 0.18 0.15 0.17 0.16 0.17 0.16 1.21 1.02  1.11  2.91E-01 6.89E-03 1.62E-01 
   Exon 2   Gln 0.01 0.00 0.00 0.02 0.00 0.01 4.06 0.05  0.34        
      Glu 0.81 0.85 0.83 0.82 0.82 0.83 - - -       
                                
                                














binding Ala 0.03 0.04 0.04 0.04 0.04 0.04 0.95  0.99  0.98  
   






Val 0.77 0.80 0.79 0.83 0.78 0.81 - - - 
             













Asn 0.23 0.20 0.21 0.17 0.22 0.19 1.16  1.27  1.20  3.16E-01 1.61E-01 2.16E-01 
  Exon 2  
KIR3DL2 
binding Asp 0.77 0.80 0.79 0.83 0.78 0.81 - - -       
    
Pocket F 
binding Ser 0.00 0.00 0.00 0.00 0.00 0.00 2.70  0.52  1.17        
                                
                                


















Leu 0.19 0.17 0.17 0.13 0.18 0.15 1.54  1.70  1.59  
   
   
Val 0.39 0.28 0.39 0.30 0.39 0.29 1.86  1.75  1.80  
             















Arg 0.41 0.30 0.43 0.31 0.42 0.31 2.27  1.96  2.09 1.10E-05 1.14E-04 2.44E-09 
  Exon 3    Ile 0.23 0.38 0.26 0.38 0.25 0.38 - - -       
      Met 0.36 0.32 0.31 0.31 0.33 0.31 1.89  1.43 1.61        
                                
                                


















Phe 0.19 0.17 0.17 0.14 0.18 0.15 1.35 1.49  1.40  
   
   
Tyr 0.63 0.74 0.62 0.75 0.63 0.74 - - - 
             







Arg 0.23 0.38 0.26 0.38 0.25 0.38 0.47  0.51  0.50  7.18E-05 2.84E-05 2.78E-09 
   Exon 3   Gln 0.18 0.17 0.17 0.18 0.18 0.17 0.80 0.74  0.77        







Glu 0.01 0.01 0.00 0.01 0.01 0.01 0.74 0.21 0.39        
      His 0.58 0.44 0.56 0.43 0.57 0.43 - - -       
                                


















binding His 0.01 0.01 0.00 0.01 0.01 0.01 1.30 0.37 0.67  
   
   
Tyr 0.58 0.44 0.56 0.43 0.57 0.43 1.75 1.70 1.72 
             














Ala 0.22 0.37 0.25 0.36 0.24 0.36 0.44 0.60 0.53 1.04E-05 1.10E-03 6.64E-08 
   Exon 3 
T-cell 
receptor 
binding Trp 0.01 0.01 0.00 0.01 0.01 0.01 0.74  0.24  0.41        
      Val 0.67 0.50 0.63 0.53 0.64 0.52 - - -       
      Glu 0.11 0.12 0.12 0.10 0.11 0.11 0.70 1.00 0.85       
                                
                                












07, A*24:08, A*24:10,A*24:20 




Gln 0.41 0.53 0.42 0.48 0.41 0.50 - - - 
   
   
Leu 0.48 0.34 0.46 0.42 0.47 0.38 1.79  1.27  1.49  
   
   
Trp 0.11 0.12 0.11 0.09 0.11 0.10 1.21  1.41  1.30  
                   
                                
 
Association calculation was performed using Fisher Exact Test by 2x3 table testing affection status (Case or Control) against the respective amino acid frequencies. 












ding b37 pos 
PSNP-
Combined Codon Change 
Residue 
Change TYPE PROVEAN SIFT Polyphen-2 
  
acid 
pos   SNP           SCORE PREDICT SCORE PREDICT FPR PREDICT 
1 AA-15 1.37E-05 rs1143146 29910358 1.37E-05 CTC [C/G]TC CTG Leu>Val non-Syn -1.009 Neutral 0.716 Tolerated 1 benign 
2 AA9 5.36E-05 rs1136659 29910557 1.46E-01 TTC [T/A]TC ACA Phe>Ile non-Syn -1.508 Neutral 0.006 Damaging 0.142 benign 
   






Tolerated 1/0.239 benign/benign 
            3 AA62 2.10E-09 rs1059455 29910716 3.74E-05 GAC [C/G]AG GAG Gln>Glu non-Syn -0.108 Neutral 0.405 Tolerated 1 benign 






Tolerated 1/1 benign/benign 
4 AA66 5.60E-05 rs199474436 29910730 5.60E-05 CGG AA[T/A] GTG Asn>Lys non-Syn -0.907 Neutral 0.696 Tolerated 1 benign 
               5 AA70 3.01E-08 rs78306866 29910742 3.01E-08 GCC CA[G/C] TCA Gln>His non-Syn 0.299 Neutral 1 Tolerated 1 benign 
6 AA74 2.20E-04 rs1136683 29910752 2.20E-04 ACT [G/C]AC CGA Asp>His non-Syn 0.544 Neutral 0.331 Tolerated 0.0693 
possibly 
damaging 
               7 AA90 7.73E-07 rs1136692 29910801 7.73E-07 GAG G[C/A]C GGT Ala>Asp non-Syn -3.751 Deleterious 0.343 Tolerated 1 benign 








Tolerated 1/1 benign/benign 
               9 AA97 2.44E-09 rs199474485 29911063 4.65E-05 CAG A[T/G]A ATG Ile>Arg non-Syn 1.945 Neutral 0.458 Tolerated 0.253 benign 
      rs1136695 29911064 1.95E-08 CAG AT[A/G] ATG Ile>Met non-Syn 1.192 Neutral 0.284 Tolerated 1 benign 














               11 AA105 7.06E-07 rs1136700 29911086 7.06E-07 GGG [T/C]CG GAC Ser>Pro non-Syn 4.902 Neutral 1 Tolerated 1 benign 





               
13 AA114 2.78E-09 rs3173420 29911114 4.60E-08 TAC C[G/A]G CAG Arg>Gln non-Syn 0.368 Neutral 0.329 Tolerated 0.0766 
possibly 
damaging 




Tolerated N/A N/A 









               15 AA127 5.24E-05 rs1059509 29911154 5.24E-05 CTG AA[C/A] GAG Asn>Lys non-Syn -4.998 Deleterious 0.358 Tolerated 0.556 benign 
16 AA142 1.41E-04 rs1059516 29911198 1.41E-04 CAG A[T/C]C ACC Ile>Thr non-Syn -2.974 
Deleterio
us 0.673 Tolerated 0.0399 
probably 
damaging 
               
17 AA145 1.41E-04 rs1059520 29911207 1.41E-04 AAG C[G/A]C AAG Arg>His non-Syn -2.975 Deleterious 0.235 Tolerated 0.0346 
probably 
damaging 




















               
19 AA163 7.95E-07 rs3129017 29911260 1.02E-06 GGC [A/C]CG TGC Thr>Pro non-Syn -2.372 Neutral 0.079 Tolerated 0.0803 
possibly 
damaging 
      rs3129018 29911261 1.02E-06 GGC A[C/G]G TGC Thr>Arg non-Syn -1.125 Neutral 1 Tolerated 0.556 benign 
	  20 AA184 7.94E-05 rs1136741 29911901 7.94E-05 GAC [C/G]CC CCC Pro>Ala non-Syn -4.184 Deleterious 0.552 Tolerated 0.0289 
probably 
damaging 
               
21 AA193 7.42E-07 rs1059563 29911928 1.09E-06 CAC [C/G]CC ATC Pro>Ala non-Syn -4.682 Deleterious 0.501 Tolerated 0.0368 
probably 
damaging 




Tolerated N/A N/A 
22 AA194 7.42E-07 rs9260179 29911931 7.42E-07 CCC [A/G]TC TCT Ile>Val non-Syn -0.098 Neutral 1 Tolerated 1 benign 
               
23 AA207 7.42E-07 rs9260180 29911970 7.42E-07 CTG [G/A]GC TTC Gly>Ser non-Syn -3.712 Deleterious 0.51 Tolerated 0.0707 
possibly 
damaging 
24 AA253 7.42E-07 rs2231095 29912108 7.42E-07 GGA [G/C]AG GAG Glu>Gln non-Syn -1.538 Neutral 0.752 Tolerated 0.0709 
possibly 
damaging 
               25 AA276 2.11E-08 rs1136903 29912280 1.95E-08 GAG C[T/C]G TCT Leu>Pro non-Syn 4.119 Neutral 1 Tolerated 1 benign 
      rs1136917 29912281 5.28E-01 GAG CT[G/A] TCT Leu Syn 0 Neutral 0.188 Tolerated N/A N/A 
26 AA294 6.58E-07 rs3179982 29912333 6.58E-07 CTC [C/T]TT GGA Leu>Phe non-Syn -1.693 Neutral 0.54 Tolerated 0.0112 
probably 
damaging 
               27 AA321 1.95E-08 rs2231119 29912856 1.95E-08 TAC [A/T]CT CAG Thr>Ser non-Syn 0.211 Neutral 1 Tolerated 1 benign 
 
Syn=Synonymous mutation; non-Syn=Single amino acid change; pph2_FPR=Polyphen-2 false positive rate 
Multiple testing threshold amino acid NPC association=1.37E-04 


















	  Appendix J: Multivariate logistic regression of HLA-A amino acid variants adjusted for effects of HLA-A*02:06, HLA-A*02:07 and HLA-A*11:01 
 
AA1 HLA-A pos P-value AA2 
      A*02:06 A*02:07 A*11:01 
AA-15 Exon 1 1.37E-05 4.15E-05 2.56E-03 2.31E-01 
*AA9_Phe/Tyr Exon 2 1.55E-03 2.29E-04 1.23E-01 5.69E-01 
*AA62_Gln/Gly Exon 2 5.84E-06 1.47E-05 2.45E-03 9.72E-03 
AA66 Exon 2 5.60E-05 1.84E-04 8.86E-03 3.74E-01 
AA70 Exon 2 3.01E-08 9.29E-08 4.31E-06 3.39E-02 
AA74 Exon 2 2.20E-04 9.55E-04 8.23E-02 1.69E-01 
AA90 Exon 2 7.73E-07 2.28E-06 7.70E-05 3.52E-01 
*AA95_Ile/Val Exon 3 1.34E-04 5.28E-04 9.17E-03 2.28E-01 
*AA97_Arg/Ile Exon 3 1.36E-06 2.89E-06 1.82E-04 2.15E-02 
*AA99_Tyr/Cys Exon 3 2.26E-03 6.29E-04 1 1.50E-01 
AA105 Exon 3 5.50E-07 1.65E-06 5.80E-05 2.81E-01 
AA107 Exon 3 9.61E-05 4.54E-04 4.78E-02 1.03E-01 
*AA114_Arg/His Exon 3 1.37E-06 3.17E-06 5.24E-04 9.62E-02 
*AA116_Asp/Tyr Exon 3 5.02E-05 1.64E-04 7.62E-03 5.27E-01 
AA127 Exon 3 3.80E-05 1.27E-04 6.70E-03 3.37E-01 
AA142 Exon 3 1.41E-04 6.27E-04 6.14E-02 1.38E-01 
AA145 Exon 3 1.41E-04 6.27E-04 6.14E-02 1.38E-01 
*AA152_Ala/Val Exon 3 1.22E-08 3.91E-08 2.43E-06 7.44E-02 
AA163 Exon 3 7.95E-07 2.39E-06 8.39E-05 3.40E-01 
AA184 Exon 4 7.94E-05 3.05E-04 3.02E-02 1.28E-01 
AA193 Exon 4 7.42E-07 2.94E-06 2.24E-04 3.61E-02 
AA194 Exon 4 7.42E-07 2.94E-06 2.24E-04 3.61E-02 
AA207 Exon 4 7.42E-07 2.94E-06 2.24E-04 3.61E-02 
AA253 Exon 4 7.42E-07 2.94E-06 2.24E-04 3.61E-02 
AA276 Exon 5 2.11E-08 6.38E-08 3.00E-06 2.58E-02 
AA294 Exon 5 6.58E-07 2.63E-06 2.14E-04 3.04E-02 
AA321 Exon 6 2.11E-08 6.38E-08 3.00E-06 2.58E-02 
 
Multiallelic variants are denoted by (*). Logistic regression calculations for multiallelic variants were done only using the strongest amino acid combinations. 
Amino acid 1 (AA1) is adjusted against effects of amino acid 2 (AA2) assuming an additive model. Results are also adjusted for age, gender and principal component 1 (PC1). 
Reduction in association strength is expressed in log10 values. 
 
 




AA2 A*02:06 A*02:07 A*11:01 
P-value 6.22E-03 7.71E-05 4.84E-07 
AA-15 3.12E-02 1.77E-02 1.43E-03 
*AA9_Phe/Tyr 8.95E-03 8.11E-02 7.27E-04 
*AA62_Gln/Gly 1.37E-01 1.17E-01 9.51E-01 
AA66 3.48E-02 1.55E-02 3.36E-04 
AA70 3.73E-02 2.62E-02 3.47E-01 
AA74 4.60E-02 3.01E-02 5.38E-05 
AA90 3.46E-02 1.28E-02 2.91E-02 
*AA95_Ile/Val 4.66E-02 3.50E-01 1.51E-03 
*AA97_Arg/Ile 2.02E-01 4.06E-01 5.77E-01 
*AA99_Cys/Tyr 3.24E-03 1 5.96E-05 
AA105 3.56E-02 1.40E-02 3.74E-02 
AA107 5.33E-02 4.36E-02 6.58E-05 
*AA114_Arg/His 1.52E-01 1.14E-02 3.82E-01 
*AA116_Asp/Tyr 3.92E-02 1.88E-02 8.16E-05 
AA127 3.68E-02 1.69E-02 3.67E-04 
AA142 4.97E-02 3.60E-02 5.69E-05 
AA145 4.97E-02 3.60E-02 5.69E-05 
*AA152_Ala/Val 5.56E-02 1.07E-01 3.17E-01 
AA163 3.55E-02 1.36E-02 2.74E-02 
AA184 4.28E-02 3.45E-02 9.45E-05 
AA193 4.87E-02 4.39E-02 4.35E-03 
AA194 4.87E-02 4.39E-02 4.35E-03 
AA207 4.87E-02 4.39E-02 4.35E-03 
AA253 4.87E-02 4.39E-02 4.35E-03 
AA276 3.60E-02 2.08E-02 4.58E-01 
AA294 4.71E-02 4.06E-02 5.89E-03 
AA321 3.60E-02 2.08E-02 4.58E-01 
 
Multiallelic variants are denoted by (*). Logistic regression calculations for multiallelic variants were done only using the strongest amino acid combinations. 
Amino acid 1 (AA1) is adjusted against effects of amino acid 2 (AA2) assuming an additive model. Results are also adjusted for age, gender and principal component 1 (PC1). 
Reduction in association strength is expressed in log10 values. 
 
	  Appendix L: Replication of previously reported GWAS SNPs with genome-wide significance association to NPC. 
 
No SNP ID Gene CHR Position Risk Panel Case, RAF Control, RAF P-value OR Reference Population 
        b36 Allele         (95% CI)     
1 rs169188 ITGA9 3 37482453 A Cohort 1 (GWAS) 0.07  0.02  4.74E-03 3.66 (1.49-8.99) Ng et al., 2009 Malaysian Chinese 
  1/2=A/G         Cohort 2 0.06  0.02  4.28E-02 2.5 (1.03-6.05)     
            Combined 0.06  0.02  5.88E-04 3 (1.6-5.63)     
2 rs197721 ITGA9 3 37485040 T Cohort 1 (GWAS) 0.08  0.03  2.24E-03 3.96 (1.64-9.57) Ng et al., 2009 Malaysian Chinese 
 1/2=T/G     Cohort 2 0.06  0.03  5.29E-02 2.28 (0.99-5.26) 
        Combined 0.07  0.03  3.36E-04 3 (1.65-5.47) 
  3 rs149816 ITGA9 3 37485770 G Cohort 1 (GWAS) 0.07  0.03  3.02E-03 3.84 (1.58-9.33) Ng et al., 2009 Malaysian Chinese 
  1/2=G/C         Cohort 2 0.06  0.03  5.29E-02 2.28 (0.99-5.26)     
            Combined 0.07  0.03  4.07E-04 2.97 (1.62-5.42)     
4 rs169111 ITGA9 3 37490537 G Cohort 1 (GWAS) 0.08  0.03  2.06E-03 3.81 (1.63-8.92) Ng et al., 2009 Malaysian Chinese 
 1/2=G/A     Cohort 2 0.06  0.03  2.00E-02 2.61 (1.16-5.88) 
        Combined 0.07  0.03  1.13E-04 3.16 (1.76-5.66) 
  5 rs197770 ITGA9 3 37490831 C Cohort 1 (GWAS) 0.08  0.03  2.16E-02 2.47 (1.14-5.32) Ng et al., 2009 Malaysian Chinese 
  1/2=C/T         Cohort 2 0.08  0.04  1.91E-02 2.42 (1.16-5.08)     
            Combined 0.08  0.03  8.92E-04 2.47 (1.45-4.22)     
6 rs2212020 ITGA9 3 37492466 T Cohort 1 (GWAS) 0.15  0.09  7.72E-02 1.58 (0.95-2.62) Ng et al., 2009 Malaysian Chinese 
 1/2=T/C     Cohort 2 0.15  0.09  1.38E-03 2.38 (1.4-4.03) 
        Combined 0.15  0.09  5.46E-04 1.91 (1.32-2.76) 
  7 rs189897 ITGA9 3 37493549 T Cohort 1 (GWAS) 0.08  0.03  9.64E-03 3 (1.31-6.88) Ng et al., 2009 Malaysian Chinese 
  1/2=T/A         Cohort 2 0.08  0.04  1.19E-02 2.64 (1.24-5.63)     
            Combined 0.08  0.03  2.72E-04 2.82 (1.61-4.92)     
8 rs197757 ITGA9 3 37497832 T Cohort 1 (GWAS) 0.08  0.03  2.16E-02 2.47 (1.14-5.32) Ng et al., 2009 Malaysian Chinese 
 1/2=T/C     Cohort 2 0.08  0.04  1.91E-02 2.42 (1.16-5.08) 
        Combined 0.08  0.03  8.92E-04 2.47 (1.45-4.22) 
  9 rs6774494 MDS1-EVI1 3 170565327 G Cohort 1 (GWAS) 0.70  0.60  4.38E-02 1.45 (1.01-2.09) Bei et al., 2010 Southern Chinese 
  1/2=A/G         Cohort 2 0.69  0.67  6.70E-01 1.08 (0.76-1.52)     
            Combined 0.69  0.63  7.93E-02 1.25 (0.97-1.6)     
10 rs2267633 GABBR1 6 29678819 T Cohort 1 (Omni) 0.81  0.75  2.03E-02 1.59 (1.07-2.35) Tse et al., 2009 Taiwanese 
 1/2=C/T     Cohort 2 (550k) 0.79  0.73  5.48E-01 1.18 (0.69-1.99) Tang et al., 2012 
       Combined 0.80  0.74  1.72E-02 1.46 (1.07-1.99) 
  11 rs2076483 GABBR1 6 29679523 A Cohort 1 (Omni) 0.81  0.75  1.97E-02 1.59 (1.08-2.35) Tse et al., 2009 Taiwanese 
  1/2=G/A         Cohort 2 (550k) 0.79  0.73  5.48E-01 1.18 (0.69-1.99)     
            Combined 0.80  0.74  1.69E-02 1.46 (1.07-1.99)     
12 rs29230 GABBR1 6 29684371 A Cohort 1 (Omni) 0.81  0.75  2.16E-02 1.58 (1.07-2.32) Tse et al., 2009 Taiwanese 
 1/2=G/A     Cohort 2 (550k) 0.79  0.73  5.48E-01 1.18 (0.69-1.99) Tang et al., 2012 
       Combined 0.80  0.74  1.78E-02 1.45 (1.07-1.98) 
  13 rs29232 GABBR1 6 29719410 G Cohort 1 (GWAS) 0.47  0.53  3.42E-02 1.45 (1.03-2.04) Tse et al., 2009 Taiwanese 
  1/2=A/G         Cohort 2 0.56  0.46  3.52E-03 1.66 (1.18-2.33)     
            Combined 0.55  0.46  2.64E-04 1.56 (1.23-1.98)     
14 rs3129055 HLA-F 6 29778239 C Cohort 1 (Omni) 0.36  0.31  1.51E-01 1.3 (0.91-1.87) Tse et al., 2009 Taiwanese 
 1/2=C/T     Cohort 2 (550k) 0.35  0.30  7.77E-02 1.57 (0.95-2.58) 
  
	        Combined 0.35  0.30  3.40E-02 1.37 (1.02-1.82) 
  15 rs9258122 HLA-F 6 29779719 A Cohort 1 (Omni) 0.36  0.30  1.16E-01 1.34 (0.93-1.94) Tse et al., 2009 Taiwanese 
  1/2=A/G         Cohort 2 (550k) 0.35  0.30  7.77E-02 1.57 (0.95-2.58)     
            Combined 0.35  0.30  2.67E-02 1.39 (1.04-1.85)     
16 rs2860580 HLA-A 6 30014670 C Cohort 1 (GWAS) 0.75  0.60  7.28E-06 2.23 (1.57-3.17) Bei et al., 2010 Southern Chinese 
 1/2=T/C     Cohort 2 0.73  0.62  1.29E-03 1.8 (1.26-2.58) 
        Combined 0.74  0.61  1.86E-08 2.04 (1.59-2.62) 
  17 rs417162 HLA-A 6 30024484 A Cohort 1 (GWAS) 0.76  0.62  6.71E-06 2.31 (1.6-3.33) Tang et al., 2012 Southern Chinese 
  1/2=G/A         Cohort 2 0.75  0.62  4.94E-04 1.96 (1.34-2.85)     
            Combined 0.75  0.62  6.89E-09 2.16 (1.66-2.8)     
18 rs2517713 HLA-A 6 30026078 A Cohort 1 (GWAS) 0.76  0.61  6.68E-06 2.31 (1.6-3.32) Tse et al., 2009 Taiwanese 
 1/2=C/A     Cohort 2 0.74  0.63  2.25E-03 1.78 (1.23-2.57) Tang et al., 2012 
       Combined 0.75  0.62  3.46E-08 2.06 (1.6-2.67) 
  19 rs2975042 HLA-A 6 30028515 A Cohort 1 (GWAS) 0.76  0.62  6.68E-06 2.31 (1.6-3.32) Tse et al., 2009 Taiwanese 
  1/2=C/A         Cohort 2 0.74  0.63  2.25E-03 1.78 (1.23-2.57)     
            Combined 0.75  0.63  3.46E-08 2.06 (1.6-2.67)     
20 rs9260734 HCG9 6 30040644 G Cohort 1 (Omni) 0.79  0.65  8.25E-06 2.39 (1.63-3.5) Tse et al., 2009 Taiwanese 
 1/2=A/G     Cohort 2 (550k) 0.79  0.66  2.35E-04 2.1 (1.41-3.12) Tang et al., 2012 
       Combined 0.79  0.65  2.96E-09 2.29 (1.74-3) 
  21 rs3869062 HCG9 6 30042870 G Cohort 1 (GWAS) 0.81  0.66  2.61E-06 2.57 (1.73-3.81) Tse et al., 2009 Taiwanese 
  1/2=A/G         Cohort 2 0.80  0.68  3.51E-04 2.11 (1.4-3.17)     
            Combined 0.80  0.67  1.73E-09 2.37 (1.79-3.14)     
22 rs5009448 HCG9 6 30048467 C Cohort 1 (GWAS) 0.75  0.60  8.04E-06 2.28 (1.59-3.27) Tse et al., 2009 Taiwanese 
 1/2=T/C     Cohort 2 0.74  0.62  4.68E-03 1.68 (1.17-2.41) Tang et al., 2012 
       Combined 0.75  0.61  8.97E-08 1.99 (1.55-2.57) 
  23 rs16896923 HCG9 6 30108665 T Cohort 1 (Omni) 0.85  0.73  2.19E-05 2.46 (1.62-3.74) Tse et al., 2009 Taiwanese 
  1/2=C/T         Cohort 2 (550k) 0.84  0.77  1.29E-01 1.58 (0.87-2.87)     
            Combined 0.85  0.75  1.25E-05 2.11 (1.51-2.95)     
24 rs2894207 HLA-B/C 6 31371730 T Cohort 1 (GWAS) 0.88  0.84  1.03E-01 1.52 (0.92-2.52) Bei et al., 2010 Southern Chinese 
 1/2=C/T     Cohort 2 0.88  0.81  8.39E-01 1.05 (0.67-1.63) 
        Combined 0.88  0.82  2.00E-01 1.24 (0.89-1.74) 
  25 rs28421666 HLA-DQ/DR 6 32700715 A Cohort 1 (GWAS) 0.95  0.91  8.82E-02 1.8 (0.92-3.52) Bei et al., 2010 Southern Chinese 
  1/2=G/A         Cohort 2 0.93  0.92  2.63E-02 2.1 (1.09-4.04)     
            Combined 0.94  0.91  7.91E-03 1.87 (1.18-2.96)     
26 rs1412829 CDNK2A/2B 9 22033926 T Cohort 1 (GWAS) 0.90  0.90  7.56E-01 0.92 (0.53-1.59) Bei et al., 2010 Southern Chinese 
 1/2=C/T     Cohort 2 0.90  0.88  1.02E-01 1.54 (0.92-2.59) 
        Combined 0.90  0.89  4.03E-01 1.17 (0.81-1.69) 
  27 rs1572072 TNFRSF19 13 23025210 T Cohort 1 (GWAS) 0.25  0.23  2.33E-01 1.27 (0.86-1.88) Bei et al., 2010 Southern Chinese 
  1/2=T/G         Cohort 2 0.24  0.21  3.74E-01 1.19 (0.81-1.73)     
            Combined 0.24  0.22  1.39E-01 1.23 (0.94-1.61)     
28 rs9510787 TNFRSF19 13 23103195 G Cohort 1 (GWAS) 0.36  0.33  9.65E-01 0.99 (0.69-1.42) Bei et al., 2010 Southern Chinese 
 1/2=G/A     Cohort 2 0.41  0.34  4.58E-03 1.62 (1.16-2.26) 
              Combined 0.39  0.34  3.42E-02 1.3 (1.02-1.65)    
 
1=minor allele; 2=major allele; RAF=Risk allele frequency; P-val=Logistic regression additive model P-value adjusting for age, gender and PC1; OR=Odds ratio; 95% CI= 95% confidence interval 
Cohort 1 (GWAS): Cases, n=184; Controls, n=236; Total, n=420; Cohort 2: Cases, n=260; Controls, n=245; Total, n=505; Combined: Cases, n=444; Controls, n=481; Total, n=925 
	  Appendix M: Results from NPC GWAS Meta-Analysis. Only top 100 associations are shown. 
 

















1 rs7702277 5:14073756 8.04E-08 1.39(1.23-1.56) 0.14/0.13/0.12 0.33(0.07) 0.46(0.16) 0.16(0.18) +++ 4.34E-06 3.87E-03 3.64E-01 
2 rs11968138 6:105902519 1.33E-07 1.48(1.28-1.72) 0.1/0.07/0.07 0.59(0.08) 0.09(0.22) -0.81(0.24) ++- 2.91E-12 6.88E-01 7.26E-04 
3 rs4714505 6:41756125 1.69E-07 0.71(0.62-0.81) 0.11/0.1/0.1 -0.32(0.08) -0.36(0.17) -0.48(0.19) --- 2.88E-05 3.79E-02 1.31E-02 
4 rs6774494 3:170565327 4.00E-07 0.81(0.74-0.88) 0.36/0.35/0.4 -0.27(0.05) -0.27(0.11) 0.17(0.12) --+ 7.11E-08 1.29E-02 1.72E-01 
5 rs1063192 9:21993367 2.35E-06 0.77(0.69-0.86) 0.16/0.17/0.15 -0.27(0.07) -0.12(0.14) -0.48(0.17) --- 4.95E-05 3.97E-01 5.58E-03 
6 rs16853480 3:170511110 2.37E-06 0.78(0.7-0.86) 0.18/0.17/0.2 -0.29(0.06) -0.47(0.14) 0.16(0.14) --+ 5.70E-06 6.58E-04 2.56E-01 
7 rs9820110 3:70552648 2.56E-06 1.24(1.13-1.35) 0.3/0.29/0.29 0.2(0.05) 0.22(0.12) 0.28(0.14) +++ 1.21E-04 6.61E-02 3.91E-02 
8 rs1412829 9:22033926 2.79E-06 0.72(0.63-0.83) 0.1/0.11/0.08 -0.33(0.08) -0.23(0.17) -0.46(0.22) --- 5.07E-05 1.78E-01 3.51E-02 
9 rs2802402 13:46583361 2.87E-06 0.77(0.69-0.86) 0.16/0.18/0.2 -0.28(0.07) -0.16(0.14) -0.29(0.15) --- 3.25E-05 2.30E-01 5.01E-02 
10 rs6795074 3:89599342 3.27E-06 1.38(1.21-1.58) 0.09/0.1/0.1 0.3(0.08) 0.31(0.17) 0.45(0.2) +++ 2.02E-04 8.06E-02 2.16E-02 
11 rs6931820 6:93963094 3.47E-06 0.82(0.76-0.89) 0.4/0.41/0.4 -0.24(0.05) -0.12(0.11) -0.02(0.12) --- 1.33E-06 2.55E-01 8.38E-01 
12 rs7626735 3:89589648 4.13E-06 1.38(1.2-1.58) 0.09/0.1/0.1 0.3(0.08) 0.34(0.18) 0.4(0.19) +++ 2.60E-04 5.22E-02 3.69E-02 
13 rs7014115 8:62812121 6.09E-06 1.33(1.17-1.5) 0.13/0.11/0.11 0.27(0.07) 0.49(0.17) 0.11(0.18) +++ 1.67E-04 3.84E-03 5.67E-01 
14 rs17801001 3:89497245 7.71E-06 1.32(1.17-1.49) 0.12/0.12/0.12 0.26(0.07) 0.45(0.16) 0.18(0.18) +++ 3.39E-04 5.69E-03 3.19E-01 
15 rs2157719 9:22023366 8.26E-06 0.73(0.64-0.84) 0.1/0.1/0.08 -0.3(0.08) -0.24(0.17) -0.46(0.22) --- 1.68E-04 1.64E-01 3.51E-02 
16 rs9836340 3:89488444 8.64E-06 1.32(1.17-1.49) 0.12/0.12/0.12 0.26(0.07) 0.42(0.16) 0.18(0.17) +++ 3.30E-04 8.02E-03 2.99E-01 
17 rs4977756 9:22058652 9.72E-06 0.8(0.72-0.88) 0.21/0.21/0.19 -0.22(0.06) -0.16(0.13) -0.34(0.15) --- 2.02E-04 2.02E-01 2.68E-02 
18 rs6468749 8:102078004 9.96E-06 1.21(1.11-1.31) 0.37/0.37/0.36 0.19(0.05) 0.04(0.11) 0.39(0.13) +++ 1.84E-04 7.20E-01 1.67E-03 
19 rs870898 3:89499754 1.13E-05 1.31(1.16-1.48) 0.12/0.12/0.12 0.25(0.07) 0.43(0.16) 0.18(0.17) +++ 4.90E-04 6.68E-03 2.92E-01 
20 rs11672613 19:6656246 1.13E-05 0.83(0.77-0.9) 0.4/0.41/0.43 -0.18(0.05) -0.14(0.1) -0.25(0.12) --- 2.45E-04 1.91E-01 3.01E-02 
21 rs573687 9:22001642 1.22E-05 0.74(0.65-0.85) 0.1/0.11/0.09 -0.3(0.08) -0.2(0.17) -0.47(0.22) --- 1.88E-04 2.37E-01 2.82E-02 
22 rs1430438 3:170550293 1.29E-05 0.83(0.76-0.9) 0.34/0.32/0.38 -0.25(0.05) -0.18(0.11) 0.17(0.12) --+ 7.06E-07 9.76E-02 1.60E-01 
23 rs10796139 10:13932304 1.31E-05 0.82(0.76-0.9) 0.36/0.33/0.38 -0.19(0.05) -0.2(0.12) -0.18(0.13) --- 1.79E-04 8.72E-02 1.54E-01 
24 rs1324103 6:93957737 1.37E-05 0.84(0.77-0.91) 0.43/0.44/0.44 -0.21(0.05) -0.17(0.11) -0.04(0.12) --- 2.20E-05 1.10E-01 7.66E-01 
25 rs4955568 3:170565789 1.42E-05 1.21(1.11-1.32) 0.33/0.34/0.29 0.22(0.05) 0.3(0.11) -0.18(0.13) ++- 1.64E-05 5.76E-03 1.77E-01 
26 rs6990434 8:62806337 1.55E-05 1.31(1.16-1.49) 0.12/0.12/0.11 0.27(0.07) 0.47(0.17) 0.05(0.18) +++ 2.43E-04 4.92E-03 7.66E-01 
27 rs6671127 1:68343808 1.63E-05 1.2(1.11-1.31) 0.38/0.37/0.37 0.21(0.05) 0.07(0.11) 0.15(0.13) +++ 2.16E-05 5.20E-01 2.28E-01 
28 rs1879796 3:170545815 1.65E-05 0.83(0.76-0.9) 0.34/0.32/0.38 -0.25(0.05) -0.18(0.11) 0.17(0.12) --+ 1.10E-06 9.97E-02 1.79E-01 
29 rs11865086 16:30037994 1.85E-05 1.2(1.1-1.31) 0.36/0.34/0.38 0.23(0.05) 0.08(0.11) 0.04(0.12) +++ 4.96E-06 4.78E-01 7.64E-01 
30 rs9510787 13:23103195 1.92E-05 1.2(1.1-1.3) 0.35/0.35/0.34 0.25(0.05) 0.21(0.11) -0.27(0.13) ++- 6.73E-07 5.33E-02 3.10E-02 
31 rs9849779 3:170525046 2.04E-05 1.21(1.11-1.31) 0.31/0.32/0.27 0.22(0.05) 0.29(0.11) -0.16(0.13) ++- 2.71E-05 7.63E-03 2.24E-01 
32 rs1991007 5:56003775 2.45E-05 1.38(1.19-1.6) 0.08/0.08/0.07 0.31(0.09) 0.49(0.19) 0.14(0.24) +++ 4.26E-04 1.16E-02 5.56E-01 
33 rs1296284 5:55970695 2.89E-05 1.21(1.1-1.32) 0.34/0.36/0.38 0.2(0.05) 0.26(0.14) 0.08(0.12) +++ 1.18E-04 6.84E-02 5.09E-01 
34 rs1286041 6:6784191 3.11E-05 1.26(1.13-1.41) 0.16/0.17/0.18 0.23(0.07) 0.34(0.14) 0.08(0.16) +++ 3.89E-04 1.36E-02 6.24E-01 
35 rs1307541 7:158268005 3.19E-05 0.84(0.78-0.91) 0.48/0.49/0.47 -0.23(0.05) -0.08(0.11) 0.09(0.12) --+ 1.08E-06 4.80E-01 4.26E-01 
36 rs3109384 11:40075174 3.34E-05 0.83(0.75-0.9) 0.27/0.26/0.29 -0.19(0.05) -0.1(0.12) -0.29(0.13) --- 3.55E-04 3.95E-01 2.81E-02 
37 rs1567415 18:1941127 4.08E-05 1.19(1.09-1.29) 0.43/0.42/0.45 0.18(0.05) 0.31(0.11) -0.06(0.13) ++- 2.62E-04 3.88E-03 6.55E-01 
38 rs2886189 11:113006865 4.31E-05 0.83(0.76-0.91) 0.3/0.31/0.31 -0.21(0.05) -0.05(0.11) -0.22(0.13) --- 8.61E-05 6.67E-01 9.45E-02 
39 rs9924017 16:25756822 4.66E-05 1.19(1.1-1.3) 0.34/0.36/0.32 0.19(0.05) 0.09(0.12) 0.18(0.13) +++ 1.47E-04 4.17E-01 1.46E-01 
40 rs1331627 9:134081700 4.71E-05 0.84(0.78-0.92) 0.42/0.41/0.38 -0.16(0.05) -0.18(0.11) -0.21(0.13) --- 7.88E-04 9.95E-02 1.02E-01 
41 rs842448 7:158258978 4.91E-05 0.85(0.78-0.92) 0.47/0.49/0.47 -0.23(0.05) -0.08(0.11) 0.11(0.12) --+ 1.54E-06 4.80E-01 3.58E-01 
	  42 rs12570170 10:70471839 5.26E-05 1.19(1.09-1.29) 0.38/0.37/0.39 0.17(0.05) 0.12(0.11) 0.27(0.12) +++ 8.31E-04 2.67E-01 2.85E-02 
43 rs11971753 7:158265034 5.45E-05 0.85(0.78-0.92) 0.43/0.45/0.43 -0.23(0.05) -0.15(0.11) 0.17(0.12) --+ 2.96E-06 1.74E-01 1.65E-01 
44 rs11209216 1:68344019 5.48E-05 1.18(1.09-1.28) 0.44/0.42/0.42 0.2(0.05) 0.05(0.11) 0.12(0.12) +++ 3.70E-05 6.67E-01 3.45E-01 
45 rs9538032 13:57883848 5.53E-05 1.21(1.1-1.33) 0.25/0.23/0.24 0.2(0.06) 0.16(0.13) 0.21(0.14) +++ 4.44E-04 1.99E-01 1.25E-01 
46 rs1509513 11:113010123 5.88E-05 0.84(0.77-0.91) 0.31/0.31/0.32 -0.21(0.05) -0.04(0.11) -0.2(0.13) --- 8.91E-05 7.35E-01 1.15E-01 
47 rs4936612 11:120708330 6.25E-05 0.85(0.78-0.92) 0.41/0.41/0.47 -0.21(0.05) -0.09(0.11) -0.03(0.12) --- 2.50E-05 4.30E-01 7.87E-01 
48 rs3731239 9:21964218 6.34E-05 0.77(0.68-0.88) 0.12/0.13/0.11 -0.27(0.07) -0.08(0.16) -0.43(0.19) --- 3.36E-04 5.88E-01 2.78E-02 
49 rs6897035 5:56030704 6.54E-05 0.83(0.75-0.91) 0.25/0.23/0.24 -0.2(0.06) -0.34(0.13) 0.05(0.14) --+ 3.10E-04 7.67E-03 7.21E-01 
50 rs6459896 7:158199341 6.55E-05 0.85(0.78-0.92) 0.44/0.44/0.43 -0.24(0.05) -0.06(0.11) 0.13(0.12) --+ 1.09E-06 5.54E-01 2.58E-01 
51 rs6799444 3:170471911 7.03E-05 0.85(0.78-0.92) 0.4/0.39/0.43 -0.21(0.05) -0.09(0.11) 0.01(0.12) --+ 1.64E-05 3.94E-01 9.47E-01 
52 rs610118 3:27311217 7.26E-05 1.32(1.15-1.51) 0.1/0.1/0.08 0.35(0.08) 0.13(0.18) -0.08(0.22) ++- 1.13E-05 4.71E-01 7.16E-01 
53 rs695207 9:113095990 7.33E-05 1.2(1.09-1.31) 0.28/0.3/0.29 0.2(0.05) 0.14(0.11) 0.1(0.13) +++ 1.50E-04 2.29E-01 4.31E-01 
54 rs2536075 7:151050535 7.53E-05 0.83(0.76-0.91) 0.27/0.28/0.29 -0.25(0.05) 0.08(0.12) -0.12(0.13) -+- 5.15E-06 5.18E-01 3.59E-01 
55 rs11637457 15:85373510 7.69E-05 0.8(0.71-0.89) 0.15/0.13/0.14 -0.26(0.07) -0.12(0.15) -0.11(0.17) --- 6.82E-05 4.21E-01 5.36E-01 
56 rs11636069 15:85335934 9.16E-05 0.8(0.71-0.89) 0.15/0.13/0.14 -0.26(0.07) -0.05(0.16) -0.19(0.17) --- 8.10E-05 7.38E-01 2.61E-01 
57 rs2877822 3:126127724 1.09E-04 0.68(0.56-0.83) 0.05/0.05/0.05 -0.43(0.12) -0.33(0.25) -0.23(0.28) --- 3.12E-04 1.80E-01 4.16E-01 
58 rs2978663 8:30685487 1.09E-04 0.85(0.78-0.92) 0.48/0.49/0.48 -0.17(0.05) -0.13(0.11) -0.12(0.13) --- 3.13E-04 2.34E-01 3.56E-01 
59 rs6800118 3:44116161 1.24E-04 0.84(0.77-0.92) 0.29/0.31/0.29 -0.22(0.05) -0.01(0.11) -0.14(0.13) --- 5.11E-05 9.19E-01 2.97E-01 
60 rs10799180 1:4022324 1.36E-04 1.28(1.13-1.45) 0.12/0.11/0.1 0.29(0.07) 0.19(0.17) 0.01(0.2) +++ 1.03E-04 2.55E-01 9.63E-01 
61 rs4756573 11:40067960 1.37E-04 0.84(0.77-0.92) 0.31/0.31/0.32 -0.18(0.05) -0.16(0.11) -0.12(0.12) --- 5.38E-04 1.64E-01 3.49E-01 
62 rs928021 13:69604009 1.40E-04 0.85(0.79-0.93) 0.4/0.4/0.39 -0.17(0.05) -0.14(0.11) -0.1(0.12) --- 3.99E-04 2.04E-01 4.07E-01 
63 rs12612409 2:69794791 1.42E-04 1.38(1.17-1.64) 0.06/0.06/0.06 0.36(0.1) 0.38(0.22) 0.03(0.25) +++ 3.13E-04 7.90E-02 9.01E-01 
64 rs1643415 5:65482843 1.46E-04 0.86(0.79-0.93) 0.44/0.44/0.44 -0.1(0.05) -0.29(0.1) -0.33(0.12) --- 2.95E-02 5.77E-03 7.87E-03 
65 rs1430435 3:170561887 1.47E-04 0.84(0.77-0.92) 0.28/0.27/0.32 -0.21(0.05) -0.27(0.12) 0.16(0.13) --+ 8.18E-05 1.93E-02 2.10E-01 
66 rs9928448 16:29980031 1.54E-04 1.17(1.08-1.27) 0.42/0.41/0.44 0.2(0.05) 0.05(0.11) 0.04(0.12) +++ 4.16E-05 6.26E-01 7.66E-01 
67 rs6949364 7:83241093 1.60E-04 0.84(0.77-0.92) 0.27/0.26/0.26 -0.21(0.05) -0.03(0.12) -0.17(0.14) --- 1.45E-04 7.98E-01 2.14E-01 
68 rs4274923 4:6264523 1.68E-04 1.18(1.08-1.29) 0.3/0.29/0.31 0.2(0.05) 0.06(0.12) 0.11(0.12) +++ 1.43E-04 5.78E-01 3.85E-01 
69 rs27084 5:65471042 1.68E-04 0.86(0.79-0.93) 0.49/0.48/0.49 -0.1(0.05) -0.3(0.1) -0.27(0.12) --- 3.22E-02 3.52E-03 2.48E-02 
70 rs10120688 9:22046499 1.81E-04 0.84(0.77-0.92) 0.28/0.3/0.28 -0.21(0.05) -0.11(0.12) -0.05(0.13) --- 1.36E-04 3.51E-01 7.10E-01 
71 rs4832183 2:85769998 1.88E-04 0.85(0.78-0.93) 0.37/0.37/0.37 -0.17(0.05) -0.2(0.11) -0.05(0.12) --- 7.10E-04 6.59E-02 7.15E-01 
72 rs6938042 6:93890157 1.91E-04 0.86(0.79-0.93) 0.46/0.49/0.45 -0.17(0.05) -0.02(0.11) -0.24(0.12) --- 4.60E-04 8.71E-01 5.14E-02 
73 rs1505194 11:4662613 1.97E-04 0.84(0.76-0.92) 0.25/0.25/0.26 -0.21(0.06) -0.22(0.12) 0.03(0.13) --+ 2.55E-04 7.82E-02 8.45E-01 
74 rs959678 7:50031156 1.98E-04 0.79(0.7-0.9) 0.12/0.13/0.15 -0.26(0.07) -0.12(0.16) -0.19(0.17) --- 3.53E-04 4.48E-01 2.64E-01 
75 rs8182037 15:73921656 2.02E-04 0.85(0.79-0.93) 0.39/0.39/0.38 -0.17(0.05) -0.02(0.11) -0.23(0.12) --- 4.33E-04 8.58E-01 6.10E-02 
76 rs35907069 2:69794284 2.08E-04 1.37(1.16-1.62) 0.06/0.06/0.06 0.35(0.1) 0.36(0.22) 0.03(0.25) +++ 4.29E-04 9.46E-02 8.89E-01 
77 rs1432216 2:137591086 2.09E-04 1.19(1.08-1.3) 0.26/0.27/0.24 0.21(0.05) 0.16(0.12) -0.05(0.14) ++- 1.29E-04 1.79E-01 7.33E-01 
78 rs8092774 18:5152142 2.10E-04 1.25(1.11-1.41) 0.13/0.13/0.16 0.24(0.07) 0.25(0.16) 0.12(0.17) +++ 7.82E-04 1.20E-01 4.78E-01 
79 rs7760531 6:37760708 2.15E-04 0.85(0.79-0.93) 0.36/0.38/0.39 -0.11(0.05) -0.19(0.11) -0.41(0.12) --- 3.18E-02 7.77E-02 7.49E-04 
80 rs3779647 8:30680429 2.20E-04 0.86(0.79-0.93) 0.42/0.43/0.43 -0.17(0.05) -0.09(0.11) -0.16(0.13) --- 5.93E-04 4.37E-01 1.91E-01 
81 rs300905 4:144459923 2.21E-04 1.19(1.09-1.31) 0.25/0.24/0.25 0.21(0.05) 0.03(0.12) 0.09(0.14) +++ 9.24E-05 7.80E-01 4.97E-01 
82 rs8054507 16:29953543 2.24E-04 1.17(1.07-1.26) 0.45/0.44/0.46 0.18(0.05) 0.13(0.11) 0(0.12) +++ 1.90E-04 2.17E-01 9.69E-01 
83 rs6813517 4:168759326 2.25E-04 0.82(0.74-0.91) 0.19/0.21/0.19 -0.22(0.06) -0.17(0.15) -0.12(0.16) --- 5.51E-04 2.35E-01 4.34E-01 
84 rs2149196 10:108844488 2.26E-04 0.8(0.71-0.9) 0.13/0.12/0.13 -0.22(0.07) -0.53(0.17) 0.07(0.17) --+ 1.99E-03 1.36E-03 6.73E-01 
85 rs12210498 6:93973981 2.28E-04 0.86(0.79-0.93) 0.5/0.5/0.49 -0.21(0.05) -0.05(0.1) 0.04(0.12) --+ 2.47E-05 6.07E-01 7.59E-01 
86 rs1989229 17:40668676 2.29E-04 0.84(0.76-0.92) 0.24/0.24/0.23 -0.25(0.06) 0.02(0.12) 0.01(0.15) -++ 9.74E-06 8.76E-01 9.19E-01 
87 rs9282978 5:56021062 2.34E-04 0.84(0.77-0.92) 0.26/0.25/0.28 -0.18(0.05) -0.21(0.12) -0.07(0.13) --- 9.21E-04 8.37E-02 5.83E-01 
	  88 rs6459900 7:158269704 2.44E-04 1.16(1.07-1.26) 0.44/0.41/0.45 0.2(0.05) 0.15(0.11) -0.12(0.12) ++- 4.53E-05 1.61E-01 3.07E-01 
89 rs12576387 11:4660338 2.47E-04 0.82(0.74-0.91) 0.18/0.18/0.18 -0.22(0.06) -0.24(0.14) 0(0.15) --+ 4.21E-04 8.31E-02 9.97E-01 
90 rs1560579 2:137592445 2.54E-04 1.18(1.08-1.29) 0.29/0.29/0.26 0.2(0.05) 0.18(0.12) -0.08(0.14) ++- 1.59E-04 1.24E-01 5.78E-01 
91 rs1545326 4:96133447 2.56E-04 0.81(0.73-0.91) 0.15/0.15/0.17 -0.26(0.07) -0.05(0.15) -0.12(0.15) --- 1.24E-04 7.57E-01 4.16E-01 
92 rs12154722 7:48450166 2.58E-04 1.22(1.1-1.37) 0.17/0.16/0.14 0.23(0.06) 0.23(0.15) -0.05(0.18) ++- 3.00E-04 1.14E-01 7.72E-01 
93 rs3181088 1:100971296 2.64E-04 1.28(1.12-1.47) 0.1/0.11/0.12 0.28(0.08) 0.09(0.17) 0.25(0.19) +++ 4.70E-04 5.91E-01 1.80E-01 
94 rs10508196 13:107277967 2.66E-04 1.24(1.11-1.4) 0.14/0.14/0.16 0.28(0.07) -0.04(0.16) 0.18(0.17) +-+ 9.07E-05 8.22E-01 2.65E-01 
95 rs4964060 12:27424634 2.71E-04 0.85(0.79-0.93) 0.36/0.35/0.35 -0.19(0.05) -0.14(0.11) 0.02(0.13) --+ 1.98E-04 2.09E-01 8.73E-01 
96 rs16868855 8:103066156 2.71E-04 1.2(1.09-1.33) 0.21/0.21/0.23 0.25(0.06) 0.2(0.13) -0.21(0.14) ++- 2.58E-05 1.31E-01 1.45E-01 
97 rs4239237 17:28457752 2.75E-04 1.16(1.07-1.26) 0.47/0.48/0.48 0.1(0.05) 0.41(0.11) 0.1(0.12) +++ 3.39E-02 8.14E-05 3.93E-01 
98 rs9928735 16:25771045 2.86E-04 1.23(1.1-1.38) 0.15/0.15/0.14 0.24(0.07) 0.14(0.14) 0.08(0.18) +++ 3.12E-04 3.20E-01 6.69E-01 
99 rs4583255 16:29896442 2.96E-04 1.16(1.07-1.26) 0.45/0.45/0.47 0.19(0.05) 0.06(0.1) 0(0.12) +++ 6.80E-05 5.95E-01 9.74E-01 







	  Appendix N: Gene set enrichment analysis (GSEA) of pathways calculated by MAGENTA for SNP data, GSA-SNP for gene differential expression 













1 GOTERM axonemal dynein complex 12 0.0198 1.27E-24 1.50E-24 4.15E-21 
2 GOTERM microtubule-based movement 84 0.0586 3.70E-22 1.15E-21 3.18E-18 
3 GOTERM cilium axoneme 25 0.3817 6.63E-21 1.23E-19 3.38E-16 
4 GOTERM microtubule motor activity 75 0.3037 1.45E-20 2.11E-19 5.81E-16 
5 REACTOME G2_M_CHECKPOINTS 43 0.8911 2.86E-18 1.06E-16 2.92E-13 
6 GOTERM cilium 75 0.5618 4.29E-18 1.00E-16 2.76E-13 
7 REACTOME DNA_STRAND_ELONGATION 31 0.4469 2.16E-17 3.87E-16 1.07E-12 
8 REACTOME MITOTIC_PROMETAPHASE 91 0.2758 2.49E-16 2.63E-15 7.24E-12 
9 GOTERM condensed chromosome kinetochore 52 0.243 1.68E-15 1.49E-14 4.11E-11 
10 REACTOME ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS 37 0.8521 5.67E-15 1.64E-13 4.52E-10 
11 REACTOME E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION 32 0.4676 1.52E-14 2.38E-13 6.56E-10 
12 REACTOME UNWINDING_OF_DNA 11 0.4315 2.08E-13 2.78E-12 7.66E-09 
13 PANTHER_MOLECULAR_FUNCTION Microtubule_binding_motor_protein 59 0.1686 3.33E-13 1.77E-12 4.88E-09 
14 GOTERM kinetochore 53 0.4093 7.94E-13 9.67E-12 2.67E-08 
15 GOTERM ciliary or flagellar motility 10 0.103 1.16E-12 3.66E-12 1.01E-08 
16 GOTERM cell projection organization 24 0.3417 1.53E-12 1.54E-11 4.23E-08 
17 REACTOME ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX 30 0.4053 3.70E-12 4.23E-11 1.17E-07 
18 Panther 5-Hydroxytryptamine_degredation 26 0.1707 1.70E-11 8.01E-11 2.21E-07 
19 REACTOME E2F_TRANSCRIPTIONAL_TARGETS_AT_G1_S 21 1 4.54E-11 1.13E-09 3.10E-06 
20 KEGG KEGG_DNA_REPLICATION 36 0.8206 7.14E-11 1.44E-09 3.97E-06 
21 GOTERM DNA replication initiation 16 1 8.46E-11 2.05E-09 5.65E-06 
22 GOTERM phosphoinositide-mediated signaling 33 0.4703 1.10E-10 1.28E-09 3.53E-06 
23 REACTOME SYNTHESIS_OF_DNA 89 0.2412 4.08E-10 2.37E-09 6.53E-06 
24 GOTERM spindle organization 13 1 6.06E-10 1.35E-08 3.71E-05 
25 GOTERM mitotic sister chromatid segregation 13 1 1.89E-09 3.98E-08 1.10E-04 
26 PANTHER_MOLECULAR_FUNCTION Microtubule_family_cytoskeletal_protein 47 0.9095 5.16E-09 9.47E-08 2.61E-04 
27 KEGG KEGG_DRUG_METABOLISM_CYTOCHROME_P450 58 0.9575 6.26E-09 1.19E-07 3.29E-04 
28 KEGG KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 56 0.9574 1.49E-08 2.71E-07 7.48E-04 
29 PANTHER_BIOLOGICAL_PROCESS Chromosome_segregation 96 0.3315 3.49E-08 2.23E-07 6.14E-04 
30 GOTERM chromosome, centromeric region 46 0.0235 3.54E-08 1.82E-08 5.02E-05 
31 GOTERM tubulin binding 13 1 4.42E-08 7.93E-07 2.19E-03 
32 REACTOME E2F_ENABLED_INHIBITION_OF_PRE_REPLICATION_COMPLEX_FORMATION 10 0.4002 4.46E-08 3.36E-07 9.28E-04 
33 REACTOME METABLISM_OF_NUCLEOTIDES 70 0.2435 4.96E-08 2.32E-07 6.40E-04 
34 GOTERM chromosome segregation 45 0.3696 9.54E-08 6.40E-07 1.76E-03 
35 GOTERM cAMP-dependent protein kinase regulator activity 16 0.5563 1.03E-07 1.01E-06 2.78E-03 
36 BIOCARTA MCM_PATHWAY 18 1 1.69E-07 2.80E-06 7.72E-03 
37 PANTHER_BIOLOGICAL_PROCESS Other_carbon_metabolism 77 0.719 1.77E-07 2.14E-06 5.91E-03 
38 GOTERM dynein complex 16 1 2.07E-07 3.40E-06 9.37E-03 
39 REACTOME TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRON_CONTAINING_TRANSCRIPT 51 0.7013 4.43E-07 4.97E-06 1.37E-02 
	  40 KEGG KEGG_ONE_CARBON_POOL_BY_FOLATE 17 0.2048 4.55E-07 1.60E-06 4.42E-03 
41 REACTOME LAGGING_STRAND_SYNTHESIS 20 0.6248 5.42E-07 5.39E-06 1.49E-02 
42 GOTERM spindle 83 0.9837 7.19E-07 1.07E-05 2.95E-02 
43 GOTERM nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 63 0.8029 8.50E-07 1.04E-05 2.86E-02 
44 REACTOME DNA_REPLICATION_PRE_INITIATION 76 0.2732 9.01E-07 3.99E-06 1.10E-02 
45 PANTHER_MOLECULAR_FUNCTION DNA_helicase 65 0.3574 1.20E-06 6.71E-06 1.85E-02 
46 REACTOME PURINE_RIBONUCLEOSIDE_MONOPHOSPHATE_BIOSYNTHESIS 11 1 1.50E-06 2.16E-05 5.97E-02 
47 GOTERM purine nucleotide biosynthetic process 16 1 1.60E-06 2.30E-05 6.34E-02 
48 GOTERM outer kinetochore of condensed chromosome 10 1 1.84E-06 2.62E-05 7.21E-02 
49 Panther De_novo_purine_biosynthesis 46 1 2.20E-06 3.09E-05 8.51E-02 
50 GOTERM flagellum 18 0.2474 2.71E-06 1.02E-05 2.81E-02 
51 GOTERM spindle pole 47 0.9183 2.88E-06 3.66E-05 1.01E-01 
52 REACTOME POLYMERASE_SWITCHING 14 0.4807 2.97E-06 2.06E-05 5.69E-02 
53 REACTOME EXTENSION_OF_TELOMERES 28 0.7355 3.48E-06 3.55E-05 9.80E-02 
54 GOTERM mitotic chromosome condensation 14 0.4578 4.03E-06 2.62E-05 7.22E-02 
55 KEGG KEGG_TYROSINE_METABOLISM 42 1 4.81E-06 6.38E-05 1.76E-01 
56 GOTERM microtubule bundle formation 10 1 7.62E-06 9.74E-05 2.68E-01 
57 REACTOME ETHANOL_OXIDATION 10 0.4049 9.56E-06 5.21E-05 1.44E-01 
58 GOTERM extracellular matrix structural constituent 65 0.3709 1.09E-05 5.44E-05 1.50E-01 
59 GOTERM laminin-1 complex 11 1 1.23E-05 1.52E-04 4.18E-01 
60 REACTOME REV_MEDIATED_NUCLEAR_EXPORT_OF_HIV1_RNA 31 0.7838 1.82E-05 1.73E-04 4.78E-01 
61 BIOCARTA RANMS_PATHWAY 10 1 1.91E-05 2.27E-04 6.25E-01 
62 GOTERM hormone biosynthetic process 10 1 2.02E-05 2.39E-04 6.59E-01 
63 GOTERM mRNA transport 52 0.4786 2.18E-05 1.30E-04 3.59E-01 
64 GOTERM mitotic cell cycle checkpoint 13 0.4588 2.96E-05 1.66E-04 4.57E-01 
65 PANTHER_BIOLOGICAL_PROCESS RNA_localization 33 1 3.63E-05 4.07E-04 1 
66 REACTOME NUCLEAR_IMPORT_OF_REV_PROTEIN 30 0.7779 3.84E-05 3.41E-04 9.40E-01 
67 GOTERM mitotic spindle organization 13 1 4.30E-05 4.76E-04 1 
68 REACTOME CDC6_ASSOCIATION_WITH_THE_ORC:ORIGIN_COMPLEX 11 0.4291 4.76E-05 2.41E-04 6.65E-01 
69 GOTERM nuclear envelope 99 0.8185 5.37E-05 4.85E-04 1 
70 PANTHER_MOLECULAR_FUNCTION Nucleotide_kinase 46 0.8936 6.28E-05 6.06E-04 1 
71 REACTOME NEP_NS2_INTERACTS_WITH_THE_CELLULAR_EXPORT_MACHINERY 29 0.7677 6.53E-05 5.47E-04 1 
72 GOTERM nucleoside-triphosphatase activity 56 0.5644 6.81E-05 4.29E-04 1 
73 REACTOME G2_M_TRANSITION 83 0.9121 8.15E-05 7.81E-04 1 
74 GOTERM microtubule basal body 34 0.4863 8.18E-05 4.43E-04 1 
75 GOTERM collagen 21 0.067 8.69E-05 7.60E-05 2.10E-01 
76 GOTERM epithelial cell differentiation 35 0.8147 9.61E-05 8.19E-04 1 
77 GOTERM mismatch repair 21 1 1.03E-04 1.04E-03 1 
78 REACTOME ASSOCIATION_OF_LICENSING_FACTORS_WITH_THE_PREREPLICATIVE_COMPLEX 12 1 1.09E-04 1.10E-03 1 
79 REACTOME TRANSPORT_OF_THE_SLBP_INDEPENDENT_MATURE_MRNA 32 0.7938 1.14E-04 9.33E-04 1 
80 KEGG KEGG_SMALL_CELL_LUNG_CANCER 84 0.3711 1.45E-04 5.83E-04 1 
81 REACTOME SNRNP_ASSEMBLY 48 0.6898 1.47E-04 1.03E-03 1 
82 GOTERM midbody 21 0.6731 1.53E-04 1.05E-03 1 
83 GOTERM platelet-derived growth factor binding 11 0.4003 1.65E-04 7.01E-04 1 
84 PANTHER_BIOLOGICAL_PROCESS Other_carbohydrate_metabolism 54 0.2572 1.76E-04 4.99E-04 1 
85 REACTOME REPAIR_SYNTHESIS_OF_PATCH_27_30_BASES_LONG_BY_DNA_POLYMERASE 15 1 1.78E-04 1.71E-03 1 
	  86 BIOCARTA G2_PATHWAY 24 0.6897 1.82E-04 1.26E-03 1 
87 KEGG KEGG_MISMATCH_REPAIR 22 1 1.85E-04 1.77E-03 1 
88 PANTHER_MOLECULAR_FUNCTION Other_cytokine 20 1 1.88E-04 1.80E-03 1 
89 REACTOME PURINE_METABOLISM 30 0.7461 1.91E-04 1.40E-03 1 
90 REACTOME M_G1_TRANSITION 61 0.316 1.96E-04 6.61E-04 1 
91 GOTERM cellular aldehyde metabolic process 12 0.4649 2.03E-04 9.69E-04 1 
92 PANTHER_MOLECULAR_FUNCTION Replication_origin_binding_protein 12 1 2.81E-04 2.58E-03 1 
93 REACTOME TRANSPORT_OF_RIBONUCLEOPROTEINS_INTO_THE_HOST_NUCLEUS 29 0.7601 3.77E-04 2.63E-03 1 
94 GOTERM mitotic metaphase plate congression 10 1 3.95E-04 3.49E-03 1 
95 GOTERM collagen fibril organization 29 0.7095 5.02E-04 3.18E-03 1 
96 REACTOME REMOVAL_OF_THE_FLAP_INTERMEDIATE 14 0.4856 5.08E-04 2.30E-03 1 
97 GOTERM spindle microtubule 22 1 5.19E-04 4.45E-03 1 
98 REACTOME MRNA_3_END_PROCESSING 34 0.7853 5.81E-04 3.96E-03 1 
99 REACTOME LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 62 0.7978 6.26E-04 4.30E-03 1 
100 REACTOME SYNTHESIS_AND_INTERCONVERSION_OF_NUCLEOTIDE_DI_AND_TRIPHOSPHATES 17 0.5839 7.33E-04 3.75E-03 1 
 
aMAGENTA GSEA P-values were calculated based on 95th percentile cutoff.  Gene boundaries – 10 kb upstream and 2 kb downstream of gene start and end site. 
bGene set enrichment analysis (GSEA) of pathways calculated by GSA-SNP using GEO2R gene differential expression values of study GSE12452. 
 GSE12452 consists of mRNA from laser-captured epithelium of 31 nasopharyngeal carcinomas and 10 non-NPC nasopharynx tissues from a Taiwanese case control cohort. 
cCombined GSEA from MAGENTA (SNP data) and GSA-SNP (differential gene expression data). 


















	  Appendix O: Pathways showing nominal association in SNP GSEA as well as gene expression GSEA. 
 
Pathway gene count aMAGENTA GSEA P-val bGSA-SNP GSEA P-val cCombined P-val dPBonf-Combined 
GOTERM axonemal dynein complex 12 0.0198 1.27E-24 1.50E-24 4.15E-21 
GOTERM chromosome, centromeric region 46 0.0235 3.54E-08 1.82E-08 5.02E-05 
GOTERM serine-type endopeptidase inhibitor activity 86 0.0114 7.58E-03 8.95E-04 1 
GOTERM calcium-independent cell-cell adhesion 21 0.0193 8.11E-03 1.53E-03 1 
GOTERM ATP-dependent DNA helicase activity 24 0.0249 8.74E-03 2.05E-03 1 
BIOCARTA PLATELETAPP_PATHWAY 13 0.0177 1.23E-02 2.06E-03 1 
GOTERM basal plasma membrane 19 0.0091 1.46E-02 1.32E-03 1 
GOTERM steroid biosynthetic process 34 0.0037 3.05E-02 1.14E-03 1 
 
aMAGENTA GSEA P-values were calculated based on 95th percentile cutoff.  Gene boundaries – 10 kb upstream and 2 kb downstream of gene start and end site. 
bGene set enrichment analysis (GSEA) of pathways calculated by GSA-SNP using GEO2R gene differential expression values of study GSE12452. 
 GSE12452 consists of mRNA from laser-captured epithelium of 31 nasopharyngeal carcinomas and 10 non-NPC nasopharynx tissues from a Taiwanese case control cohort. 
cCombined GSEA from MAGENTA (SNP data) and GSA-SNP (differential gene expression data). 





















GENE ID GENE 
aMAGENTA 








FC AmpliSeq probe 
Axonemal 
dynein complex 
1767 DNAH5 1.30E-02 rs79716918 5:13929045 3.07E-07 -2.64 232381_s_at 1.28E-06 -2.82 AMPL7777818 
1769 DNAH8 8.22E-01 rs7742625 6:38719850 7.40E-01 -0.05 233052_at 2.09E-02 -2.14 AMPL7229148 
1770 DNAH9 3.80E-02 rs143419873 17:11822799 6.79E-08 -2.16 240857_at 5.60E-06 -3.59 AMPL7582404 
7802 DNALI1 4.23E-01 rs2273013 1:38019747 4.24E-09 -3.05 227081_at 4.31E-24 -5.60 AMPL9300885 
8632 DNAH17 3.74 E-01 rs870909 17:76573682 3.34E-01 -0.11 1553470_at 3.81E-04 2.51 AMPL15650095 
8701 DNAH11 4.37E-01 rs2270022 7:21775210 5.37E-06 -0.64 1553159_at 2.52E-04 -2.31 AMPL11272646 
10126 DNAL4 6.03E-01 rs14040 22:39175267 7.65E-03 -0.45 204008_at 3.05E-01 0.35 AMPL29440192 
25981 DNAH1 9.07E-01 rs13060192 3:52378540 3.14E-07 -0.59 232005_at 3.66E-05 -1.83 AMPL32441374 
55567 DNAH3 4.85E-02 rs61040030 16:20955155 2.82E-08 -0.99 215266_at 2.84E-06 -4.40 AMPL31221340 
56171 DNAH7 1.62E-01 rs12469956 2:196739009 1.83E-07 -1.72 214222_at 1.19E-05 -3.33 AMPL31192670 
64446 DNAI2 4.64E-01 rs117482863 17:72272516 3.04E-07 -2.48 220636_at 1.96E-16 -6.81 AMPL34853673 




332 BIRC5 1.38E-02 rs11868371 17:76217059 1.05E-05 1.56 202095_s_at 1.39E-04 1.58 AMPL513992 
1058 CENPA 8.96E-01 rs10193936 2:27002655 1.68E-04 1.27 204962_s_at 5.78E-04 1.46 AMPL10749776 
1059 CENPB 5.82E-01 rs2281478 20:3759528 3.96E-02 0.22 212437_at 3.70E-01 0.27 AMPL7212562 
1062 CENPE 7.34E-01 rs151231177 4:104046962 4.25E-05 1.18 205046_at 3.22E-02 1.17 AMPL8434722 
1063 CENPF 6.65E-01 rs2666833 1:214796532 3.73E-06 1.51 207828_s_at 1.14E-04 1.66 AMPL30585834 
2491 CENPI N/A N/A 23:N/A 3.97E-04 0.83 214804_at 1.06E-03 1.28 AMPL13146859 
3070 HELLS 3.17E-01 rs11188018 10:96313334 7.11E-08 2 227350_at 6.98E-04 1.13 AMPL31246801 
3619 INCENP 8.51E-01 rs61893683 11:61920784 2.76E-01 -0.1 219769_at 4.63E-01 0.26 AMPL4157675 
4288 MKI67 1.27E-01 rs147469261 10:129922549 2.79E-05 0.94 212023_s_at 3.29E-02 1.06 AMPL9212051 
5515 PPP2CA 6.48E-01 rs138241880 5:133537935 4.14E-01 0.2 208652_at 4.40E-01 0.31 AMPL9219992 
5516 PPP2CB 8.28E-01 rs78850094 8:30662069 1.22E-01 -0.22 201374_x_at 1.35E-01 0.45 AMPL727414 
5518 PPP2R1A 4.54E-01 rs148005542 19:52704184 7.12E-01 -0.08 200695_at 5.43E-01 0.15 AMPL25082376 
5525 PPP2R5A 7.31E-01 rs142025328 1:212496253 2.41E-03 -0.55 202187_s_at 6.88E-05 -1.12 AMPL26982415 
5527 PPP2R5C 1.38E-01 rs2403002 14:102326791 7.45E-02 -0.54 201877_s_at 1.26E-06 -1.50 AMPL9724293 
5663 PSEN1 7.42E-02 rs214278 14:73605495 1.00E-01 -0.13 1559206_at 2.53E-01 -0.27 AMPL14470 
 
6839 SUV39H1 N/A N/A 23:N/A 5.37E-01 0.08 218619_s_at 5.09E-02 0.45 AMPL7418075 
 
8690 JRKL 7.10E-01 rs145081521 11:96119879 1.16E-01 -0.14 1557790_at 8.26E-01 -0.09 AMPL8371445 
 
10403 NDC80 5.16E-01 rs8088444 18:2605753 4.00E-06 1.97 204162_at 3.10E-02 0.97 AMPL27552849 
 
10664 CTCF 2.33E-01 rs143533938 16:67604490 4.59E-02 -0.31 202521_at 8.95E-02 -0.51 AMPL13507696 
 
10951 CBX1 1.40E-01 rs76984226 17:46155393 6.32E-03 0.82 201518_at 1.06E-07 2.28 AMPL12805162 
	   
11004 KIF2C 1.81E-01 rs60766209 1:45229849 1.19E-04 0.9 209408_at 1.29E-04 1.57 AMPL12243426 
 
11339 OIP5 5.11E-01 rs117218429 15:41618290 1.87E-04 1.48 213599_at 3.72E-05 1.85 AMPL12283293 
 
23421 ITGB3BP 6.04E-01 rs28693657 1:63938039 1.89E-04 0.77 205176_s_at 9.65E-02 0.78 AMPL8828072 
 
27309 ZNF330 6.76E-01 rs7677757 4:142149096 4.27E-01 -0.13 213760_s_at 3.56E-01 0.25 AMPL25156875 
 
54069 MIS18A 6.65E-01 rs56768797 21:33640966 6.51E-04 1.16 228597_at 2.30E-04 0.83 AMPL33086698 
 
55143 CDCA8 5.31E-01 rs7822 1:38174987 2.32E-02 0.38 221520_s_at 1.79E-03 1.19 AMPL34142667 
 
55166 CENPQ 7.77E-01 rs7769646 6:49421241 1.40E-03 0.79 219294_at 4.77E-02 0.91 AMPL34139973 
 
55320 MIS18BP1 7.29E-01 rs75849724 14:45690014 1.23E-02 0.55 226630_at 1.66E-01 -0.40 AMPL32632467 
 
55355 HJURP 3.85E-01 rs965835 2:234748814 1.52E-03 0.63 218726_at 6.63E-04 1.33 AMPL31859115 
 
55920 RCC2 6.02E-01 rs78045454 1:17758660 6.13E-03 0.47 224578_at 1.75E-03 1.05 AMPL4649182 
 
79075 DSCC1 4.31E-01 rs10088205 8:120836392 4.95E-06 1.49 219000_s_at 1.33E-03 1.57 AMPL36827444 
 
79723 SUV39H2 2.83E-02 rs55799534 10:14926986 8.58E-04 1.27 1554572_a_at 1.73E-06 1.80 AMPL7610258 
 
81789 TIGD6 4.09E-03 rs144692725 5:149374693 9.65E-01 0.01 220986_s_at 8.56E-01 -0.11 AMPL13983353 
 
83540 NUF2 1.67E-02 rs77805972 1:163315053 2.75E-05 2.06 223381_at 1.94E-04 1.47 AMPL14708770 
 
84948 TIGD5 5.23E-01 rs117583565 8:144675491 1.65E-01 0.21 229758_at 4.03E-03 0.78 AMPL16338581 
 
91151 TIGD7 3.95E-01 rs79713839 16:3339480 5.48E-02 -0.56 224365_s_at 4.33E-01 -0.67 AMPL18657831 
 
91687 CENPL 6.66E-01 rs16846418 1:173768826 1.06E-03 0.65 232065_x_at 2.21E-03 1.13 AMPL7485532 
 
151246 SGOL2 4.34E-02 rs2577283 2:201414828 3.59E-03 0.88 230165_at 1.45E-02 0.82 AMPL34591051 
 
151648 SGOL1 1.89E-01 rs117831355 3:20206543 1.02E-02 0.22 231938_at 5.26E-04 1.30 AMPL616142 
 
166815 TIGD2 5.61E-01 rs146136452 4:90036462 1.21E-02 0.64 229983_at 3.55E-02 0.56 AMPL34316233 
 
200765 TIGD1 9.12E-01 rs2250451 2:233409013 1.29E-01 0.61 1553099_at 2.72E-02 -0.59 AMPL36151290 
 
201254 STRA13 4.17E-02 rs146404268 17:79975596 3.00E-01 0.27 209478_at 2.84E-01 0.37 AMPL36169574 
 
201798 TIGD4 6.68E-01 rs56087086 4:153695836 1.31E-01 -0.19 1552523_a_at N/A N/A N/A 
 
220359 TIGD3 3.69E-01 rs56128681 11:65114611 1.94E-01 -0.14 229789_at 4.06E-01 -0.82 AMPL36553008 
 
378708 APITD1 5.39E-01 rs138919044 1:10492849 6.94E-01 0.12 213454_at 2.97E-01 0.48 AMPL20569210 
 387103 CENPW 8.99E-01 rs141357321 6:126669065 1.04E-02 0.97 226936_at 1.85E-05 1.71 AMPL511163 
 
aGene P-val assigned using best SNP association; 10 kb UTR 2 kb DTR. 
bGene differential expression calculated by GEO2R (limma package) adjusting for log2 fold change. 
cLog2 fold change calculated in the direction of NPC cases vs non-NPC nasopharynx tissue from GSE12452. 
dGene differential expression calculated by DESeq2 from 10 NPC and 7 non-NPC nasopharynx tissues from a Malaysian cohort. 
eLog2 fold change calculated in the direction of NPC vs non-NPC nasopharynx tissue from a Malaysian cohort. 
